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Background: Non-allergenic perceived food intolerance (PFI) is a distressing condition 
reported by up to 35% of individuals, whereas the prevalence of food allergy (FA) is 0.9 – 
3%. The aim of the present paper is to systematically review the evidence for associated 
psychological, clinical and psychosocial factors in order to improve current understanding 
of PFI and contribute to future targeted interventions. 
 
Methods:  Articles published from 1970 until September 2019 were identified through 
Web of Science, Scopus, PsycINFO, MEDLINE, EMBASE and Global Health. Search terms 
involved PFI and various synonyms, combinations, operators, truncations, wild cards and 
limiters. Case-control, prospective cohort, cross-sectional and retrospective studies 
published in English that a) included a subject population of adults over 18 with PFI and 
b) examined psychological, clinical and/or psychosocial factors of PFI were reviewed in 
two stages against inclusion criteria, by three separate reviewers. The methodological 
quality was assessed, data were extracted, and a narrative synthesis was conducted. 
 
Results: Of 2,627 abstracts identified, thirty-five articles met inclusion criteria and were 
reviewed.  Data were predominantly reported at a cross-sectional level. The strongest 
evidence indicates female sex is associated with PFI. Studies consistently found individuals 
with PFI often report physical health complaints including gastrointestinal (GI) and 
extraintestinal symptoms, and GI and atopic conditions. Evidence indicating that 
psychological factors were significantly associated with PFI were inconsistent, though 
some evidence suggested increased levels of common mental disorders (CMD) and 
distress. Findings regarding psychosocial factors were mixed and sociodemographic data 
were infrequently collected.  
 
Conclusions: PFI is associated with female sex and gastrointestinal and extraintestinal 
complaints. Limited high-quality evidence supports the role of psychological factors in 
self-reported PFI. High-quality research using prospective and longitudinal designs with 
multivariate analyses is needed. Future research should explore modifiable psychological 
factors as potential targets for intervention, and to identify clinical and psychosocial risk 









Food hypersensitivity represents an area of marked interest in the public domain 
yet remains a challenge for health care professionals and patients alike, with widespread 
associated personal and social costs. The experience is distressing, and symptoms can 
range from gastrointestinal (GI) discomfort to life-threatening immunological response 
(Johansson et al., 2001; Muraro et al., 2014; Skypala, 2011).  For many, the unpredictable 
nature of symptoms, diagnostic challenges faced by healthcare professionals, and wide 
range of associated symptoms lead to repeated healthcare visits which increases 
economic burden, self-diagnosis, food avoidance, increased psychological distress, and 
reduced quality of life (Fox et al., 2013; Gupta et al., 2010; Hazeldine, Worth, Levy, & 
Sheikh, 2010; Jones & Burks, 2017; Lieberman & Sicherer, 2011; Nelson & Ogden, 2008).  
1.2 Definitions and Prevalence 
Immune-mediated food allergy (FA) is predominantly cell-mediated or antibody-
mediated. Immediate and recognisable allergenic symptoms include; itching or burning 
in the mouth and throat, swelling and throat constriction, or in severe reactions; 
anaphylactic shock following ingestion, airborne inhalation or skin contact with the 
allergen (Muraro et al., 2014; Ortolani & Pastorello, 2006; Sicherer & Sampson, 2014). 
Non-allergic reactions are typically mediated through ‘enzymatic, pharmacological and 
additional undefined’ mechanisms (Ortolani & Pastorello, 2006; Sicherer & Sampson, 
2014; Zopf, Baenkler, Silbermann, Hahn, & Raithel, 2009). Associated symptoms are 
typically delayed, and include GI symptoms of bloating, changes in bowel movements 
(constipation or diarrhoea), pain and discomfort, and extraintestinal symptoms including 
fatigue, migraines, headaches, and joint pain, or any of these symptoms in combination 
(Kelsay, 2003; Ortolani & Pastorello, 2006; Sicherer & Sampson, 2014).  
The terms ‘food sensitivity’, ‘food hypersensitivity’, ‘food intolerance’, ‘food 
allergy’ and adverse ‘food reactions’ are often used interchangeably, contributing to 
confusion for practitioners and public alike. A position statement from the European 




the umbrella term for both allergic and non-allergic reactions (Johansson et al., 2001), yet 
definitions and recommended terminology of ‘food allergy’ and ‘food intolerance’ have 
been proposed by the US National Institute of Allergy and Infectious Diseases (NIAD) 
(Sicherer & Sampson, 2018). In the current systematic review, ‘perceived food intolerance 
(PFI)’ will be used to describe nonimmune hypersensitivity reactions that are self-
reported by individuals, ‘food allergy (FA)’ will be used to describe immune-mediated 
hypersensitivity reactions, and ‘food hypersensitivity (FH)’ will be used as an umbrella 
term where appropriate.  
FH is self-reported by up to 35% of the general population, though clinically-
confirmed FA is only established in 0.9 – 3% of adults (Muraro et al., 2014; Nwaru et al., 
2014; Rona et al., 2007; Woods et al., 2002; Zuberbier et al., 2004). Though outside the 
scope of this review, evidence indicates that prevalence of FH and related hospital 
admissions is increasing (Gupta, Sheikh, Strachan, & Anderson, 2007; Nwaru et al., 2014; 
Prescott & Allen, 2011; Sicherer & Sampson, 2014, 2018), though research has 
additionally demonstrated incidence is not increasing (McGowan, Peng, Salo, Zeldin, & 
Keet, 2016; Nwaru et al., 2014). There is a significant discrepancy in prevalence between 
PFI and FA though true estimates are difficult to attain due to diagnostic challenges 
(Turnbull, Adams, & Gorard, 2015), and it is difficult to know whether reported rise in 
prevalence is due to an actual increase in FH, or increased awareness and self-reporting. 
1.3 Impact and Correlates of PFI 
Research investigating correlates of PFI is limited, though evidence suggests PFI is 
more often reported in women (Knibb et al., 1999; Lillestøl et al., 2010) and in those who 
meet criteria for Irritable Bowel Syndrome (IBS) (Atkinson, Sheldon, Shaath, & Whorwell, 
2004; Dainese, Galliani, Lazzari, Leo, & Naccarato, 1999; Lind et al., 2005; Lind, Berstad, 
Hatlebakk, & Valeur, 2013; Lind, Lied, Lillestol, Valeur, & Berstad, 2010; Lind, Lillestol, et 
al., 2010; Monsbakken, Vandvik, & Farup, 2006). IBS is a functional GI disorder (FGID) 
where, despite absence of organic pathology, symptoms persist and cause functional 
impairments and distress (Drossman, 2016; Morton, Elliott, Cleland, Deary, & Burton, 




factors can interact with biological factors to precede and precipitate IBS and may also 
contribute to perpetuating symptoms (Sibelli et al., 2016). IBS is associated with trauma, 
adverse early experiences, life stress, anxiety, depressive and somatoform disorders, and 
elevated symptoms of depression and anxiety compared to controls without IBS (Fond et 
al., 2014; Shah, Rezaie, Riddle, & Pimentel, 2014; Videlock et al., 2009; White et al., 2010; 
Whitehead, Palsson, & Jones, 2002).  
Psychological factors in PFI have not been as thoroughly investigated, though 
suggest that distress may be a characteristic feature. Lillestøl et al. (2010) reported 57% 
of individuals with PFI met criteria for any psychiatric disorder, which is above the 
reported population prevalence of common mental disorders (CMD) including depressive 
disorders and anxiety disorders in England, which is around one in six (Bebbington & 
McManus, 2020). Additionally, research in PFI indicates self-reported increased anxiety, 
depression and somatic symptoms compared to controls (Knibb et al., 1999; Lillestøl et 
al., 2010; Lind et al., 2005), though the study designs used and analyses conducted 
preclude determining the direction of the relationship,  and the findings are difficult to 
generalise to the wider population. PFI carries social implications, and perceived negative 
evaluations from others appear to be important. Qualitative research from Nettleton, 
Woods, Burrows, and Kerr (2010) highlighted an emotional impact of not having an 
authentic ‘illness identity’ and related experiences of increased anxiety, uncertainty and 
negative perceptions from others as there is no ‘explanation’ for PFI.   
A lack of a clear understanding of PFI is problematic for diagnosis and management 
(Nettleton et al., 2010), which may contribute to reported distress. Qualitative research 
additionally suggests general practitioners hold a strong association between food 
intolerance and psychological distress (Nelson & Ogden, 2008). This may impact how 
medical professionals perceive their patients’ complaints, and communicate with patients 
with PFI, though this is not known. However, communication in the doctor-patient 
relationship has been demonstrated to be important in IBS (Halpert & Godena, 2011).  
The beliefs an individual holds about their condition, known as illness perceptions, 




management strategies (Petrie & Weinman, 2006;Leventhal, 1984; Leventhal, Phillips, & 
Burns, 2016). Symptoms in PFI are attributed to food, and specific thoughts and beliefs 
can increase attention towards information in line with the belief (Brosschot, 2002), 
which might perpetuate PFI-related beliefs, though this is not known. PFI poses challenges 
for psychological, social and health-related well-being, however, little is known about the 
role of psychological, clinical, and psychosocial factors associated with PFI.  
PFI is not well understood, and it is important to rigorously consider the evidence 
for psychological, clinical and psychosocial correlates of PFI to better understand this 
condition including its sequelae and potential risk factors. There are similarities between 
PFI and IBS, and it is possible that these represent similar conditions, however, this is not 
known. It is important to identify factors that are significant in PFI, as these may 
contribute to outcome, including managing symptoms and the psychological impact of 
PFI. Enhancing our understanding is necessary in order to conceptualise PFI using a 
biopsychosocial model, whereby symptoms can be understood to occur from an 
interaction of genetic and environmental vulnerabilities, psychological and psychosocial 
factors. This can inform which modifiable correlates are necessary to address in a future 
successful intervention to help individuals manage PFI.   
1.4 Rationale and Aims 
It is likely that in PFI, symptoms are the result of multiple interactions, however, 
current understanding is limited by a paucity of data specifically exploring factors 
associated with PFI, and a lack of high-quality evidence to draw from. To the authors 
knowledge, there has been no previous systematic review examining the evidence for 
correlates of PFI, and it is hoped that the results of this review can help to further the 
current understanding of people with PFI. The ability to identify modifiable psychological 
correlates in addition to associated clinical and psychosocial factors can contribute a 
greater understanding of PFI for the public and medical professionals alike and can help 
advance evidence-based and theory-informed interventions to improve outcomes, as has 




The current review aims to systematically identify and evaluate the existing literature 
for evidence of (a) modifiable psychological correlates that are associated with PFI, as 
primary objectives, (b) and clinical or psychosocial correlates that are associated with PFI, 
as secondary objectives.  For the purpose of this review, psychological variables were 
defined as those related to emotions, beliefs and attitudes which could potentially be 
modified in treatment, trait characteristics such as personality, and psychosomatic 
variables. Clinical factors were defined as comorbid physical health conditions. 
Psychosocial factors were defined as demographic and socioeconomic factors.  
 Methods 
2.1 Search Strategy 
The systematic review protocol was registered on the International Prospective 
Register of Systematic Reviews (PROSPERO; ID: CRD42019122826) and was conducted in 
accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (Moher, Liberati, Tetzlaff, Altman, & Group, 2010). Electronic 
databases (Web of Science, Scopus, PsycINFO, MEDLINE, EMBASE and Global Health) 
were systematically searched from 1970 to September 23, 2019 by the first author (A.D.), 
and two independent reviewers (S.M.) and (D.R.). Reference lists of articles meeting 
inclusion criteria were hand-searched for additional relevant studies. Search terms 
involved combining key word searches for perceived food intolerance using various 
synonyms, combinations, operators, truncations, wild cards and limiters and terms were 
selected to identify studies on PFI and reduce capturing those on FA. For example, food 
intolerance was searched for by the key words (“food intolerance” or “food 
hypersensitiv* or “food sensitiv*) and perceived was searched for using the key words 
(“perceived” or “self-report*” or “self report*” or “subjective”). As this is an understudied 
area, the decision was made to only use these terms, and manually screen out studies 
that did not meet criteria. See Appendix I for further details of the PRISMA checklist, and 









 ‘a priori’ PICOS Screening Table 
 
2.2  Study Screening and Selection 
Articles identified in the initial search strategy were screened in two stages 
following inclusion and exclusion criteria, by the three independent reviewers (A.D., S.M 
and D.R.). When necessary, disagreements were resolved through a discussion with a 
fourth independent reviewer (E.G./L.H.). Identified papers were examined for duplicates 
and initially screened by title and abstract. The second stage involved reviewing full-text 
articles for relevance and inclusion using PICOS criteria and an a priori screening table 
(see Table 1). Where the full text was not available, attempts to contact study authors 
Inclusion Criteria 
PICOS inclusion criteria 
Exclusion Criteria 
PICOS exclusion criteria 
(i) Subject population included adults >18 who 
self-reported PFI. 
(ii) Any comparators to be included 
(iii)  Descriptive study designs (except those 
excluded) including case control, 
prospective, cohort, retrospective, and 
cross-sectional studies with n = >5 
participants. 
(iv)  Examined psychological, clinical and/or 
psychosocial factors associated with 
perceived food intolerance 
 
To guide the selection of appropriate studies, 
factors that were deemed relevant included;  
(i) Psychological factors including affect, CMD 
and/or distress, information relating to beliefs or 
cognitive patterns; personality traits; symptoms 
and symptom severity 
(ii) Clinical factors including self-reported and 
confirmed diagnoses 
(iii) Psychosocial factors including demographic 
and socioeconomic information 
(i) Caregivers; or children and adolescents under 
18 where data was not separated 
(ii) Medically diagnosed nut allergy and 
anaphylactic allergy 
(iii)  Individuals with a diagnosis of Coeliac Disease 
or Inflammatory Bowel Disease 
(iv) Focus on food additives such as sulphite, food 
colouring, or alcohol intolerance, as this was 
not the aim of the current review 
(v) Only included prevalence information (with no 
additional psychological, clinical or 
psychosocial information), or an outcome of 
PFI (including food/nutrient intake, dietary 
patterns or changes, diet adherence, 
pathophysiological changes, and impact on 
quality of life) 
(vi)  Any of the following study designs: 
intervention study, outcome study, 
randomised controlled trial, replication study, 
study abstract, single-N case study, letter, 
consensus statement, incomplete report, book 




were made. Inter-rater agreement was assessed using Cohen’s Kappa. At the abstract 
screening stage, Cohen’s Kappa was 0.78 between A.D. and S.M., and 0.82 between A.D. 
and D.R. At the full-text stage, Cohen’s Kappa was 0.80 between A.D. and S.M. and 0.76 
between A.D. and D.R.  
 
2.2.1 Inclusion Criteria 
Studies were included if they had (i) a subject population of adults >18 who self-
reported PFI, (ii) descriptive study designs including case control, prospective, cohort, 
retrospective, and cross-sectional studies with N = > 5 participants, (iii) any comparators, 
and (iv) examined psychological, clinical and/or psychosocial factors associated with PFI.  
To guide the selection of appropriate studies, factors that were deemed relevant 
included; (i) Psychological factors including affect, CMD and/or distress, information 
relating to beliefs or cognitive patterns; personality traits; symptoms and symptom 
severity (ii) Clinical factors including self-reported and confirmed diagnoses (iii) 
Psychosocial factors including demographic and socioeconomic information. 
 
2.2.2 Exclusion Criteria 
Studies were excluded if they had (i) a subject population including caregivers, 
children and/or adolescents <18 where data were not reported separately, individuals 
with medically diagnosed nut or anaphylactic allergy, Coeliac Disease or Inflammatory 
Bowel Disease, and/or a food additive or alcohol intolerance, (ii) study designs including 
intervention, outcome, replication, single-N case studies, randomised controlled trials, 
study abstracts, letters, consensus statements, incomplete reports, book chapters, theses 
and reviews; (iii) only included prevalence information (with no additional psychological, 
clinical or psychosocial information), or an outcome of PFI (including food/nutrient intake, 
dietary patterns or changes, diet adherence, pathophysiological changes, and impact on 





2.3 Data Extraction and Synthesis 
Information deemed relevant to the review question was extracted and tabulated 
by three reviewers (A.D., S.M. and D.R). Extracted data included publication data, country 
of origin, study design, recruitment method, sample characteristics, data analysis 
methodology, data collection methodology (including any outcome measures used), and 
main findings related to psychological variables, clinical variables, and psychosocial 
variables. The reporting of summary measures were not possible and a meta-analysis was 
not conducted due to the heterogeneity of data from included studies and broad research 
question. A narrative synthesis was conducted (Campbell et al., 2020), and data specific 
to psychological, clinical, and psychosocial factors were conceptually organised.   
 
2.4 Quality Assessment 
Methodological quality of each study included was assessed by three reviewers (A.D., 
S.M. and D.R) using adapted criteria from the Effective Public Health Practice Project 
(EPHPP) Quality Assessment Tool for Quantitative Studies ("Effective Public Health 
Practice Project," 1998a; "Effective Public Health Practice Project," 1998b). This 
instrument was developed in order to support the quality of systematic reviews and 
assesses the methodological quality of an article across eight areas of potential bias, 
including A) selection bias; B) study design; C) confounders; D) blinding; E) data collection 
method, F) withdrawals and dropouts G) intervention integrity and H) analysis. The EPHPP 
then rates the article as ‘strong’, ‘moderate’ or ‘weak’ on components A-F, which are used 
to determine the global rating.  The current review did not include criteria concerning 
blinding (D) or intervention integrity (G), as we did not include controlled trials or 
intervention studies. Each article included was rated on five areas of potential bias: 
selection bias; study design; confounders; data collection method, and withdrawals and 
dropouts (see Appendix III for the adapted EPHPP used in the current review). Scores from 
each section translate into an overall methodological quality score of ‘Strong’ (no ratings 
of ‘weak’), ‘Moderate’ (one rating of ‘weak’) or ‘Poor’ (two or more ratings of ‘weak’). 




D.R. regarding the global ratings of methodological quality. All discrepancies were 
resolved through discussion with a fourth independent reviewer (E.G./L.H.). 
 Results 
 
3.1 Results of the Search  
A total 2,627 articles were identified through the initial electronic database search. 
The hand-search yielded 3 additional articles, which were excluded. 683 duplicates were 
removed, and 1944 papers were screened. 145 papers were eligible for full-text review, 
of which 110 did not meet eligibility criteria. The most common reason for exclusion was 
incorrect target population, followed by type of publication (e.g. study design or 
publication such as conference abstract). 35 articles were included in the final review. 
Figure 1 presents the PRISMA flow diagram for the selection and inclusion process. 
 
3.2 Study Characteristics 
3.2.1 Overview of Studies 
The characteristics of included studies and their samples are presented in Table 2. Thirty-
five articles, including a total of 167,663 participants were eligible for inclusion. Sample 
sizes ranged from 43 (Rix, Pearson, & Bentley, 1984) to 64,316 participants (Jakobsen, 
Braaten, Obstfelder, & Abelsen, 2016)  and the median sample size was 427 (IQR = 129 - 
2251). Participants were recruited from 24 countries including Korea, Hungary, Sweden, 
Argentina, Netherlands, Norway, Mexico, Canada, Iceland, France, Australia, Italy, Turkey, 
Iran, Germany, United Kingdom, Finland, Japan, USA, Belgium, Switzerland, Ireland, Spain, 
and New Zealand. Most studies (83%) were cross-sectional (n = 29), with remaining 
studies of case-control (n = 5) or longitudinal (n = 1) designs. Statistical analyses were 
predominantly descriptive, inferential and bivariate, and few studies used multivariate 
analyses including regression and mediation analyses. Included studies were conducted 
within clinical (n = 15), community (n = 12), and population-based (n = 8) settings. Three 
studies investigated wheat and/or gluten intolerance (PFI-G) and five studies investigated 







Figure 1. PRISMA flow diagram (Moher et al., 2010) 
 
3.2.2 Sample Characteristics 
Sample characteristics are presented in Table 2. The age of participants ranged 
from 18 – 90, and the median age across studies is 40.3 (IQR = 35 – 47). Nine studies did 
not report sample age, of which three did not report sample characteristics (Barr, 2013; 
Gelincik et al., 2008; Jansen et al., 1994; Lee et al., 2019; Liden, Kristjnsson, Valtysdottir, 




& Ekerljung, 2015; Soost et al., 2009; Vierk, Koehler, Fein, & Street, 2007). There was a 
global trend of a high proportion of female participants, and the median of percentage of 
females is 68.5% (IQR= 55 – 79).  
Nine studies were national/population based. Seven studies were community-
based, of which three were comprised of populations from previously defined cohort 
studies (Jakobsen et al., 2016; Patelis et al., 2014; Woods, Abramson, Bailey, & Walters, 
2001). Fifteen studies were comprised of outpatients recruited from gastrointestinal, 
allergy, and medical outpatient departments, including patients with gastrointestinal 
conditions (n = 5), PFI (n = 8), Rheumatoid Arthritis (n = 1), and Chronic Fatigue (n = 1). 
 
3.2.3 PFI Characteristics: Prevalence, Offending Foods and Common Symptoms 
In population-based studies, prevalence ranged from 7.3% (PFI-G) (Golley, Corsini, 
Topping, Morell, & Mohr, 2015) to 9.5% (Gelincik et al., 2008). In a population study,  
Monsbakken et al. (2006) reported a PFI prevalence of 70% however, this study only 
included respondents who reported IBS with ‘alarm symptoms’, thus was not 
representative of the general population. In community studies, PFI prevalence ranged 
from 6.2% (PFI-G) (van Gils et al., 2016) to 51.2% (Elieson, Domotor, & Koteles, 2017). In 
clinical samples (excluding PFI outpatient samples), PFI was reported by 19% (Nybacka et 
al., 2018) to 84% (Bohn, Storsrud, Tornblom, Bengtsson, & Simren, 2013) of IBS 
outpatients, 13.5% of patients with Chronic Fatigue (Manu, Matthews, & Lane, 1993) and 
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BDI = Beck Depression Inventory; CIS  = Clinical Interview Schedule; CJSQ = Cooper's Job Stress Questionnaire; 
EPQ = Eysenck Personality Questionnaire; FFS = FibroFatigue Scale; HADS = Hospital Anxiety Depression 
Scale; HCAMQ = Holistic Complementary and Alternative Medicine Questionnaire; HSCL-10 = Hopkin Symptom 
Check List 10; IBS-SQ = IBS Symptom Questionnaire; IBS-SSS = IBS Severity Scoring System; K6 = Kessler 6-
item Scale; MADRS = Montgomery–Åsberg Depression Rating Scale; GHQ = General Health Questionnaire (28 
and 30); MHBS = Milk Health Beliefs Scale; MHW = Modern Health Worries; MINI = Mini International 
Neuropsychiatric Interview;  NEO = NEO Personality Inventory; NIMH-DIS = National Institute of Mental Health 
Diagnostic Interview Schedule; PHQ-15 = Patient Health Questionnaire; SCL-90 = Symptom Checklist 90; 
SHAI  = Short Health Anxiety Inventory; SHC = Subjective Health Complaints Inventory; SRT = Symptom Rating 
Test; SSAS = Somatosensory Amplification Scale; UCL = Utretcht Coping List; VSI = Visceral Sensitivity Index; WI 
= Whitely Index; WMH-CIDI = World Mental Health Composite International Diagnostic Interview;  
 
Legend: N/S = no diagnostic status; NR = not reported; PFI = Perceived Food Intolerance; IBS = Irritable 
Bowel Syndrome; GI = gastrointestinal; CFS = Chronic Fatigue Syndrome 
 
Commonly reported offending foods were wheat, gluten, dairy (including milk and 
cheese), fruits, vegetables (including legumes and cruciferous vegetables), and eggs. 
Individuals with PFI often reported symptoms in response to more than one food (Bohn 
et al., 2013; Elieson et al., 2017; Lee et al., 2019; Lind et al., 2005; Lind, Olafsson, Hjelland, 
Berstad, & Lied, 2008; Monsbakken et al., 2006; Nybacka et al., 2018), and one study 
indicated that women reported more food items than men (Bohn et al., 2013). The most 
commonly reported GI symptoms were bloating, flatulence, abdominal discomfort, 
abdominal pain, nausea, altered bowel habits (constipation and/or diarrhea). The most 
commonly reported extraintestinal symptoms were tiredness, headache, joint/muscle 





3.3 Methodological Quality Assessment 
Results from the quality assessment are presented in Table 3 and Figure 2. Table 3 
depicts individuals quality ratings for each included article, and Figure 2 demonstrates 
percentage proportions of component ratings and global rating across all articles. Overall, 
11.4% (n = 4) of articles received a global rating of ‘Strong’, 40% (n = 14) of ‘Moderate’, 
and 48.6% of ‘Weak’ (n = 17).  
According to EPHPP criteria, most studies were subject to selection bias, largely due 
to consecutive and convenience sampling methods by means of self-selection or clinic 
referrals, and thus might not be representative of the general population. Eight studies 
used probability sampling methods including random digit dialing and postal 
questionnaires (Barr, 2013; Gelincik et al., 2008; Golley et al., 2015; Monsbakken et al., 
2006; Patten & Williams, 2007; Saberi-Firoozi et al., 2007; Soost et al., 2009; Vierk et al., 
2007), however this resulted in lower response rates, contributing to ‘moderate’ and 
‘weak’ ratings. Study design was a primary area of bias in 29 studies, who received ratings 
of ‘weak’ due to their cross-sectional design, which does not allow for variables of interest 
to be measured over time, and many did not account for confounding or extraneous 
variables that may have influenced psychological or clinical correlates. Six articles 
received a rating of ‘moderate’ on study design; five employed a case-control design with 
age- and sex-matched controls (Lillestøl et al., 2010; Lind et al., 2005; Lind, Lillestol, et al., 
2010; Lind et al., 2008; Manu et al., 1993) which can reduce the chance that findings were 
due to uncontrolled variables, and one employed a longitudinal design (Patelis et al., 
2014).  Sixteen studies used known reliable and valid measures, though most validated 
measures used were self-report, which may be prone to biases in reporting due to their 
subjective nature. As most studies were one-time survey studies, EPHPP criteria indicates 
that the withdrawal and dropout component is not applicable for these studies and was 
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Barr, S. I. (2013) - - X +  X - 
Berstad, A., et al. (2012) + - X +  X + 
Bohn, L., et al. (2013) + - X ++  X + 
Cabrera-Chavez, F., et al. (2017) - - X + X - 
Dainese, R., et al. (2014) + - X ++  X + 
Elieson, L. M., et al. (2017) - - - -  X - 
Gelincik, A., et al. (2008) +  - X +  X + 
Golley, S., et al. (2015) - - X -  X - 
Hidese, S., et al. (2019)  - - - ++ X - 
Jakobsen, M. D., et al. (2016) + - X + X + 
Jansen, J. J. N., et al. (1994) + - X - X - 
Knibb, R. C., et al. (1999) - - X ++ X - 
Lee, H. J., et al. (2019) + - - ++ X - 
Liden, M., et al. (2010)  - - - - X - 
Lillestol, K., et al. (2010)  + + ++ ++ X ++ 
Lind, R., et al. (2005) + + ++ +  X ++ 
Lind, R., et al. (2008)  + + ++ -  X + 
Lind, R., Lied, G., et al. (2010) + - X ++ X + 
Lind, R., Lillestol, K. et al. (2010) + + ++ - X + 
Manu, P., et al. (1993) + + ++ ++ X ++ 
Monsbakken, K. W., et al. (2006) + - X ++ X + 
Nybacka, S., et al. (2018) + - - ++  X - 
Parker, S. L., et al. (1990) + - X - X - 
Patelis, A., et al. (2014) + + X +  + ++ 
Patten, S. and Williams, J. (2007) + - X ++ X + 
Puente-Fernandez, C., et al. 
(2016) 
- - X ++ X - 
Rentzos, G., et al. (2015) + - X - X - 
Rix, K. J., et al. (1984)  + - X ++  X + 
Saberi-Firoozi, M., et al. (2007)  - - X -  X - 
Soost, S., et al. (2009) -  - X +  X - 
Tomba, C., et al. (2012) + - ++ ++  X + 
van Gils, T., et al. (2016) - - X +  X - 
Vesa, T. H., et al. (1998)  + - X ++  X + 
Vierk, K. A., et al. (2007) - - X ++ X - 
Woods, R. K., et al. (2001) + - X +  X + 
       




 Figure 2. Adapted EPHPP quality assessment rating across studies 
 
3.4 Identification and Measurement of Psychological Variables 
Psychological variables were identified and grouped thematically through 
discussion between A.D., E.G., and L.H. Fifteen variables were identified and were 
categorised into five groups; (a) Common Mental Disorders (CMD) and Distress: anxiety; 
health anxiety; symptom anxiety; depression; psychological distress in sixteen studies, (b) 
Personality: neuroticism, extraversion, psychoticism in three studies (c) Somatisation: 
somatic complaints, symptom severity in twelve studies, (d) Stress and Coping: stress, 
coping in one study (e) Beliefs and Cognitions: health-related; food-related; healthcare-
related in five studies. The findings for each variable are discussed below under relevant 
subheadings and are summarised in detail in Appendix IV.  
Psychological correlates were measured using a range of validated self-report 
measures and diagnostic assessments, which are described in Table 2. The most 
frequently used self-report measures were the Hospital Anxiety and Depression scale 
(HADS; n = 5) (Zigmond & Snaith, 1983), the IBS Severity Scoring System (IBS-SSS; n = 5 )  
(Francis, Morris, & Whorwell, 1997), and the Subjective Health Complaints Inventory 























EPHPP Quality Assessment Across Included Studies (n = 35)




questions relating to medical history in purpose-created questionnaires (Golley et al., 
2015; Jakobsen et al., 2016; van Gils et al., 2016). Measures used were primarily self-
report, however, five studies (Berstad, Undseth, Lind, & Valeur, 2012; Lillestøl et al., 2010; 
Manu et al., 1993; Patten & Williams, 2007; Rix et al., 1984) used interviewer-conducted 
diagnostic instruments including the Mini-International Neuropsychiatric Interview 
(MINI) (Sheehan et al., 1998), National Institute of Mental Health Diagnostic Interview 
Schedule (NIMH-DIS) (Robins, Helzer, Croughan, & Ratcliff, 1981), the World Mental 
Health Composite International Diagnostic Interview (WMH-CIDI) (Kessler & Üstün, 2004), 
and the Clinical Interview Schedule  (CIS) (Goldberg, Cooper, Eastwood, Kedward, & 
Shepherd, 1970).  
 
3.5 Psychological Correlates 
Twenty-two studies investigated psychological correlates of PFI (17/22 cross-
sectional and 5/22 case-control), summarised under the five psychological variables, CMD 
and Distress, Personality, Somatisation, Stress and Coping, and Beliefs and Cognitions. See 
Table 4 for a plot summary of statistical results at the bivariate and multivariate level, and 
Appendix V for a summary chart of methodological quality rating of studies which 
included psychological factors.  
3.5.1 Common Mental Disorders and Distress 
Sixteen studies investigated CMD and Distress (14/16 cross-sectional, 2/16 case-
control) in PFI under five variables; anxiety (n = 11; 9/11 cross-sectional, 2/11 case-
control), health anxiety (n = 2 cross-sectional), symptom anxiety (n = 3 cross-sectional), 
depression (n = 12; 10/12 cross-sectional, 2/12 case-control), and distress (n = 6; 5/6 
cross-sectional, 1/6 case-control).  
3.5.1.1 Anxiety 
Eleven studies examined anxiety and PFI, using a range of measures to gauge 
reported anxiety. Six studies used validated self-report measures, four studies used 
diagnostic interviews to assess the incidence of reported anxiety, and one study relied on 




design, whereby individuals with PFI were compared against a matched control group. 
Only four studies conducted multivariate analyses, which would allow one to look at 
contributing factors to PFI. Results were inconsistent. Six studies reported significant 
findings, and five studies did not determine significantly increased anxiety in PFI (Bohn et 
al., 2013; Lind, Lied, et al., 2010; Manu et al., 1993; Rix et al., 1984; Tomba, Baldassarri, 
Coletta, Cesana, & Basilisco, 2012).  
Two studies established an increased prevalence of reported anxiety in PFI (Patten 
& Williams, 2007; van Gils et al., 2016). Patten and Williams (2007) assessed prevalence 
in the Canadian population using the WMH-CIDI, drawing on a large sample (n = 36,984), 
to establish increased incidence of social phobia in individuals with PFI. However, 
confidence intervals for respondents with and without PFI overlap, therefore the 
significance of this finding is mixed.  van Gils et al. (2016) determined individuals with PFI 
were at increased odds of reporting anxiety, however, this community study relied on 
self-reported medical history. Lillestøl et al. (2010) additionally reported 34% of PFI 
outpatients met criteria for an anxiety disorder on the MINI, however, the proportion of 
matched controls who met criteria was not reported, and it is difficult to assess the 
significance of this finding.  
Four studies determined significantly increased anxiety on self-report measures 
in PFI compared to those without PFI (Dainese et al., 2014; Knibb et al., 1999; Lillestøl et 
al., 2010; Nybacka et al., 2018), and two additionally found women with PFI reported 
higher levels of anxiety than men (Knibb et al., 1999; Lillestøl et al., 2010). Of note, mean 
scores were below clinical cut-off in two of the studies (Lillestøl et al., 2010; Nybacka et 
al., 2018) and Lillestøl et al. (2010) did not determine group differences in case-level 
anxiety. Dainese et al. (2014) concluded HADS-anxiety scores were significantly increased 
and above clinical threshold in PFI-L, however, following logistic regression, significant 
findings were not retained.  
In summary, the evidence is inconsistent. There is some evidence of a higher 
prevalence of anxiety in PFI, and four studies concluded anxiety was increased compared 




only study that reported clinically significant levels of anxiety did not retain a significant 
association between anxiety and PFI-L at multivariate analyses (Dainese et al., 2014).  
3.5.1.2 Health Anxiety 
Health anxiety refers to a conceptual fear of illness and disease that can contribute 
to hypervigilance and the misinterpretation of symptoms as an indication of a serious 
illness (Salkovskis, Rimes, Warwick, & Clark, 2002). Two studies measured health anxiety 
at a multivariate level.  
In a cross-sectional community study from Hungary, Elieson et al. (2017) 
determined health anxiety was significantly associated with reported PFI, and further 
determined health anxiety was a significant mediator of reported PFI (Elieson et al., 2017). 
Of note, the methodological quality of this study was poor; sample characteristics and the 
level of confounders controlled in analysis or criterion variables set were not adequately 
described. Conversely, a population-based study from Australia found no association 
between PFI-G and health anxiety (Golley et al., 2015). 
3.5.1.3 Symptom Anxiety 
GI symptom-specific anxiety (GSA) has been thought to contribute to distress and 
symptomatology in IBS patients (Labus, Mayer, Chang, Bolus, & Naliboff, 2007), a patient 
group that frequently reports PFI. The Visceral Sensitivity Index (VSI) (Labus et al., 2004) 
is used to measure GSA (Labus et al., 2004). A related construct of somatosensory 
amplification (SSA) refers to the tendency to be hypervigilant to the experience of somatic 
sensations and appraise them as aversive (Barsky, Goodson, Lane, & Cleary, 1988).   
Three studies explored symptom anxiety. Elieson et al. (2017) concluded SSA was 
significantly associated with PFI. A cross-sectional study by Lind, Lied, et al. (2010) 
explored whether symptom anxiety relates to symptom severity that individuals with PFI 
report. The authors determined higher scores on the VSI were reported by those who 
scored above threshold on the HADS-A, a measure of general anxiety. Conversely, Bohn 
et al. (2013) found no significant correlations between GSA and PFI. In summary, the 
evidence is inconsistent, and the role of symptom anxiety and visceral sensitivity should 





Twelve studies examined depression and PFI. Seven studies used validated self-
report measures, two studies used diagnostic interviews to assess the incidence of 
depression, and three studies relied on self-reported medical history.  Ten studies were 
cross-sectional, and two were case-control design with a matched control group. Four 
studies conducted multivariate analyses, and the remainder of the studies reported 
descriptive and inferential data. Results were inconsistent. Significant findings were 
reported in seven studies. Five did not report significant findings (Bohn et al., 2013; 
Lillestøl et al., 2010; Lind, Lied, et al., 2010; Manu et al., 1993; Tomba et al., 2012). 
Two population studies determined an increased prevalence of depression in PFI. 
Patten and Williams (2007) employed a structured psychiatric interview, however, Golley 
et al. (2015) relied on self-reported medical history, and so diagnoses cannot be 
confirmed. Two community-based studies reported increased odds of PFI amongst 
individuals with self-reported depression (Hidese, Nogawa, Saito, & Kunugi, 2019; 
Jakobsen et al., 2016), and of interest, Hidese et al. (2019) established severity of PFI was 
associated with depression. Both studies had very large samples (11,876 and 64,316 
respectively), however, they were cross-sectional designs and did not account for 
additional variables that could explain their findings. Three studies determined individuals 
with PFI self-reported significantly higher levels of depression than those without PFI 
(Dainese et al., 2014; Knibb et al., 1999; Nybacka et al., 2018), however, this was below 
clinical threshold and Dainese et al.'s (2014) findings were not retained at multivariate 
analysis. One study concluded women with PFI reported higher depression than men with 
PFI and male and female controls (Knibb et al., 1999).  
Overall, though significant findings were reported in seven studies, no high-quality 
studies support a role of depression in PFI. Studies that reported significantly increased 
scores on measures of self-reported depression were not able to establish this above a 
normal level, and one study that did determine between-group differences was not able 
to establish this at a multivariate level. Importantly, Patten and Williams (2007) provided 
population-based confirmation of an increased prevalence of depression in PFI, though 





Psychological distress was included as a variable when outcome measures that 
provided an overall measure of psychological distress without separating anxiety or 
depression were used. Six studies explored psychological distress. Five of the studies were 
cross-sectional, and one was case-control; all studies used validated self-report measures 
to assess distress. Multivariate analyses were conducted in two studies. Two studies did 
not report significant findings (Monsbakken et al., 2006; Tomba et al., 2012).   
Four studies reported increased distress in PFI (Hidese et al., 2019; Knibb et al., 
1999; Lillestøl et al., 2010; Rix et al., 1984), however Lillestøl et al. (2010) finding was 
significant in women only. Knibb et al. (1999) measured distress as a higher likelihood of 
meeting psychiatric caseness, and this was additionally found in the female-PFI subgroup. 
(Knibb et al., 1999; Lillestøl et al., 2010). However, Knibb et al. (1999) note that the 
percentage of women meeting case-level distress was not more than a reference group 
comprised of university and NHS staff. Of interest, Hidese et al. (2019) reported that 
distress increased with PFI severity (increased number of offending foods).  
Overall, there is limited evidence indicating increased psychological distress in PFI. 
Two studies found women report increased distress, and one study found severity of PFI 
may influence distress, however, further high-quality evidence is needed.  
 
3.5.2 Personality Traits 
Three studies, two of which were cross-sectional and one case-control, explored 
personality traits and PFI, of which one conducted multivariate analysis.  
Three studies investigated neuroticism and PFI, of which two reported levels of 
neuroticism were significantly higher in PFI, in both male and female subgroups (Knibb et 
al., 1999; Lillestøl et al., 2010), as compared to controls. At a multivariate level, Golley et 
al. (2015) did not determine any association between neuroticism and PFI. One study 
measured extraversion and psychoticism, and determined levels of extroversion were 
found to be significantly higher in women with PFI compared to women without PFI, and 
compared to men with PFI, and increased levels of psychoticism in men with PFI 




In summary, it is not possible to conclude personality traits influence PFI. Only one 
study investigated more than one personality trait, and though reported significant group 
differences, the methodological quality of this study is poor, and response rate was low. 
Further, the scores obtained by both the PFI and control groups were not significantly 
different from a norm group consisting of undergraduates and professionals.  
 
3.5.3 Somatisation 
Somatisation includes reported extraintestinal symptoms (pain, stiffness, 
headache, fatigue) and GI symptoms (bowel changes, gas, bloating, pain, discomfort), and 
can be measured by the reported frequency of somatic complaints and reported 
symptom severity in relation to PFI. Thirteen studies investigated somatisation in PFI 
(9/13 cross-sectional and 4/13 case-control), and ten demonstrated significant findings.  
3.5.3.1 Somatic Complaints 
Somatic complaints were measured by increased frequency of complaints, total 
number of symptoms reported, or scores on measures of somatisation. Eight studies 
measured somatic complaints, four were case-control, and four were cross-sectional. 
Two reported data at the multivariate level. 
At a bivariate level, five studies determined individuals with PFI reported more 
somatic complaints as compared to individuals with chronic fatigue (Manu et al., 1993), 
controls (Knibb et al., 1999; Lind et al., 2005; Lind, Lillestol, et al., 2010), and increased 
reporting in women (Knibb et al., 1999; Lind, Lied, et al., 2010). At a multivariate level, 
two studies demonstrated a significant association between somatic complaints and PFI 
(Jakobsen et al., 2016; Tomba et al., 2012). One study indicated that women report more 
GI symptoms than men but did not provide a test statistic (Lind et al., 2008).  
Of interest, three studies with PFI samples measured somatic complaints using 
the Subjective Health Complaints (SHC) inventory (Eriksen et al., 1999), concluding that 
individuals with PFI reported increased frequency of somatic complaints over a 30-day 
period than controls (Lind et al., 2005; Lind, Lillestol, et al., 2010), and that women 




studies, the most common complaints were bloating, diarrhoea, gas discomfort, stomach 
pain headache, tiredness, and back pain (Lind et al., 2005; Lind, Lied, et al., 2010; Lind, 
Lillestol, et al., 2010). In summary, individuals with PFI report more somatic complaints 
and report them more frequently than those without PFI.  
 
3.5.3.2 Symptom Severity 
Nine studies, seven cross-sectional and two case-control, investigated GI and 
extraintestinal symptom severity in individuals with PFI, of which seven reported 
significant findings.  
Five studies were comprised of IBS samples. At a multivariate level, one 
determined a significant association between GI symptom severity and PFI-L (Dainese et 
al., 2014). At a bivariate level, three studies determined that individuals with increased 
severity of PFI (who reported more offending foods) had increased GI symptom severity 
(Bohn et al., 2013; Lee et al., 2019; Nybacka et al., 2018) and extraintestinal symptom 
severity (Bohn et al., 2013). Nybacka et al. (2018) additionally concluded individuals with 
IBS and PFI report greater extraintestinal symptom severity, but not GI symptom severity, 
than those with IBS alone. One study did not report significant findings (Monsbakken et 
al., 2006). 
Four studies were comprised of PFI outpatients. Two case-control studies 
concluded that individuals with PFI report increased GI and extraintestinal symptom 
severity compared to controls (Lind et al., 2005; Lind, Lillestol, et al., 2010).  Two cross-
sectional studies were comprised of PFI outpatients only. Lind, Lied, et al. (2010) reported 
that symptom anxiety was significantly associated with GI symptom severity, but only 
explained 7% of the variance. The authors additionally concluded women had significantly 
increased extraintestinal symptom severity than men (Lind, Lied, et al., 2010). One study 
did not provide a test statistic, though reported 55% of PFI outpatients had severe GI 
symptoms (Berstad et al., 2012).  
Overall, evidence supports increased GI and extraintestinal symptom severity in 
PFI. Of note, five studies were comprised of IBS samples, and a large proportion of PFI 





3.5.4 Stress and Coping 
Stress impacts gastrointestinal motility and function and has been reported as a 
contributing factor in functional gastrointestinal disorders (FGID) (Mayer, 2000; Mayer, 
Naliboff, Chang, & Coutinho, 2001; Suarez, Mayer, Ehlert, & Nater, 2010). Stress and 
coping were investigated by one case-control study with PFI outpatients (Lind, Lillestol, et 
al., 2010). The authors investigated job stress and determined PFI outpatients reported 
significantly lower job stress than controls. The authors additionally concluded that both 
groups used similar coping strategies, with no significant group differences. Overall, 
limited evidence precludes drawing conclusions regarding the contributing effects of 
perceived stress and coping strategies, and additional high-quality research is required.  
 
3.5.5 Beliefs and Cognitions 
Beliefs and cognitions, including those towards health, food and healthcare were 
investigated in five studies (4/5 cross-sectional and 1/5 case control).  
3.5.5.1 Health Related 
Health-related beliefs were reported by three studies. At a multivariate level, no 
association between PFI and health worries was found (Elieson et al., 2017), on the 
Modern Health Worries Scale (Petrie et al., 2001). One study with a female-only sample 
reported a significant association between PFI and poor perceived health, though this was 
collected through reported history, and not measured on a standardised assessment 
(Jakobsen et al., 2016). At a bivariate level, Lind et al. (2005) found no group differences 
in sum scores of health-related worries between individuals with PFI, controls and the 
general population.  
3.5.5.2 Food Related  
Food related worries and beliefs were reported in three studies. At a multivariate 
level, (Elieson et al., 2017) reported no associated between food-related worries and PFI. 
At a bivariate level, Lind et al. (2005) determined PFI outpatients were significantly more 
worried about food additives and genetically modified food than controls, and Barr (2013) 




3.5.5.3  Healthcare Beliefs 
 Healthcare beliefs were assessed in two cross-sectional studies, which 
determined PFI and PFI-G were significantly associated with positive beliefs about 
complementary and alternative medicine (Elieson et al., 2017; Golley et al., 2015), and 
less receptiveness towards conventional medicine (Golley et al., 2015). 
Overall, research into the role of cognitions and beliefs to PFI is limited, and further 
evidence exploring PFI-related beliefs is required.   
 
3.6 Clinical Correlates 
Twenty-six articles (21/26 cross-sectional, 4/26 case control and 1/26 
longitudinal) reported clinical correlates including reported health conditions. The results 
are described below under relevant subheadings and are summarised in detail in 
Appendix VI. These were grouped into gastrointestinal (GI) (16 studies; 13/16 cross-
sectional, 3/16 case control), atopic (12 studies; 11/12 cross-sectional, 1/12 longitudinal), 
and long-term conditions (6 studies; 5/6 cross-sectional, 1/6 case control). GI correlates 
refer to diagnoses of IBS or described family histories. Atopy refers to a genetic or 
hereditary predisposition to develop allergic disease including allergies, dermatitis and 
asthma. Long-term conditions refer to chronic fatigue syndrome, rheumatoid arthritis, 
fibromyalgia and musculoskeletal pain, and other reported conditions. See Table 4 for a 
plot summary of statistical results at the bivariate and multivariate level, and Appendix 
VII for a summary chart of methodological quality rating of studies which included clinical 
factors. 
3.6.1.1 Gastrointestinal  
Sixteen articles provided evidence of GI correlates of PFI. In five studies with PFI-
only samples, 71% - 99% met criteria for IBS (Berstad et al., 2012; Lillestøl et al., 2010; 
Lind et al., 2005; Lind, Lied, et al., 2010; Lind, Lillestol, et al., 2010). Five studies recruited 
individuals with IBS (Bohn et al., 2013; Dainese et al., 2014; Lee et al., 2019; Monsbakken 
et al., 2006; Nybacka et al., 2018), of which PFI was reported in each study. Two of these 
studies additionally reported that participants with IBS had a significantly higher 




In community and population-based studies, four concluded reporting PFI 
increased the odds of IBS (Puente-Fernandez et al., 2016; Saberi-Firoozi et al., 2007; van 
Gils et al., 2016; Vesa, Seppo, Marteau, Sahi, & Korpela, 1998) at a multivariate level. 
Additionally, van Gils et al. (2016) determined individuals with PFI-G more often reported 
a family history of Coeliac Disease. At a bivariate level, two studies reported IBS was 
significantly more prevalent in PFI-G (Cabrera-Chavez et al., 2017; Golley et al., 2015). In 
summary, there is strong evidence for gastrointestinal clinical correlates of PFI.   
3.6.1.2 Atopy 
Twelve studies investigated atopy and PFI. Of note, three studies used previously-
defined samples investigating respiratory health (Patelis et al., 2014; Woods et al., 2001), 
and asthma (Rentzos et al., 2015), and one study used a pre-determined sample of adults 
with rheumatoid arthritis (Liden et al., 2010).  
Four studies with non-clinical samples reported significant findings at multivariate 
level. Allergy, dermatitis (Gelincik et al., 2008; Puente-Fernandez et al., 2016; Soost et al., 
2009), a family history of atopy (Gelincik et al., 2008; Puente-Fernandez et al., 2016), and 
asthma (Gelincik et al., 2008; Woods et al., 2001) were positive predictors of PFI, and 
atopy was found to be associated with PFI in a study spanning 15 countries (Woods et al., 
2001). Five studies reported bivariate significant findings. Prevalence of PFI was 
significantly higher in patients with IBS and atopy (Nybacka et al., 2018) and individuals 
with asthma (Rentzos et al., 2015). Allergies (Jansen et al., 1994; Liden et al., 2010; Patelis 
et al., 2014); skin-related manifestations (Liden et al., 2010; Patelis et al., 2014); asthma 
(Patelis et al., 2014; Rentzos et al., 2015); and family history of atopy (Jansen et al., 1994; 
Puente-Fernandez et al., 2016) were more often reported by those with PFI. Two studies 
with PFI outpatients did not report a test statistic; 38% reported at least one atopic 
disease (Berstad et al., 2012), and 30% reported a family history of atopy (Parker, Leznoff, 
Sussman, Tarlo, & Krondl, 1990). One study did not report significant findings (Dainese et 




3.6.1.3 Long-Term Conditions  
Six studies described long-term conditions. Four studies reported comorbidities 
described by individuals with PFI, and two articles investigated PFI in pre-determined 
clinical conditions including rheumatoid arthritis (Liden et al., 2010) and chronic fatigue 
(Manu et al., 1993), with 27% and 13.5% reporting PFI, respectively.  
At a multivariate level, in a female-only community sample, Jakobsen et al. (2016) 
determined that the odds of PFI increased with increasing comorbidities reported. The 
authors additionally concluded self-reported chronic fatigue, and hypothyroidism, and 
fibromyalgia were significantly associated with PFI (Jakobsen et al., 2016), yet conversely, 
van Gils et al. (2016) community sample found no association between these conditions 
and PFI-G (wheat and/or gluten intolerance). One study did not report a test statistic, 
though indicated chronic fatigue and fibromyalgia was reported by 85% and 71% of PFI 
outpatients, respectively (Berstad et al., 2012). Monsbakken et al. (2006) did not report 
any significant findings.  In summary, there is some evidence that individuals with PFI 
report comorbid long-term conditions. This was self-reported in three studies, with no 
medical evidence to confirm, and two studies used pre-defined clinical samples and are 
thus not representative of the general population. 
 
3.7 Psychosocial Correlates 
Twenty-four studies reported psychosocial correlates (23/24 cross-sectional and 
1/24 case-control, 1/25 longitudinal), including demographic factors of sex, age, and 
ethnicity, and socioeconomic factors of employment, education, and living. The results 
are described below and in Table 4, and summarised in detail in Appendix VIII. See Table 
4 for a plot summary of statistical results at the bivariate and multivariate level, and 
Appendix IX for a summary chart of methodological quality rating of studies which 
included psychosocial factors. 
3.7.1.1 Demographic Factors: Sex, Age and Ethnicity 
Twenty-one studies explored sex differences and PFI. Fifteen reported significant 
findings. Across included studies, a large proportion of the samples were female (see 




PFI (Golley et al., 2015; Puente-Fernandez et al., 2016; Saberi-Firoozi et al., 2007; Soost 
et al., 2009; van Gils et al., 2016; Vesa et al., 1998; Woods et al., 2001). Eight studies 
reported the prevalence of PFI was significantly higher in females (Barr, 2013; Cabrera-
Chavez et al., 2017; Golley et al., 2015; Hidese et al., 2019; Jansen et al., 1994; Patelis et 
al., 2014; Puente-Fernandez et al., 2016; Vierk et al., 2007), and one study found women 
reported more symptomatic foods than men (Bohn et al., 2013). One study described 
significant findings but did not describe these further (Elieson et al., 2017). Six studies did 
not report significant findings (Dainese et al., 2014; Gelincik et al., 2008; Lee et al., 2019; 
Monsbakken et al., 2006; Rix et al., 1984; Tomba et al., 2012). 
Nineteen cross-sectional studies explored age and PFI, eight of which determined 
age was a significant correlate of PFI. At a multivariate level, two studies reported younger 
age was a positive predictor of PFI (Gelincik et al., 2008; Jakobsen et al., 2016). At a 
bivariate level, four studies reported younger age was more common in PFI (Barr, 2013; 
Hidese et al., 2019; Soost et al., 2009; van Gils et al., 2016). However, Soost et al. (2009) 
did not report significance levels. Contrarily, Parker et al. (1990) reported PFI was 
associated with older age. One study reported significant findings but did not describe 
these further (Elieson et al., 2017). Eleven studies did not report significant findings (Bohn 
et al., 2013; Cabrera-Chavez et al., 2017; Dainese et al., 2014; Jansen et al., 1994; Lee et 
al., 2019; Monsbakken et al., 2006; Rix et al., 1984; Saberi-Firoozi et al., 2007; Vesa et al., 
1998; Vierk et al., 2007; Woods et al., 2001).  
Two cross-sectional studies included information regarding ethnicity. Barr (2013) 
found a higher proportion of non-Caucasians reported PFI-L, and Vierk et al. (2007) 
reported no findings. 
Overall, there is strong evidence for an association between PFI and female sex. 
There is some evidence that PFI is associated with a younger age, however, further 
exploration is required.  
3.7.1.2 Socioeconomic Factors: Employment, Education and Living Circumstances 
Six studies explored employment and PFI, and three reported significant findings. 
Not being in full-time employment was significantly associated with PFI in a female-only 




employed PFI outpatients reported more health complaints than matched-controls 
without PFI. Rix et al. (1984) reported a larger proportion of PFI outpatients were more 
likely employed in ‘professional’ careers. Three studies reported no significant findings 
(Jansen et al., 1994; Lee et al., 2019; Parker, Krondl, & Coleman, 1993).  
Seven studies investigated education, and three studies reported significant 
findings. A higher level of education was more often reported in those with PFI (Vierk et 
al., 2007), significantly associated with PFI (Jakobsen et al., 2016; Soost et al., 2009), and 
approached significance in one study (van Gils et al., 2016). Three studies did not report 
findings (Jansen et al., 1994; Lee et al., 2019; Parker et al., 1993). 
Three cross-sectional studies explored living circumstances with significant 
findings. Jakobsen et al. (2016) determined that not living with a partner, poor childhood 
economic living conditions, and living in an urban region predicted PFI. van Gils et al. 
(2016) additionally determined living in an urban region predicted PFI-G. Woods et al. 
(2001) study spanning 15 countries determined that living in Germany, Iceland, Sweden 
and Norway were all significant predictors of PFI.   
In summary, there is some evidence that a higher level of education is associated 
with PFI, and that not being in full-time employment is reported by some with PFI. 
Evidence surrounding living conditions and living in an urban region is limited and may be 






Table 4. Summary of Statistical Findings 
 Number of studies reporting significant findings (refer to Table 1 for reference numbers) 
  Cross-Sectional Case-Control Longitudinal 
Descriptive/Bivariate Multivariate Descriptive/Bivariate Multivariate Descriptive/Bivariate Multivariate 


















Anxiety (n = 11) 525,32,5,12, 22 43,18,28, 31  15 1 15 1 20       
Health Anx.  (n = 2)   1 6 1 8         
Symp. Anx. (n= 3)  1 3 2 6,18          
Depression (n = 12) 58,25,5,12,22 3 3, 18,31 2 9,10 15  2 15,20       
Distress (n = 6) 2 12,28 2 21, 31 1 9  1 15        
Personality Neuroticism (n = 3) 112 1 8   1 15        
 Extraversion (n= 1) 112            
 Psychoticism (n=1) 112            
Somat-
isation 
Somatic Comp.  (n =8)  212,18  210,31  3 16,19,20 1 17       
Symptom Severity 
 (n = 9) 
518,5,3,13,22 22*,21   2 16, 19        
Stress & 
Coping 
Stress (n = 1)  
Coping (n = 1) 
     1 19 
1 19 
      
Beliefs & 
Cognitions 
Health & Illness (n = 3)   110 1 6 1 16        
Food (n = 3) 11   1 6 1 16        



































 3 15,16,19        
Atopy 
 
 (n = 12) 522,27,11,14,26 35, 2*, 23* 435,26,7, 
30 
     124    
Long-Term 
Conditions 
 (n = 6)  210,32 12*, 
14**,21** 
110   1 21*       




   Cross-Sectional Case-Control Longitudinal 
   Descriptive/Bivariate Multivariate Descriptive/Bivariate Multivariate Descriptive/Bivariate Multivariate 

























     1 24    
Age (n = 19) 51,9,32,23, 6 12 3,4,5,11, 
13,21,28,29,33,
34, 35, 30* 
2 7, 10          
Ethnicity (n = 2) 1 1 1 34           
Socio- 
economic 
Employment (n = 6) 1 28 3 11,13,23 1 10  1 19        
Education (n = 7)  1 34  411,13,23, 32+ 2 10, 30          
Living Circumstances  
(n = 4) 
  1 10,32, 
35 
         
Legend: p < 0.05 = significant at the .05 level, NS = not significant, * = no test statistic used so cannot determine significance 
Reference numbering refers to numbering described in Table 1 
Note: Anxiety and Depression; Ref. 5 had significant findings at bivariate level and no significant findings at multivariate level 
** Long-term conditions; Refs 14** & 21** 100% of samples had Rheumatoid Arthritis and Chronic Fatigue respectively 















4.1 Summary of Findings 
The purpose of the current systematic review was to evaluate the literature for 
evidence of psychological, clinical and psychosocial factors that may be associated with 
reported PFI. Thirty-five studies that met inclusion criteria and described psychological (n 
= 22), clinical (n = 26), and psychosocial (n = 24) correlates of PFI were reviewed. 
Psychological correlates included fifteen psychological variables summarised under five 
groups; CMD and distress, personality, somatisation, stress and coping, and beliefs and 
cognitions. Clinical correlates were summarised under gastrointestinal, atopic and long-
term conditions. Psychosocial correlates were summarised under demographic and 
socioeconomic categories.  
Prevalence of PFI was reported by up to 9.5% in population studies, up to 51.2% 
in community studies, and up to 84% in clinical samples. Evidence consistently indicates 
PFI is more often reported in women as compared to men, and that PFI is associated with 
frequent reporting of GI and extraintestinal symptoms. Evidence found individuals with 
PFI often concurrently report GI and atopic conditions. Some evidence suggested 
increased levels of common mental disorders (CMD) and distress, though data were 
inconsistent, and often reported at a cross-sectional bivariate level, precluding causal 
inferences. Findings regarding age were mixed and sociodemographic data were 
infrequently collected.  
4.1.1 Summary of Findings: Psychological Correlates 
The evidence supports a significant association between somatisation and PFI. 
These individuals are more likely to report GI and extraintestinal complaints including 
bloating, headache, diarrhea, gas, discomfort and tiredness, and increased symptom 
severity as compared to controls and clinical samples. This suggests that common 
reactions experienced by those with PFI is consistent with symptoms described in non-




There is some evidence that individuals with PFI self-report elevated anxiety, 
depression, and distress compared to those without PFI, however, this was 
predominantly at a descriptive level by comparing mean scores on self-report measures. 
Exploring this further, it was evident that most of these scores fell below what would be 
considered clinical threshold, suggesting that case-level distress may not be a significant 
correlate of PFI. However, studies that measured affect only did so at one time-point, so 
it is not possible to know the direction of this relationship, if affect fluctuates over time, 
and what factors are important in contributing to affect. This demonstrates the need for 
future high-quality research using multivariate analyses and exploring affect at different 
time points to better understand its role in PFI. Further, prospective research would help 
identify if affect, thoughts or beliefs are associated with the onset of PFI, as this has not 
been established  
Findings relating to personality traits, stress and coping, and beliefs and cognitions 
were limited, as these variables were only explored in a small number of studies of poor 
and moderate quality, and it is difficult to draw conclusions regarding the importance of 
these factors in PFI  Research in PFI has not yet explored the specific beliefs or illness 
perceptions that individuals may hold about PFI, and further research should explore 
worries related to GI sensations (GSA). This would be of interest, as illness perceptions 
and GSA have been evidenced to contribute to distress IBS (Chilcot & Moss-Morris, 2013; 
De Gucht, 2015; Knowles et al., 2017; Labus et al., 2004; Labus et al., 2007; Mayer & 
Raybould, 1990; Rutter & Rutter, 2002), and have been demonstrated as a mechanism of 
change and improved outcome in psychological interventions for individuals with IBS 
(Chilcot & Moss-Morris, 2013; Garland et al., 2012; Wolitzky-Taylor, Craske, Labus, Mayer, 
& Naliboff, 2012). 
Few of the studies were methodologically strong. The strongest studies had a 
case-control design whereby outpatients were compared with matched controls, 
reducing confounding variables in analyses. However, results do not support causal 
inferences, without which it is not possible to identify modifiable targets to address in 




and CAM-related beliefs are infrequently assessed in the literature and were not 
measured in a way that allowed for directionality to be understood. Personality, 
specifically neuroticism, is a widely measured construct in relation to health-behaviours, 
but it’s specificity has been critiqued, and it has been suggested that it is most useful as a 
marker of risk of psychopathology (Ormel et al., 2013; Ormel, Rosmalen, & Farmer, 2004). 
The results from included studies were generally inconsistent, of poor methodological 
quality, and study designs employed do not allow causal inferences to be drawn. Further, 
results do not provide evidence of specific modifiable targets to address in intervention.   
If future work should wish to identify contributing factors that can be targeted in 
intervention, high-quality research is needed using multivariate analyses and conducted 
across multiple time points. Future research should explore factors that have been 
demonstrated to be important in IBS, including GSA and illness perceptions, as IBS and 
PFI have considerable characteristic overlap.  
4.1.2 Summary of Findings: Clinical Correlates 
Evidence demonstrates a strong relationship between IBS and PFI, possibly 
alluding to shared mechanisms in PFI and IBS. However, it is also possible that individuals 
with IBS may be more likely to attribute symptoms to PFI, or that GI symptom overlap 
between these two conditions mean that many individuals with PFI meet criteria for IBS. 
Evidence from multiple population-based studies demonstrated individuals with PFI 
reported comorbid atopic conditions including rhinitis, dermatitis/eczema and asthma. 
Scant evidence supports an increased prevalence of PFI in comorbid long-term conditions. 
The evidence does not support a better understanding of the relationship between 
clinical comorbidities and PFI, and whether this is related to stress, immune functioning, 
neuroendocrine pathways, or other additional mechanisms. Only four studies received a 
global rating of strong, and all studies were subject to selection bias, including self-
selection and purposive sampling methods. High-quality evidence elucidating the role of 
clinical comorbidities in PFI is required to understand if specific health comorbidities 
contribute to reporting PFI, or vice versa, and if so, the mechanism of this relationship. 
This is necessary in order to identify groups that are more likely to experience PFI, and 




4.1.3 Summary of Findings: Psychosocial Correlates 
The results provide consistent evidence for an increased prevalence of PFI in 
women. This finding is of interest, as there is a higher reported prevalence of IBS in 
women (Lovell & Ford, 2012a, 2012b; Sperber et al., 2017), demonstrating further 
similarities between these two conditions. However, this only demonstrates incidence of 
reporting IBS and PFI, and in light of shortcomings with current evidence, it is not possible 
to conclude if these represent similar yet separate conditions that women more often 
report, if PFI is a manifestation of IBS, or if IBS mediates PFI. Research in PFI has not 
rigorously examined mechanisms posited to underlie IBS, though this could be done in 
the future with a sample of adults with PFI-only, IBS-only, PFI+IBS, and controls. 
Some studies demonstrated an association between PFI and younger age; a higher 
level of education; and living in an urban region, though evidence was limited. Only one 
study explored early living conditions and demonstrated a relationship between poor 
childhood economic conditions and PFI. Early adverse experiences are an established 
correlate of IBS (Videlock et al., 2009). There are characteristic similarities between PFI 
and IBS, though drawing conclusions about any further likeness between these conditions 
is not yet supported by high-quality research. It is possible that early adverse experiences 
may be a factor associated with PFI, though prospective research is required. 
A significant proportion of studies were methodologically moderate and poor, and 
the only study to receive a global rating of strong was a longitudinal study that only 
reported on sex differences as a psychosocial correlate. The results indicate psychosocial 
factors are infrequently measured and high-quality research is needed in order to better 
understand psychosocial correlates of PFI, as this can help to provide a better 
understanding of common factors in PFI, and can identify potential factors that may be 
associated with risk of reporting PFI  
 
4.2 Implications for Future Research and Clinical Practice 
The findings of the current review provide evidence that further high-quality 
research with individuals with PFI is necessary. To better understand factors involved in 




in individuals both with and without PFI at baseline is needed. It would be important to 
assess the presence of IBS and other existing conditions (to separate data for individuals 
with IBS and other conditions to reduce confounding effects), and measure psychological 
factors known to contribute to IBS including perceived stress, GSA and illness perceptions, 
and a defined set of psychosocial predictors that have been demonstrated to contribute 
to the aetiology and maintenance of IBS including early adverse events and life stressors 
(Videlock et al., 2009; White et al., 2010; Whitehead et al., 2002).  
High-quality evidence of correlates that perpetuate PFI can inform a 
biopsychosocial model and future psychological interventions to address modifiable 
factors that influence illness and symptom attributions, unhelpful behaviours such as 
avoidance, increased vigilance towards visceral sensations, and perceived stress and 
related distress. The aim would be to improve outcome and QoL for the individual and to 
help to manage symptoms and the related thoughts and emotions experienced in the 
context of PFI, as these may contribute to avoidance behaviours. Furthermore, if 
individuals feel better able to manage PFI and its sequelae, this may contribute to fewer 
visits to healthcare providers, reduced economic burden, and potentially increased self-
efficacy, which is integral to self-management of health conditions (Pimm & Weinman, 
1998; Schwarzer & Fuchs, 1996). An intervention could include components of 
psychoeducation, as well as both cognitive and behaviour-based strategies, which have 
been implicated in successful interventions in IBS (Chilcot & Moss-Morris, 2013; Garland 
et al., 2012; Hunt, Moshier, & Milonova, 2009; Wolitzky-Taylor et al., 2012). Further, 
promoting awareness of the various contributors and correlates of PFI may help inform a 
physician’s response to food intolerance in primary care and may shape the language 
used to describe reasons for why an individual can experience such distressing symptoms.  
Skepticism about the existence of PFI can contribute to practitioners perceptions of 
patients (Nelson & Ogden, 2008), and differing perceptions about the severity and impact 
of the condition between medical professionals and individuals with FGID have been 
reported (Dalton, Drossman, Hathaway, & Bangdiwala, 2004). Communication and the 




(Oates, Weston, & Jordan, 2000; Stewart et al., 1999). In IBS, communication has been 
demonstrated to contribute to the patients experience (Halpert & Godena, 2011), and 
the doctor-patient relationship  contributes to an individual’s understanding of their IBS, 
which is associated with improved QoL and acceptance (Hulme, Chilcot, & Smith, 2018), 
and may influence the experience of PFI and related outcome.  This has not been explored 
in PFI but might be an important consideration in understanding factors that may 
contribute to outcome.  
4.3 Strengths and Limitations 
Significant effort was made to improve the reliability of the current review. The 
author, in addition to a second and third reviewer, screened the titles and abstracts of all 
studies, and assessed relevant full text of articles against inclusion and exclusion criteria. 
Further, data extraction and quality assessment of all included studies was conducted 
independently by the author, and the second and third reviewer, to reduce bias and 
enhance rigor. Methodological quality was assessed with an adapted EPHPP, however, a 
tool designed for cross-sectional studies may have been more appropriate given the 
significant proportion of cross-sectional studies included in the review. However, quality 
assessment tools for cross-sectional studies provide an appraisal only, such as the AXIS 
tool (Downes, Brennan, Williams, & Dean, 2016), without an overall rating of study 
quality. Further, the Newcastle-Ottawa Scale (NOS) (Wells et al., 2015) has been adapted 
for use in cross-sectional studies, however a recently published review assessing the AXIS 
and NOS demonstrated poor to moderate reliability for these tools (Moskalewicz & 
Oremus, 2019). It is possible that the use of either the AXIS or NOS may have contributed 
to a stronger quality appraisal, but this might not have reflected evident methodological 
issues described in the included papers.  Finally, findings clearly demonstrate the need 
for data beyond what cross-sectional studies provide and exploring PFI across multiple 
time points would provide a more accurate representation of factors associated with PFI.  
The results of the current review are limited by the quality of included studies, 
which were largely moderate and poor. Only one study included data collected at multiple 




conclusions to be drawn regarding the nature or direction of correlates of PFI. Only a small 
number of psychological variables apart from CMD and distress have been investigated, 
and these were not studied in a way that advances a potential model of PFI, or related 
evidence. There is no high-quality research studying factors that are hypothesised 
contribute to IBS including illness perceptions, perceived stress, or GSA. Further, factors 
evidenced in influencing the onset of IBS including gut infection and early life events have 
not been fully explored in PFI, and given some reported similarities between IBS and PFI, 
it is possible that there are aetiological factors important in PFI that have already been 
established in IBS. Only one study was retrieved in the search exploring PFI following a 
giardiasis outbreak (Litleskare et al., 2015), however, it did not meet age inclusion criteria, 
as individuals under the age of 18 were included and data were not separated. Though 
most studies reported sex and age characteristics, ethnicity and socioeconomic data were 
rarely collected, therefore it is difficult to understand their role in PFI. Finally, additional 
factors that contribute to adverse food reactions not accounted for in this review may 
influence PFI, such as food aversions or food poisoning. 
4.4 Conclusions 
This is the first systematic review in PFI to the authors’ knowledge, and provides an 
overview of psychological, clinical and psychosocial correlates reported in PFI. Prevalence 
of PFI was reported by up to 9.5% in population studies, up to 51.2% in community 
studies, and up to 84% in clinical samples. The findings suggest PFI is associated with 
female sex, and that those with PFI report more frequent and severe GI and 
extraintestinal symptoms than those without PFI. There is some cross-sectional evidence 
that CMD and distress are increased in PFI, though not at clinical threshold, and generally 
not of high-quality. The findings of the current review indicate similarities with IBS, which 
should be explored further. These findings have implications for further research which 
will allow for a better understanding of PFI and may inform future psychological models 
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page #  
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Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
Title page 
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Structured 
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background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration 
number.  
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INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what 
is already known.  
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Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
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METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 




6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 




7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
Appendix 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 




10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
7 
Data items  11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
8 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 





information is to be used in any data synthesis.  
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 




14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
9 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 




16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
9 
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 




18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
10 + Figure 
1 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  





20 For all outcomes considered (benefits or harms), present, 
for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  




21 Present results of each meta-analysis done, including 




Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 




23 Give results of additional analyses, if done (e.g., sensitivity 





24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy 
makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
18 -  
Conclusions  26 Provide a general interpretation of the results in the 




Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 






Appendix II: Search Strategy 
 
MEDLINE 
1. food intolerance.mp. or exp Food Hypersensitivity/ or exp Food Intolerance/  
2. (food hypersensitivit* or food sensitivit*).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, floating sub-heading word, keyword 
heading word, organism supplementary concept word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier, synonyms]  
3. 1 or 2  
4. (perceived or self-report* or self report* or subjective).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, floating sub-heading word, 
keyword heading word, organism supplementary concept word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms]  
5. 3 and 4  
 
PsycINFO 
1. (food intolerance or food hypersensitivit* or food sensitivit*).mp. [mp=title, 




1. (food intolerance or food hypersensitivit* or food sensitivit*).mp. [mp=title, 
abstract, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword, floating subheading word, candidate term 
word]  
2. nutritional intolerance.mp. or exp nutritional intolerance/  
3. 1 or 2  
4. (perceived or self-report* or self report* or subjective).mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword, floating subheading word, candidate term word]  
5. 3 and 4  
 
Global Health 
1. (food intolerance or food hypersensitivit* or food sensitivit*).mp. [mp=abstract, 
title, original title, broad terms, heading words, identifiers, cabicodes]  
2. (perceived or self-report* or self report* or subjective).mp. [mp=abstract, title, 
original title, broad terms, heading words, identifiers, cabicodes]  
3. 1 and 2 
Web of Science 
TI=(food intolerance* OR food sensitivit* OR food hypersensitivit*) AND TI=(perceived OR 
subjective OR self-report*) 
 
Scopus 
( TITLE-ABS-KEY ( food  AND intolerance  OR  food  AND hypersensitivit*  OR  food  AND 
sensitivit* )  AND  TITLE-ABS-KEY ( perceived  OR  self-report*  OR  self  AND report*  OR  





Appendix III: Adapted EPHPP 
Adapted EPHPP, modified for suitability for cross-sectional and case-control studies with no 
intervention.  
A) Selection Bias 
Q1- Are the individuals selected to participate in the study likely to be representative of the target 
population? 
1. Very likely  
2. Somewhat likely 
3. Not likely 
4. Can't tell 
Q2 – What percentage of selected individuals agreed to participate? 
1. 80 – 100% agreement 
2. 60 – 79% agreement  
3. Less than 60% agreement 
4. Not applicable 
5. Can’t tell 
Rate this section Strong Moderate Weak 
See dictionary 1 2 3 
 
B) Study Design 
1.  Randomised controlled trial 
2. Controlled clinical trial 
3. Cohort analytic (two group pre +post) 
4. Case-control 
5. Cohort (one group pre + post) 
6. Interrupted time series 
7. Other (specify) 
8. Can't tell 
Rate this section Strong Moderate Weak 
See dictionary 1 2 3 
 
C) Confounders 
Q1 – Were there important differences between groups? 
1. Yes 
2. No 
3. Can’t tell 
The following are examples of confounders; race, sex, marital status/family, age, SES (income or class), 
education, health status 





1.  80-90% 
2. 60-79%  
3. Less than 60% 
4. Can’t tell 
Rate this section Strong Moderate Weak 
See dictionary 1 2 3 
 
D) Data Collection Method 
Q1 – Were data collection tools shown to be valid? 
1. Yes 
2. No 
3. Can’t tell 
 
Q2- Were data collection tools shown to be reliable? 
1. Yes 
2. No 
3. Can’t tell 
 
Rate this section Strong Moderate Weak 
See dictionary 1 2 3 
 
E) Withdrawals and Drop Outs 
Q1 -   For longitudinal studies, were withdrawals and drop-outs in terms of numbers and/or reasons? 
1. Yes 
2. No  
3. Can’t tell 
4. Not applicable (one-time survey) 
 




3. Less than 60% 
4. Can’t tell 
4. Not applicable 
 
Rate this section Strong Moderate Weak 





1 Strong (no weak ratings) 
2 Moderate (one weak rating) 




Appendix IV: Psychological correlates summary of findings 
 
Author (year)  Variable 
(Measure) 
CMD and Distress Findings 
 
Bohn, L.,  









Anxiety: PFI (as defined as food-related GI symptoms) not significantly correlated with anxiety (r = -0.11; p = 0.13) 
Depression: PFI (as defined as food-related GI symptoms) not significantly correlated with depression (r = -0.05; p = 0.50)  
Symptom Anxiety:  No significant correlations between food-related GI symptoms and symptom specific anxiety (r = 0.04; p = 
0.55) 




 Depression  
(BDI) 
Anxiety: PFI-L had higher median HADS-A scores (Mdn = 13[IQR = 8–14] vs. Mdn =  8[IQR = 5–12], p < 0.01). No significant 
association found (OR = 1.270, p = 0.29).  
Depression: PFI-L (vs. non) had higher median BDI scores (Mdn = 8 [IQR = 5–10] vs. Mdn = 3[IQR = 2–7], p < 0.01). No association 
found (OR = 1.138, p = 0.32).   
 
Elieson, L.M.,  
et al. (2017)  





Health Anxiety: PFI associated with health anxiety (OR = 1.103, p < 0.001), and health anxiety is a significant mediator of PFI 
(b = 1.002, p <0.001). PFI (vs non-PFI) had higher SHAI scores (M = 33.98(SD = 5.521) vs. M = 29.79(SD = 7.812)), no p value. 
Symptom Anxiety: PFI associated with somatosensory amplification (OR = 1.041, p = 0.028). Following mediation analysis, 
mediated by health anxiety (b = -0.0040 ± 0.214, NS).  PFI (M = 28.05, SD = 6.768) had higher mean SSAS scores than non-PFI 





Golley, S., et al. (2015)  Health Anxiety (WI) 
Depression  
(Medical History) 
Health Anxiety: No significant associations (OR = 1.18; 95% CI [0.88-1.58], p = 0.26). 
Depression: PFI-G (vs. non-PFI-G) more likely to report history of depression (32.9% vs. 19.5%, χ2 (1)= 8.47, p < 0.004). 
 






Depression:  PFI significant and positive predictor for a self-reported lifetime history of clinical depression (OR = 1.46, 95% CI 
[1.13–1.88], p = 0.0037,).  Individuals with 2 (OR = 1.75), 3 (OR = 2.02), and 4 (OR = 2.27) allergens were significantly more 
common in the depression group (p < 0.001). 
Distress: PFI (vs non-PFI) associated with severe psychological distress (K6 ≥ 13) (OR = 1.32, p < 0.001).   
Jakobsen, M.D., et al. 

















Anxiety: Higher scores in PFI sample t(533)=3.1, p < 0.002, PFI women vs. non-PFI women, (t(116)=3.2, p < 0.002), and PFI 
women vs. PFI men ( t(134)=3.3, p < 0.001).  
Depression: Higher scores in all PFI (t(187)52.53, p < 0.01), PFI women vs. non-PFI women, (t(106)=2.6, p < 0.02), and PFI 
women vs. PFI men (t(136)=2.1, p < 0.04).  
Distress: PFI associated with “at-risk for diagnosis of minor psychiatric disorder”, x2(3)=8.7, p < 0.03. PFI women (vs. PFI men) 
scored significantly higher for psychiatric caseness, t(136)=2.40, p < 0.02.  










Anxiety: 34.2% PFI met anxiety disorder criteria on MINI (most frequently, GAD and panic disorder).  PFI women scored 
significantly higher than controls on HADS-A (M =5.3, SD = 3.7 vs. M = 4.0, SD = 3.3 p =0.013) and HAD-Total (p = 0.021). Case-
level HADS-A (≥8) found in 23.5% of PFI vs. 12.5% controls (p > 0.05; NS). 
Depression: 15.8% PFI met depressive disorder criteria on MINI; lower prevalence in MADRS findings (8%). No significant 
difference in HADS-D scores (M = 2.6, SD = 2.3 vs. M = 2.1, SD = 3.0, p = 0.168).   Case-level HADS-D in 2.5% PFI vs. 8.3% (NS). 
Distress: 56.6% PFI met psychiatric disorder criteria on MINI.  PFI associated with higher GHQ-30 scores (p = 0.022) in women 
only. 










Anxiety: Mean HADS-A score (M = 4.9, SD = 3.5). Case-level HADS-A (≥8) found in 24%.  Gender or symptom severity (SHC & 
IBS-SQ) not associated.   
Depression: Mean HADS-D score (M = 4.6, SD = 2.4). Case-level HADS-D (≥8) found in 14%.  Gender or symptom severity (SHC 
& IBS-SQ) not associated.  
Symptom Anxiety: Symptom anxiety and HAD-A significantly correlated (r = 0.48, p < 0.0001).  Higher VSI scores found in 
individuals with HADS-A score ≥8 (p = 0.0004), and IBS-SQ score ≥25 (p= 0.001). Symptom anxiety was a significant predictor 
of GI symptom severity (IBS-SQ) (β = 0.186; p = 0.02).    






Anxiety: Anxiety disorder prevalence similar between groups (11.1% vs. 14.8%). 
Depression:  Prevalence of depressive disorders similar between groups (66.6% vs. 62.9%).  No significant differences in 







Monsbakken, K. W., et 
al. (2006)  
Distress  
(HSCL-10) 
Distress: No significant differences in HSCL-10 scores between PFI (M = 1.61, SD = 0.55) and non-PFI (M = 1.52, SD = 0.30), p 
= 0.35. No significant correlation between PFI and distress (rs = 0.04, p = 0.73).  
Nybacka, S.,  





Anxiety:  PFI scored significantly higher than non-PFI (M =  9.2 vs 7.5 p = 0.029). 
Depression:  PFI scored significantly higher than non-PFI (M = 5.6 vs 4.5 p = 0.049).  






Anxiety: Significant differences in social phobia prevalence [95% CI] in adults >45 with PFI (3.5% [2.3-4.7]) vs. non-PFI (1.8% 
[1.5-2.2]), p < 0.05.  Of entire social phobia group (all ages) 14.5% [9.7-19.4] were PFI adults >45, p < 0.05. Panic disorder NS.  
Depression:  Significant differences in MDD prevalence [95% CI] in adults >45 with PFI (5.7% [4.2-7.2]) vs. non-PFI (3.0% [2.6-





Rix, K.J.,  






Anxiety:  Psychiatry outpatients had higher mean scores on CIS anxiety (M = 2.05 vs. M = 1.89, no SD) and anxious manifest 
abnormalities (M = 0.17 vs. M = 0.9, no SD) than PFI outpatients (p < 0.05) 
Distress:  Mean CIS scores for PFI (M = 20.5, Range:10-36) significantly higher than dFA (M = 5, Range: 2-8), p < 0.01, but not 
significantly different than psychiatry outpatients (M = 21.4, no SD), p >0.05. No significant findings on SRT; psychological 
changes were not induced by food in PFI outpatients. No significant differences on psychiatric diagnosis, personal/family 
history of psychiatric disorder, or number who had seen a psychiatrist.  







Anxiety: PFI-L did not have significantly higher anxiety t scores, (p >0.05; NS). 
Depression: PFI-L did not have significantly higher depression t scores, (p >0.05; NS). 
Distress:  PFI-L did not have significantly higher global severity index (distress) t scores, (p > 0.05; NS). Note no M(SD) reported 
for any of the above.  
van Gils, T., et al. (2016)  Anxiety  
(Medical History) 
Anxiety: 16.3% of PFI-G reported anxiety vs 3.1% non-PFI-G (OR = 6.0, 95% CI [2.5-14.3], p < 0.001) 




Golley, S.,  




PFI-G not associated with neuroticism (OR = 0.82; 95% CI [0.55-1.21], p = 0.31). 








Neuroticism: Higher scores in all PFI (t(516) = 4.25, p < 0.0001), PFI women vs non-PFI women, (t(283) = 3.5, p < 0.001), and 
PFI men vs non-PFI men, t(231) = 2.44, p < 0.02), indicating more neurotic.  
Extroversion:  Higher scores in PFI women vs. non-PFI women, (t(283) = 2.1, p < 0.04), and vs. PFI men, (t(129) = 2.67, p < 
0.008), indicating more extroverted. 
Psychoticism: Higher scores in PFI men vs. PFI women, (t(101) = 2.74, p < 0.007), indicating less socially compliant. Scores 
increased with an increase in social deprivation (r = 0.18, p < 0.04) in PFI.  
Lillestol, K., et al. (2010)  Neuroticism 
(EPQ-N) 
PFI (M = 9.2, SD = 5.2) had significantly higher scores than controls (M = 6.5, SD = 5.5) p < 0.001. This was found in male as 
well as in female subgroups (scores not reported).  
Author (year)  Variable (Measure) Somatisation Findings 
Berstad, A., 
et al. (2012)  
Symptom severity  
(IBS-SSS) 










Degree of PFI associated with increasing IBS symptom severity (p = 0.004) and increasing extraintestinal symptom severity (p 
= 0.030), such that IBS patients who reported a higher number of food items causing GI symptoms had increased symptom 
severity.  





IBS patients with PFI-L had higher symptom severity scores [305 (192–326) vs. 233 (129–304) p = 0.05].  PFI-L was significantly 
associated with IBS symptom severity 
(OR = 1.019, 95% CI [1.002–1.037], p = 0.02) 
Knibb, R. C., et al. (1999)  Somatic complaints 
(GHQ-28) 
PFI (vs. non-PFI) reported significantly more somatic symptoms, (t(533) = 3.1, p < 0.002. Also found in PFI-women vs non-PFI 
women (t(293) = 3.24, p < 0.001), and PFI-women vs. PFI men (t(136) = 2.5, p < 0.01).  
 
Lee, H.J., et al. (2019) 
χ2, Fisher’s exact 
Symptom severity  
(GI: IBS-SSS) 
Patients who reported a higher number of food items causing GI symptoms had increased IBS symptom severity (p = 0.020) 
 
Lind, R., 
et al. (2005) 
 
 
Somatic complaints  
(SHC) 
Symptom severity  
 (SHC) 
Somatic Complaints: PFI reported more complaints (Mdn = 22.5, IQR = 15.5 – 32) vs. healthy controls (Mdn = 5 IQR = 2 –9) & 
general population (Mdn = 9.5, IQR = 4 – 15.5), p < 0.0001. Five most common complaints were tiredness, bloating, headache, 
diarrhoea, & back pain. 39% of PFI reported ≥15 complaints in last 30 days.   
Symptom Severity: PFI had higher SHC severity scores, p < 0.001 (for all five domains: GI, Musculoskeletal, pseudonuerology, 
allergy, flu). 65% of PFI (vs. 14% general population) scored above normal (≥20). 
Lind, R., et al. (2008) Somatic complaints 
(no measure) 
Somatic Complaints: Concluded that results demonstrate that more women than men report GI symptoms. No test statistic 
or additional data provided. 






Symptom severity  
(Non-GI: SHC 
GI: IBS-SQ) 
Somatic Complaints: Women, had more complaints each month vs men (p = 0.03). Five most common complaints were 
tiredness, gas discomfort, stomach pain, headache, and diarrhoea. 47% reported ≥15 complaints in last 30 days.  
Symptom Severity: Women (M = 14.7, SD = 5.5) had higher SHC severity scores than men (M = 11.2, SD = 6.8), p = 0.03. IBS 
symptom severity similar in men and women. Symptom anxiety significant predictor for GI symptom severity (β =0.186, p = 
0.02). 
Lind, Lillestol, K., et al 
(2010)  
Somatic complaints  
(SHC) 
Symptom severity  
 (SHC) 
Somatic Complaints: PFI (M = 23.5, SD = 9.7) reported significantly more total subjective health complaints than controls (M = 
11.7, SD = 9.8), p = 0.0001. The five most common complaints were gas discomfort, diarrhoea, stomach discomfort, tiredness 
and headache. 36% of PFI reported ≥15 complaints in last 30 days.  
Symptom Severity: PFI had higher SHC severity scores on GI, p < 0.001; allergy (p < 0.001), pseudoneurology (p <0.05) and 
musculoskeletal complaints (p = 0.002). 67% of PFI (vs 17% controls) scored above normal (≥20). 
Manu, P., 
et al. (1993)  
Somatic complaints 
 (NIMH-DIS) 
PFI (vs. non-PFI) had more lifetime functional extraintestinal symptoms (p< 0.05), including irregular menstrual periods (χ2 = 
6.1, df = 1, p < 0 .02), dizziness/light headedness (χ2= 4.1, df = 1, p < 0.05), and diarrhoea (χ2 = 4, df = 1, p< 0.05).  PFI had 
significantly higher (33% vs. 7%) prevalence of somatisation disorder (p < 0.025).   
Monsbakken, K. W., et 




Musculoskeletal pain score not significantly different between PFI and non-PFI (p = 0.13, NS). However, there were significant 




Nybacka, S.,  
et al. (2018)  
Symptom severity 
(Non-GI: PHQ-15, GI: 
IBS-SSS) 
IBS with PFI patients (M = 12.9, no SD) reported more extraintestinal symptoms than non-PFI (M = 10.8, no SD) p = 0.023. No 
differences in IBS symptom severity found.  
Tomba, C.,  
et al. (2012)  
Somatic complaints 
(SCL-90R) 









Author (year)  Variable (Measure) Stress & Coping Findings 
 








Stress: PFI (vs. controls) reported lower job stress (p = 0.01) and perceived less stress according to communication (p = 0.02), 
leadership (p =0.04), and relocation (p = 0.01. No ‘workload’ group differences.  
Coping:  PFI and controls used similar coping strategies with no significant differences in total scores (M = 42.7, 95% CI 
(41.2–44.) vs. M = 42.9, 95% CI (41.6-44.2). PFI generally used an active coping pattern, scoring high on instrumental 
mastery-oriented coping and low on avoidance coping.  
Author (year)  Variable 
(Measure) 
Beliefs & Cognitions Findings 
 
 
Barr, S.I., (2013)  Food Related 
(MHBS) 
PFI-L (vs. non-PFI-L) had lower MHBS scores (M =  25.1(± SE) 0.3 vs. 29.3(± 0.1), F=158, p < 0.001), indicating fewer of those 
with PFI-L responded in a manner indicating positive beliefs about milk products. 








Healthcare (HCAMQ)  
Health Worries:  PFI (M = 71.05, SD = 24.807) higher MHW mean scores than non-PFI (M = 66.10, SD = 18.993), no p value 
reported. No significant association for health worries (OR = 1.001, p = 0.817) 
Food Worries: PFI (M = 17.31 SD = 5.941) had higher Tainted Food subscale scores than non-PFI (M = 15.13, SD = 5.213).  No 
significant association between PFI and food worries (OR = 1.035, p = 0.123) 
Healthcare Beliefs: PFI associated with positive complementary and alternative medicine attitudes (OR = 0.932, p < 0.001).  
 
Golley, S., et al. (2015)  Healthcare (History)  CAM: PFI-G significantly associated with positive receptiveness to complementary medicine (OR = 1.68, 95% CI [1.32-2.14], p 
< 0.001), and less receptiveness to conventional medicine (OR = -0.50; 95% CI [0.49-0.76], p < 0.001).  
Jakobsen, M.D., et al. 




PFI is associated with poor perceived health (OR = 2.56, p < 0.001) 








Health Worries:  Sum scores on the MHW did not differ significantly between PFI (Mdn = 66.5, IQR[46-85.5) versus controls 
(Mdn = 61.5, IQR[44-75.5) or general population (Mdn =57, SD = 43-74), p > 0.05. PFI were significantly more worried about 
overuse of antibiotics (p <0.001), amalgam in dental fillings (p < 0.01). 




























Quality Assessment: Psychological Correlates (n = 22)




Appendix VI: Clinical correlates summary of findings 
 
Author (year) Long-Term Conditions Gastrointestinal Atopy 
   Allergy  Skin-Related Asthma 
Berstad, A., et al. 
(2012) 
Fibromyalgia (71%) 
Chronic fatigue (81%) 
99% met IBS criteria  ≥1 atopic disease (38%)   
Bohn, L., et al. (2013)  100% had IBS 
 
   
Cabrera-Chavez, F., 
et al. (2017) 
 IBS (14.3% vs. 4.7%, 
p < 0.001)  
   
Dainese, R., et al. 
(2014) 
 100% had IBS.  
 
Atopic disease and family 
history atopy NS  
  
Gelincik, A., et al. 
(2008) 
  Nasal allergy 
(OR = 1.56, 95% CI [1.27-
1.78], p < 0.001) Familial 
atopy 
(OR = 4.28, 95% CI [3.58-
4.88], p < 0.001)  
Dermatitis (OR = 
3.88,95% CI [3.29 4.48], 
p < 0.001) 
OR = 1.45, 95% CI 
[1.18-1.78],  
p < 0.001 
Golley, S., et al. 
(2015) 
 IBS (21.2% vs 8.7%,  
p < 0.001). 
Food allergy 
 (p < 0.001).  
  
Jakobsen,  
M. D., et al. (2016) 
Muscle pain (OR = 1.80, p < 0.001) 
Fibromyalgia (OR = 1.72, p < 0.001) 
Back pain (OR = 1.24, p < 0.001) 
Hypothyroidism (OR = 1.61, p < 0.001) 
Chronic fatigue (OR = 2.55, p < 0.001) 
Odds of PFI increase with increasing number of 
concurrent comorbidities.  
2 concurrent comorbidities (OR = 1.16, p < 0.001),  
3 concurrent comorbidities (OR = 3.02, p < 0.001),  
4 concurrent comorbidities (OR = 4.12, p < 0.001), 
 5 or 6 concurrent comorbidities (OR = 4.82, p < 0.001). 
    
Jansen, J. J. N., et al. 
(1994) 
  Other allergies 
 (p <0.001) 
Familial allergies 
 (p < 0.0001) 
  
Lee, H. J., et al. 
(2019) 
 IBS Sample 
PFI+ IBS 79.2% vs. PFI in 
Control 44.8% p <0.001  




Liden, M., et al. 
(2010)  
100% had rheumatoid arthritis  Allergy (p < 0.001) 
childhood food allergy (p 
< 0.05) 
Eczema p < 0.05  
Author (year) Long-Term Conditions Gastrointestinal Atopy 
   Allergy Skin-related Asthma 
Lillestol, K., et al. 
(2010)  
 88.5% met IBS criteria     
Lind, R., et al. (2005)  71% met IBS criteria 
18% dyspepsia  
   
Lind, R., Lied, G. et al. 
(2010) 
 94% met IBS criteria     
Lind, R., Lillestol, K. 
et al. (2010) 
 76.5% met IBS criteria  
 
   
Manu, P., et al. 
(1993) 
100% had chronic fatigue.   
Severity or duration of fatigue (NS). 
    
Monsbakken, K. W., 
et al. (2006) 
State of health, fibromyalgia, 
musculoskeletal pain syndrome, 
musculoskeletal pain score (NS) 
100% IBS 
h.pylori, abdominal 
symptom score (NS) 
   
Nybacka, S., et al. 
(2018) 
 100% IBS 
PFI in IBS 19% vs. PFI in 
Control 6% p = 0.025 
PFI & Atopic IBS prev. (28% 
vs. 9% p = 0.002).  
  
Parker, S. L., et al. 
(1990) 
  30% reported family 
history of food allergy.  
  
Patelis, A., et al. 
(2014) 
  Rhinitis (p < 0.001) 
IgE aeroallergens  
sensitisation  
(p < 0.001).  
Eczema p < 0.001 p = 0.001 




C., et al. (2016) 
 Gastritis   
(OR = 4.26 95% CI [3.28-
5.53], p < 0.001) 
Allergic disease  
(OR = 2.09, 95% CI [1.03-
4.24], p = 0.04) Allergic 
rhinitis  
(OR = 2.01, 95% CI [1.46-
2.78], p <0.001) Maternal 
(p = 0.003) and Parental 
(p = 0.02) history food 
allergy  
Dermatitis 
(OR = 2.48, 95% CI  
[1.55-3.96], p < 0.001) 
Maternal history atopic 
dermatitis (p = 0.03) 
Parental history urticaria 
(p = 0.03) 
 
Rentzos, G., et al. 
(2015) 
    PFI prevalence: 




< 0.001. Further, 
38.2% asthmatics. 
Saberi-Firoozi, M., et 
al. (2007)  
 IBS (OR = 1.47, 95% CI [1.09-
1.98], p = 0.011) 
   
Soost, S., et al. 
(2009) 
  Allergic rhinitis (OR = 
1.38; 95% CI (1.14-1.67) p 
< 0.01) in women only  
Eczema (OR = 2.33; 95% 
CI (1.78–3.06),  
p < 0.01] in women only 
 
van Gils, T., et al. 
(2016) 
Anaemia (OR = 3 95% CI [1.3-6.8], 
p = 0.01) 
Chronic headache (OR = 4.1 95% CI [1.6-
10.6], p < 0.01) 
 
37% of PFI-G reported IBS  
(OR = 5.9 95% CI [3.1-11.1], p < 
0.001) 
Family: Coeliac disease (OR= 
3.4, 95% CI [1.4-10.5], p < 0.05) 
    
Vesa, T. H., et al. 
(1998)  
 IBS (OR = 4.6, [2.1-10.1])    
Woods, R. K., et al. 
(2001) 
  Atopy  
OR =1.38, 95% CI [1.23-
1.55]  
 Wheeze in past 12 
months  
(OR = 1.37, 95% CI 
[1.16-1.60]), 
Asthma history 




(OR = 1.44, 95% CI 
[1.21-1.70])  

































































Quality Assessment: Clinical Correlates (n = 26)




Appendix VIII: Psychosocial correlates summary of findings 
 
Author (year) Sex  Age Ethnicity        Socioeconomic 
Barr, S. I. (2013) PFI-L prevalence higher in females (20% 
vs. 12.3%, p <0.001) 
Younger Age (18.3% vs 13.3%, 
p = 0.005) 
Not white (26% v. 
15.4%, p = 0.002) 
 
Bohn, L., et al. 
(2013) 





F., et al. (2017) 
PFI-G prevalence higher in females (4.1% 
vs. 1.6%, p < 0.001).  
NS  
 
Dainese, R., et al. 
(2014) 
NS NS  
 
Elieson, L. M., et 
al. (2017) 
Significant, but not further described,  
p < 0.001 
Significant, but not further 
described, p < 0.001 
 
 
Gelincik, A., et al. 
(2008) 
NS  Younger age (OR = 1.32, 95% 
CI [1.19-1.49], p = 0.03) 
 
 
Golley, S., et al. 
(2015) 
PFI-G prevalence higher in females (11% 
vs. 3%, p < 0·001),  
PFI predicted by female sex  
(OR = 0.26, 95% CI [0.14-0.46], p < 0.001) 
  
 
Hidese, S., et al. 
(2019)  
PFI associated with female sex  
(p < 0.001)  
Younger age  
(p < 0.001). 
 
 
Jakobsen, M. D., 
et al. (2016) 
 
 
Sample all female Younger age  
(OR = 0.97, p < 0.001) 
 Living in urban region  
(OR = 1.10, p = 0.003) 
>9 years of education  
(OR = 1.69, p < 0.001) 
Not in full-time work 
(OR = 1.3, p < 0.001) 
Poor childhood conditions  
(OR = 1.2, p < 0.001) 
Jansen, J. J. N., et 
al. (1994) 
PFI prevalence higher in female sex (15% 
vs. 9%, p< 0.005).   




Lee, H. J., et al. 
(2019) 
NS NS  Education, employment, (NS) 
Lind, R., Lillestol, 
K. et al. (2010) 
 
  Part-time employed > health 
complaints (p = 0.0005). 
Monsbakken, K. 





Parker, S. L., et al. 
(1990) 
 
Older age (p < 0.05)    Education, marital status, 
employment status (NS).  
Patelis, A., et al. 
(2014) 
PFI prevalence higher in female sex (61.6% 




Fernandez, C., et 
al. (2016) 
PFI prevalence higher in female (37.5% vs 
19.8%), p < 0.001.  
PFI predicted by female sex (OR = 2.43, 95% CI 
[1.86-3.18], p < 0.001).  
  
 
Rix, K. J., et al. 
(1984)  
NS NS  PFI more likely ‘professionals’ (p < 
0.05)  
Saberi-Firoozi, M., 
et al. (2007)  
PFI-L predicted by female sex (OR = 1.29, 
95% CI [1.05-1.59], p =0.015).  
NS  
 
Soost, S., et al. 
(2009) 
PFI predicted by female sex (OR = 1.83, 
95% CI [1.39–2.39] p < 0.001)  
Younger age  
(no p reported) 
 Higher education (OR = 1.92, [1.19–
2.85], p < 0.001). 
Tomba, C., et al. 
(2012) 
NS     
 
van Gils, T., et al. 
(2016) 
PFI-G predicted by female sex  
(OR = 2.8,95% CI [1.4–5.7], p< 0.01)  
Younger age  
(p = 0.001) 
 Living in urban region (OR = 2.5 95% 
CI [1.3–4.8], p< 0.01).  Trend higher 
education  
Vesa, T. H., et al. 
(1998)  
PFI-L predicted by female sex (OR = 2.1, 
95% CI [1.1 - 4.0])  
NS  
 
Vierk, K. A., et al. 
(2007) 
PFI prevalence higher in female sex (11.4% 
vs 6.5%, p < 0.001).  
NS NS Higher education (11.3% vs 6.6% 
high school >, p < 0.001). 
Woods, R. K., et 
al. (2001) 
PFI predicted by female sex (OR = 1.47, 
95% CI [1.24-1.74], p < 0.05)   
NS  Living in Iceland, Norway, Sweden, 
Germany (OR = 1.72, 2.00, 1.98, 










































Quality Assessment: Psychosocial Correlates (n = 24)
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BACKGROUND: Reproducible adverse food reactions are a defining feature of food 
hypersensitivity (FH). Perceived food intolerance (PFI) is a poorly understood nonimmune 
FH reported by up to 35% of individuals and characterised by diagnostic challenges. PFI is 
associated with psychological distress, gastrointestinal (GI) and extraintestinal symptoms, 
food avoidance, poor quality of life (QoL) and repeated healthcare visits. However, limited 
research has explored a role of psychological factors in PFI and related distress.  
AIM: The present longitudinal study aimed to investigate illness perceptions, coping 
strategies and additional factors including perceived stress, symptom severity, functional 
impairment and PFI severity on outcome in PFI, including reported negative affect 
(anxiety and distress) and food-related QoL (FR-QoL). 
METHODS: Adults over the age of 18 who reported PFI were recruited through 
convenience sampling via advertisements on social media and King’s College London 
research recruiting and invited to participate in an online study. A purpose-built 
questionnaire was developed and administered using the Qualtrics platform at three time 
points including baseline (T1), 3-month follow up (T2), and 6-month follow up (T3). Study 
aims and hypotheses were assessed using bivariate and multivariate analyses with 
baseline data, and mediation analyses were conducted using longitudinal data.  
RESULTS: There were no significant changes in scores on outcome measures across time 
points, and average anxiety scores were above clinical cut off, indicative of elevated self-
reported anxiety in this population. Baseline cross-sectional results indicated that the 
strongest contributors to negative affect were extraintestinal symptom severity, 
emotional representations of PFI, and coping responses of self-blame and 
disengagement. The strongest contributors to poor FR-QoL were illness representations 
including illness identity and emotional representations, perceived stress, GI symptom 
severity and PFI severity, Across all measured outcomes, a coping response of positive 
reframing improved outcome. Longitudinal mediation analyses demonstrated coping 
responses of self-blame and disengagement had significant complete and partial 
mediating effects on illness perceptions in anxiety and distress, whereas illness 
perceptions had significant complete and partial mediating effects in FR-QoL.  Symptom 
severity of extraintestinal and GI symptoms, additionally contributed to poor outcome.  
CONCLUSIONS: Evidence suggests that outcome in PFI may be maintained by modifiable 
factors including illness representations and coping responses, and by cognitive, 
emotional, and behavioural reactions to somatic symptoms and additional consequences 
of PFI. A psychological intervention to improve outcome based on an Acceptance and 





1.1 Background  
The term ‘adverse food reactions’ is often used to describe negative reactions to 
food, which could be the result of toxins, food poisoning, taste aversion, or 
hypersensitivity reactions (Ortolani & Pastorello, 2006; Teufel et al., 2007). A European 
Academy of Allergy and Clinical Immunology (EAACI) position statement recommends 
when a reaction “causes objectively reproducible symptoms and signs, initiated by 
exposure to a defined stimulus at a dose tolerated by normal subjects” (p.816), in the 
context of food, the term food hypersensitivity (FH) should be used (Johansson et al., 
2001), which includes both allergic hypersensitivity (immune-mediated) and nonallergic 
hypersensitivity (nonimmune mediated).  For the purpose of this paper, allergic 
hypersensitivity, which produces immediate reactions that often occur within minutes of 
exposure to the offending food, will be referred to as ‘food allergy’ (FA). Non-immune 
nonallergic hypersensitivity, which is associated with delayed reactions that occur hours 
to days after exposure to the offending food, has been referred to in position statements 
as ‘nonallergic food hypersensitivity’ (Johansson et al., 2001) and ‘food intolerance’ 
(Boyce et al., 2011), and in the current paper will be referred to as ‘perceived food 
intolerance’ (PFI). The term ‘food hypersensitivity’ (FH) will be used as an umbrella term 
when referring to both FA and PFI. 
The term PFI was selected as an overarching term to reflect all forms of nonimmune 
food intolerance including those that are undefined and those that are more well 
understood such as lactose, fructose, and biogenic amine intolerances. The 
pathophysiology of the GI symptoms caused by lactose and fructose sugars is understood, 
however, many intolerances are subjectively experienced but difficult to investigate and 
diagnose due to lack of definable pathology and characteristic delayed onset, including, 
but not limited to, intolerances to food additives and sulphites (Ortolani & Pastorello, 
2006; Skypala, 2011). Furthermore, the current dissertation relied on self-reported 
intolerance and did not verify nor test reproducibility in the sample, hence it is difficult to 




2001). Finally, ‘intolerance’ is a more widely recognised and used  term by lay persons 
and the media (Dreborg, 2015; Reese et al., 2017). The experiences, reactions and 
symptoms that individuals with PFI have are very real, and it is hoped that this explanation 
for chosen terminology does not reflect otherwise.  
A large proportion of individuals report PFI in the absence of a verified FA, which 
contributes to diagnostic challenges for medical practitioners (Nelson & Ogden, 2008), 
repeated healthcare visits and increased economic burden (Fox et al., 2013; Hazeldine, 
Worth, Levy, & Sheikh, 2010; Jones & Burks, 2017). Fox et al., (2013) concluded that adults 
with self-reported FH visit health professionals an average of 11.17 times per year with 
an overall mean cost of care of $2016 (international dollars), compared to 7.11 visits per 
year and mean costs of $1089 for controls. Further, consequences of PFI extend to 
personal and social domains, and individuals with PFI report increased distress, food 
restriction and avoidance, worries about the perceptions of others, and limitations on 
social activities and travel, which can all contribute to poorer quality of life (QoL) (Arslan, 
Lind, Olafsson, Florvaag, & Berstad, 2004; Biesiekierski, Newnham, Shepherd, Muir, & 
Gibson, 2014; Knibb, Armstrong, et al., 1999; Knibb et al., 2000; Nettleton, Woods, 
Burrows, & Kerr, 2010; Schiefert & Matteucci, 2018).   
1.1.1 Diagnosis  
Accurate diagnosis of FH requires documented clinical history and evidence of 
exclusion of other factors and diagnoses that could account for adverse food reactions 
(e.g. Inflammatory Bowel Disease; IBD), however, relying on self-reported history alone 
may lead to over-reporting (Rona et al., 2007) or inconsistent accounts (Knibb, Booth, et 
al., 1999). This is a significant consideration as unless FH is confirmed, epidemiological 
data may not be representative of the true prevalence and incidence of FH.   Alongside a 
clinical history, evidence of immune involvement is needed to diagnose FA, and a positive 
oral food challenge is necessary to clinically confirm FH reactions (Renz et al., 2018). 
FA pathology can be demonstrated by an often-immediate immunological response 
seen from skin prick tests, which are often used as a first-line tool in allergy clinics and in 




methodology is not standardised and findings alone are not sufficient to diagnose FA 
(Muraro et al., 2014; Renz et al., 2018). The gold standard diagnostic method is the 
double-blind placebo-controlled food challenge (DBPCFC) (Muraro et al., 2014), which 
can verify both FA and PFI reactions, however, it is not often offered as a first-line 
diagnostic method as it is time-consuming, laborious and expensive (Muraro et al., 2014). 
In PFI, a lack of definable immunological pathology and the delayed nature of PFI 
reactions have led to diagnostic challenges that affect medical practitioners and those 
with PFI alike. Hydrogen breath tests have been used to test for lactose and fructose 
intolerances, however, some research has implied these tests are often unreliable and 
may have limited clinical value (Bratten, Spanier, & Jones, 2008; Yao & Tuck, 2017; Yao et 
al., 2017). A DBPCFC can be used to verify undefined PFI, though often is not due to cost 
and time requirements, and without a positive DBPCFC, diagnosis is less clear. More 
recently, complementary and alternative medicine (CAM) practitioners, pharmacies and 
direct-to-consumer companies have offered food intolerance testing such as IgG antibody 
tests, hair analysis, antigen leucocyte cellular antibody test and applied kinesiology to 
offer PFI diagnoses, though these are consistently reported to not have clinical validity 
and are not recommended (Sicherer & Sampson, 2018; Stapel et al., 2008; Teuber & 
Porch-Curren, 2003). However, as a result of diagnostic challenges individuals with PFI 
experience, they may be more likely to seek alternative explanations and evidence for 
their symptoms (Lomer, 2015). Some evidence suggests individuals with PFI report that 
they are more receptive to CAM (Elieson, Domotor, & Koteles, 2017; Golley, Corsini, 
Topping, Morell, & Mohr, 2015), and less receptive to conventional medicine (Golley et 
al., 2015), however, this was not explored in a way to measurably understand how this 
translates to the use of conventional medicine versus CAM, though research from the 
United States indicated 22% of individuals with FA had undergone CAM diagnostic 
assessments (Ko, Lee, Muñoz-Furlong, Li, & Sicherer, 2006). 
1.1.2 Prevalence and Epidemiology 
There is a large discrepancy between the reported prevalence of PFI and FA. A 




35% of the general population report PFI, and a recent systematic review (see Chapter 1) 
determined that prevalence of PFI was reported by up to 9.5% in population studies, up 
to 51.2% in community samples, and up to 84% in clinical samples (including IBS, chronic 
fatigue and rheumatoid arthritis samples). However, epidemiological studies consistently 
demonstrate that only 0.9 – 3% of adults have verified FA (Muraro et al., 2014; Nwaru et 
al., 2014; Rona et al., 2007; Woods, Abramson, Bailey, & Walters, 2001; Woods et al., 
2002; Zuberbier et al., 2004). A systematic review by Nwaru et al. (2014) reported a 
pooled lifetime prevalence of self-reported FH of 17.3%, yet only a 2.7% prevalence 
confirmed through immunological markers, and 0.9% prevalence confirmed from a 
positive food challenge.  
It has proven difficult to get an accurate estimate of the prevalence of FH because 
of the lack of an affordable and consistently reproducible diagnostic test. The DBPCFC is 
considered gold standard, but is a costly and time consuming procedure and not widely 
used (Muraro et al., 2014; Ortolani & Pastorello, 2006; Rona et al., 2007; Sicherer & 
Sampson, 2014; Skypala, 2011). Of interest, most prevalence studies in FH use diagnostic 
tools that demonstrate immune sensitisation. This can help evidence FA but may lead to 
inconsistencies in the true prevalence of PFI, as PFI is not immune mediated. However, 
the data from research that has used a food challenge suggests that ‘hypersensitivity’ 
(Johansson et al., 2001)  criteria is difficult to meet in PFI, as it appears a large portion of 
PFI reactions are not objectively reproducible, considering the discrepancy in 
prevalence’s reported in Nwaru et al.'s (2014) study. True estimates of the prevalence of 
PFI are difficult to know, though previous research has established that PFI is more often 
reported by women (see Chapter 1).  
1.1.3 Common Reactions and Offending Foods 
There is currently no cure for FA; patients must eliminate the offending food and 
receive substantial education about how to avoid the offending food. In FA, IgE reactions 
are associated with rapid-onset symptoms ranging from itching, burning, tingling and 
swelling in the mouth and/or throat, to the life-threatening reaction of anaphylactic shock 




survey reported the most commonly reported foods in FA are shellfish, milk, peanut, tree 
nut and fin fish (Gupta et al., 2019), and a European systematic review reported that cow’s 
milk, egg, peanut, tree nuts, fish, and shellfish were most often reported as trigger foods 
in FA (Nwaru et al., 2014).  
PFI symptoms are both intestinal (symptoms within the GI system; GI distress, 
bloating, abnormal bowel movements) and extraintestinal (symptoms outside of the GI 
system; fatigue, headaches, musculoskeletal pain, and skin reactions) (Kelsay, 2003; 
Ortolani & Pastorello, 2006; Sicherer & Sampson, 2014; Zopf, Baenkler, Silbermann, Hahn, 
& Raithel, 2009). A recent systematic review (see Chapter 1) concluded the most 
commonly reported GI symptoms included GI bloating, flatulence, abdominal discomfort, 
abdominal pain, nausea, constipation and diarrhea, and extraintestinal symptoms 
included tiredness, headache, joint and/or muscle pain, mood changes and/or irritability. 
Common offending foods in PFI have rarely been robustly measured, though results of a 
systematic review (see Chapter 1) determined that foods most often self-reported as 
causing symptoms were wheat, gluten, dairy (including milk and cheese), fruits, 
vegetables (including legumes and cruciferous vegetables), and eggs. However, offending 
foods and substances in PFI can also include foods containing vasoactive amines (e.g. 
histamine), salicylates, caffeine, food additives and sulphites (Ortolani & Pastorello, 2006; 
Reese et al., 2017; Skypala, 2011; Zopf et al., 2009).  
 
1.2 Biological Factors Associated with PFI 
1.2.1 Immunological Factors 
PFI reactions are not specifically immune-mediated. Immune mediation is 
characteristic of FA through food-specific immunological antibodies (predominantly IgE) 
and cellular mechanisms following ingestion, airborne inhalation or skin contact to the 
food allergen. However, some individuals may exhibit evidence of immune sensitisation 
to non-food environmental allergens, while others may suffer from both PFI and FA, 
though not to the same food. In either of these scenarios, an individual may misattribute 




systematic review (see Chapter 1) suggests an association between PFI and immune-
mediated conditions, including manifestations of atopy such as asthma, allergic rhinitis 
and eczema (ibid), and the autoimmune condition rheumatoid arthritis (Liden, 
Kristjnsson, Valtysdottir, Venge, & Hllgren, 2010). Further, some individuals with PFI may 
exhibit immune activation alongside food, as the immune system can be modulated by 
the stress response, which can contribute to GI symptoms through intestinal mast cell 
activity (Mayer, 2000; Mayer, Naliboff, Chang, & Coutinho, 2001). This perhaps could 
contribute to a conditioned response to food and the misidentification of PFI, though 
requires further investigation.  
It is important to note that the immune system can produce non-IgE antibodies in 
response in food, such as IgG antibodies and their subclass IgG4. IgG has been reported 
to rise in both allergic and healthy non-allergic individuals following ingestion of a food, 
and should not be interpreted as indicative of PFI nor FA (Gocki & Bartuzi, 2016; Stapel et 
al., 2008). Despite this, there are a large number of direct-to-consumer IgG antibody 
blood tests, though evidence consistently concludes that these are not recommended to 
be used as they have a high false positive rate (Sicherer & Sampson, 2018; Stapel et al., 
2008; Teuber & Porch-Curren, 2003). A position statement from the Canadian Society of 
Allergy and Clinical Immunology (CSACI) on the testing of IgG highlights how these tests 
may lead to false positives which can result in unnecessary dietary restrictions and 
reduced QoL (Carr, Chan, Lavine, & Moote, 2012). Further, the financial burden and risk 
of a false positive not only falls on the consumer, who may needlessly eliminate nutritious 
and innocuous foods, but may have subsequent consequential effects on healthcare 
system costs as individuals with positive results may request specialist referrals and 
further costly investigations (Carr et al., 2012).  
1.2.2 Enzymatic, Pharmacological, and Additional Mechanisms 
In PFI, pathology is often difficult to establish and may be mediated through 
enzymatic, pharmacological and additional undefined mechanisms (Ortolani & Pastorello, 




compounded by the inherent challenge that PFI reactions are delayed and may not 
appear for hours or days after exposure to the offending food. 
PFI reactions may be mediated by mechanisms such as enzymatic deficiencies such 
as the β-galactosidase deficiency implicated in lactose intolerance, pharmacological 
mechanisms such as those implicated in salicylate, caffeine and biogenic amine (e.g. 
histamine) intolerance, and additional undefined mechanisms that are still not well 
understood, such as unknown mechanisms in food additive intolerance (Ortolani & 
Pastorello, 2006; Skypala, 2011; Tuck, Biesiekierski, Schmid-Grendelmeier, & Pohl, 2019).  
A study by Litleskare et al. (2015) concluded that exposure to Giardia was 
associated with reported PFI. GI infection has been evidenced as a risk factor in Irritable 
Bowel Syndrome (IBS) (Gwee, 2010; Litleskare et al., 2015; Thabane & Marshall, 2009). 
Additionally, PFI was reported by those with Helicobacter pylori positive dyspepsia 
(Olafsson & Berstad, 2003), but to the authors knowledge, associations between infection 
and PFI has not been described elsewhere.  Finally, it is possible that changes in intestinal 
physiology, including mucosal inflammation, intestinal permeability, microbiota, or 
intestinal mast cells may be implicated in PFI, though this is outside the scope of the 
current study (Lillestøl, Helgeland, et al., 2010; Nybacka et al., 2018). 
1.2.3 Comorbid Clinical Factors 
Individuals with PFI experience GI symptoms including GI distress (bowel changes 
of constipation and diarrhoea), bloating and discomfort, and extraintestinal symptoms 
including fatigue, headaches, musculoskeletal pain, and skin reactions. Nonspecific 
symptoms have also been described, including dizziness, irregular menstrual periods 
(Manu, Matthews, & Lane, 1993), confusion, memory difficulties, and difficulty sleeping 
(Parker, Leznoff, Sussman, Tarlo, & Krondl, 1990). There is considerable symptom overlap 
between PFI and functional gastrointestinal disorders (FGID) including dyspepsia and IBS. 
A large proportion of patients with IBS report PFI, and similarly, in clinical samples of those 
suspected to have PFI, 71% - 99% met criteria for IBS (see Chapter 1). Further, PFI has 
been described in clinical samples with chronic fatigue (Manu et al., 1993), and individuals 




Valeur, 2012; Jakobsen, Braaten, Obstfelder, & Abelsen, 2016; Lind, Berstad, Hatlebakk, 
& Valeur, 2013).  
 Key findings from a qualitative study established ‘persistent physical symptoms’ 
(Picariello, Ali, Moss-Morris, & Chalder, 2015) as the preferred term to refer to symptoms 
and conditions without current medical explanation, and individuals can often experience 
symptom overlap between these conditions (Aaron & Buchwald, 2001; McKenzie, Oto, 
Graham, & Duncan, 2011; Nimnuan, Hotopf, & Wessely, 2001). Persistent physical 
symptoms (Picariello et al., 2015) cause functional impairment yet despite medical 
examination, have no organic pathology and typically respond poorly to medical 
intervention (Chalder & Willis, 2017; Rosendal et al., 2017). They are associated with 
elevated distress and are frequently seen within medical specialties and primary care, 
contributing to increased healthcare visits and costs (Barsky, Orav, & Bates, 2005; 
Rosendal et al., 2017). It is possible that reported comorbidities and symptom overlap 
between PFI, IBS and other persistent physical symptoms represents shared mechanisms, 
and there are similarities between PFI and IBS that warrant further investigation.  
 
1.3 Psychological and Cognitive Factors Associated with PFI 
1.3.1 Affect, Personality and Worries 
Previous research investigating psychological characteristics of individuals with PFI 
has focused on characteristics including negative affect (anxiety, depression, and general 
psychological distress), personality traits, and characteristics of worries, though most 
studies conducted to date have been at a cross-sectional bivariate level, which precludes 
understanding of the relationship between these factors and PFI, and what other 
variables may be contributing to any relationship described (see Chapter 1). Evidence is 
largely mixed, and some studies have determined that there are increased self-reports of 
anxiety, depression, and distress versus non-patients (see Chapter 1), though this rarely 
reached clinical threshold and was often investigated in clinical samples, which limits 
generalisability. Research examining personality traits including neuroticism is 




2010), and findings are limited by methodological quality, including using one-time 
surveys (Golley et al., 2015; Knibb, Armstrong, et al., 1999; Lillestøl, Berstad, et al., 2010), 
infrequently used measures (Golley et al., 2015), and self-selected clinical samples 
(Lillestøl, Berstad, et al., 2010). Evidence suggesting a role of symptom anxiety (Böhn, 
Störsrud, Törnblom, Bengtsson, & Simrén, 2013; Lind, Lied, Lillestol, Valeur, & Berstad, 
2010) and health anxiety (Elieson et al., 2017; Golley et al., 2015) in PFI has not been 
thoroughly explored, and results were conflicting and all of poor quality (see Chapter 1). 
Finally, there has been a paucity of research examining specific beliefs that may 
contribute to PFI.  Limited research in individuals with PFI has determined that general 
worries relating to modern health are not significant (Elieson et al., 2017; Lind et al., 
2005), though food-related worries about genetically modified foods were characteristic 
in PFI (Lind et al., 2005), however, the measure used in these studies did not capture how 
these beliefs relate to PFI specifically, or if they influence outcome . The results 
demonstrate that at this point, we are currently not able to draw solid conclusions about 
the role of affect, personality or cognitions as contributing to PFI.  
1.3.2 Somatic Symptoms 
Evidence consistently indicates that individuals with PFI report significantly more 
somatic symptoms and increased symptom severity than individuals without PFI (see 
Chapter 1). It is likely that symptoms in PFI are not mediated through pathways implicated 
in FA, and symptom overlap with FGID including IBS and persistent physical symptoms 
alludes to potential shared mechanisms (Berstad, Arslan, Lind, & Florvaag, 2005; Berstad 
et al., 2012; Böhn et al., 2013; Dainese et al., 2014; Dainese, Galliani, Lazzari, Leo, & 
Naccarato, 1999; Frissora & Koch, 2005; Lied et al., 2011; Lillestøl, Berstad, et al., 2010; 
Lind et al., 2005; Lind, Lied, et al., 2010; Lind, Lillestol, et al., 2010; Monsbakken, Vandvik, 
& Farup, 2006). 
Persistent physical symptoms were historically thought of as a psychosomatic 
syndrome whereby physical symptoms are manifestations of stress or psychological 
distress (Lipowski, 1986). However, theories exploring the role of the cognitive and 




maintenance of persistent physical symptoms, including sensitisation, illness 
representations and related coping strategies (Brosschot, 2002; Eriksen & Ursin, 2002; 
Eriksen & Ursin, 2004; Knowles et al., 2017; Moss-Morris & Chalder, 2003; Moss‐Morris, 
Petrie, & Weinman, 1996; Ursin & Eriksen, 2001; Yunus, 2007, 2008). 
1.3.3 Sensitisation and Related Theories 
Sensitisation refers to an elevated response due to increased use or stimulation 
(Eriksen & Ursin, 2002; Eriksen & Ursin, 2004; Petrie et al., 2001). Sensitisation has been 
proposed to contribute to physiological sensations and pain through mechanisms of 
central sensitivity and visceral sensitivity in the central and peripheral nervous systems 
(Bueno, Fioramonti, Delvaux, & Frexinos, 1997; Mayer & Raybould, 1990; Yunus, 2007, 
2008). The theory of sensitisation has been likened to higher-order processes of 
attentional and cognitive biases, whereby perceiving or experiencing increased threat will 
lead to the detection of more threat, and has been expanded to account for the 
experience and reporting of somatic symptoms in persistent physical symptoms 
(Brosschot, 2002; Eriksen & Ursin, 2002; Eriksen & Ursin, 2004; Ursin & Eriksen, 2001). 
Brosschot (2002)‘s theory of cognitive-emotional sensitisation hypothesises that 
individuals who are concerned about symptoms or an illness can develop a cognitive bias 
towards all illness relevant information. This bias is strengthened by illness-specific 
worries leading to an increased focus and awareness of symptoms, activation of cognitive 
networks that result in misattributions and over-reporting of bodily symptoms, 
influencing the development of a ‘cognitive-emotional sensitisation’ (Brosschot, 2002).  
Sensitisation assumes a degree of specificity of the triggering mechanism, as specific 
illness-related worries and fears activate these cognitive networks. A construct of GI 
symptom-specific anxiety (GSA) has been proposed to contribute to symptomatology in 
IBS. GSA is formed from conceptualisations of anxiety sensitivity, and posits the role of 
specific worry, fear, hypervigilance, visceral sensitivity and responses to GI sensations as 
contributing to the maintenance of IBS (Labus et al., 2004; Labus, Mayer, Chang, Bolus, & 
Naliboff, 2007; Porcelli, De Carne, & Leandro, 2014), and preliminary evidence 




bias have been considered previously, forming the model of somatosensory amplification; 
a construct that reflects cognitive and attentional biases to selectively attend to somatic 
sensations and experience them as pathological, which can enhance their perception, 
generation, and can influence how symptoms are experienced (Barsky, 1979; Barsky, 
Goodson, Lane, & Cleary, 1988; Barsky, Wyshak, & Klerman, 1990). Research  has implied 
that somatosensory amplification influences frequency of reported symptoms in FGID 
(Jones & Ebert, 2003; Jones, Schettler, Olden, & Crowell, 2004), and there is limited 
evidence in PFI, though methodologically of poor quality (Elieson et al., 2017).  
 The cognitive-emotional sensitisation theory (Brosschot, 2002) was extended to 
PFI by Berstad et al. (2005), who suggested individuals with PFI will develop a cognitive 
and attentional bias. This increases vigilance towards, and detection of PFI-related or 
ambiguous information (including thoughts, symptoms and food), and consequently 
influences the misattribution and misappraisal of the information, over-reporting of 
somatic symptoms and a tendency to over-interpret ambiguous information as in-line 
with their beliefs. This results in a cycle where repeated activation of these networks 
through ‘scanning’ for PFI-related information can lead to continued ‘threat detection’, 
and the start of another cycle, and may also influence resultant behaviour, including 
reporting symptoms and avoiding foods, which could be targeted in a behavioural 
intervention (Berstad et al., 2005) 
The role of sensitisation is hypothesised to contribute to persistent physical 
symptoms including IBS and chronic pain conditions, and recently the theory of cognitive-
emotional sensitisation has been proposed in PFI. There is some cross-sectional data 
implying a role of somatosensory amplification (Elieson et al., 2017) and GSA (Lind, Lied, 
et al., 2010) in PFI, however, these studies are not easily generalised, are limited by small, 
self-selected samples, and Elieson et al.'s (2017) study has several methodological issues 
(see Chapter 1). Specific PFI-beliefs and appraisals that activate cognitive networks and 
contribute to the development of a cognitive bias are not yet known, or how they relate 
to coping and outcome.  This information is crucial in order to identify processes that 




1.3.4 Illness Perceptions and the Common-Sense Model of Self-Regulation  
The beliefs an individual holds about their condition contributes to the 
development of a cognitive representation of the condition, which has a significant 
impact on behaviours relating to coping and self-management (Moss-Morris et al., 2002; 
Petrie, Jago, & Devcich, 2007; Petrie & Weinman, 2006). This schema is formed of specific 
thoughts or ‘illness perceptions’, as posited by the common-sense model of self-
regulation (CS-SRM/CSM) (Leventhal, 1984) and measured by the Illness Perception 
Questionnaire (IPQ) (Weinman, Petrie, Moss-Morris, & Horne, 1996). 
The CSM provides a framework for understanding the processes involved in 
managing health and illness threats (Leventhal, Phillips, & Burns, 2016). The model 
suggests individuals facing an illness threat will construct specific and parallel cognitive 
and emotional representations in order to provide a framework that underlies the 
appraisal of illness-related information, derives meaning about that information, and 
guides subsequent “action plans” that influence outcomes such as coping responses, 
mood, possible treatments and self-management  behaviours (Leventhal, Brisette, & 
Leventhal, 2003; Leventhal et al., 2016). The CSM benefits from a dynamic framework 
whereby illness perceptions can integrate with new health-threat knowledge and 
feedback obtained from the appraisal of management behaviours. This information can 
support or update representations to guide and appraise subsequent actions, thus 
providing a process for the ‘self-regulation’ of illness perceptions and health behaviours 
(Leventhal et al., 2016).  
In the original CSM, illness representations were divided into five core domains; 
identity (the label placed on the condition and perceptions of associated symptoms), 
consequences (perceived physical, social, economic and emotional consequences of the 
condition), cause (beliefs about factors responsible for the condition whether internal, 
external or environmental), control/cure (beliefs about the extent to which the condition 
can be cured or controlled), and timeline (beliefs about the length of time the condition 
will last, which can be considered to be acute or chronic) (Leventhal, 1984; Leventhal et 




the 2002 revision of the IPQ (IPQ-R) (Moss-Morris et al., 2002); emotional representations 
(emotional impact of and in response to the condition), coherence (extent to which the 
individual has a coherent understanding of their condition), and cyclical timeline beliefs 
(beliefs about changeability and unpredictability of the condition). Further, the control 
domain was separated into two subscales: personal control and treatment control. The 
IPQ-R provides a greater understanding of the role of an individual’s illness perceptions, 
allowing for the parallel and multi-level measurement of cognitive and emotional 
reactions to illness-related information and providing information on the underlying 
processes influencing outcome.  
The CSM has been applied to various physical health conditions reported alongside 
PFI, including chronic pain, chronic fatigue, rheumatoid arthritis and asthma (Foster et al., 
2008; Kaptein, Klok, Moss-Morris, & Brand, 2010; Moss-Morris & Chalder, 2003; Moss‐
Morris et al., 1996; Scharloo et al., 1998), and in IBS and allergy, conditions which have 
symptom and outcome overlap with PFI (Chilcot & Moss-Morris, 2013; De Gucht, 2015; 
Knowles et al., 2017; Rutter & Rutter, 2002, 2007). However, to the authors knowledge, 
illness perceptions have not yet been investigated in PFI. 
Illness perceptions can influence self-management behaviours and research has 
demonstrated that coping may mediate reported outcome, including distress, somatic 
symptoms, functioning, and QoL (De Gucht, 2015; Knibb & Horton, 2008; Knowles et al., 
2017; Moss‐Morris et al., 1996). In allergy populations, the CSM was used to explain 
adherence to treatment behaviours in adolescents with FA (Jones et al., 2014), concluding 
those with stronger illness identity and emotional representations of FA were more likely 
to adhere to self-care behaviours, whereas increased timeline cyclical beliefs were 
associated with poorer adherence. Additionally, illness perceptions were reported to 
explain between 6 – 26% of the variance on measures of distress in adults with any form 
of allergy (Knibb & Horton, 2008).  Knibb and Horton (2008) further concluded strong 
illness identity, consequences and emotional representations were associated with 
increased distress and somatic symptoms, and strong personal control beliefs were 




cross-sectional study and not prospective; i.e. participants were not recruited at their 
symptom onset, it is not possible to know the direction of the findings, as increased 
distress and symptom severity could equally influence illness representations.   
The CSM has been substantiated in conditions which are both relevant and related 
to PFI, to help explain factors that contribute to adjustment, self-management and 
outcome. To the authors knowledge, cognitive and emotional representations of PFI have 
not yet been investigated, and so it is difficult to draw conclusions about how individuals 
with PFI think about and manage their condition, or if they even perceive it to be a 
condition. The current study will explore the CSM in relation to PFI, to better understand 
how individuals perceive and respond to PFI and how this influences outcome.   
1.3.5 Coping  
Coping includes both cognitive and behavioural responses and strategies when 
faced with a perceived threat to help manage (reduce, tolerate, or master) the threat 
(Lazarus, 1990; Lazarus & Folkman, 1984). According to the theory of stress and coping 
(Folkman, Lazarus, Dunkel-Schetter, DeLongis, & Gruen, 1986; Lazarus, 1990; Lazarus & 
Folkman, 1984), coping ultimately determines adaptational and functional outcome, and 
was originally considered as coping styles, to be either emotion-focused (used to regulate 
distressing emotions) or problem-focused (used to initiate problem-solving or ‘change’) 
(Folkman & Lazarus, 1985). This view was eventually expanded to account for various 
coping strategies that an individual uses and instruments such as the Coping Orientation 
to Problems Experienced (COPE) scale were developed by Carver, Scheier, and Weintraub 
(1989). The COPE incorporated 14 domains of coping clustered into two groups; those 
that are theoretically more adaptive and those that may not be as functional (Carver et 
al., 1989). Subsequent research using the COPE has suggested strategies such as denial, 
behavioural disengagement and mental disengagement were associated with increased 
distress whereas strategies including positive reframing, acceptance, planning and 
seeking emotional support were associated with decreased distress and better 
adjustment (Carver, 1997; Carver et al., 1993; Carver & Scheier, 2002; Knibb & Horton, 




forms of allergy found that lesser use of coping including positive reinterpretation, 
acceptance, active coping and planning and increased use of strategies such as focusing 
on and venting emotions were associated with elevated stress and anxiety (Knibb & 
Horton, 2008), however, the design of this study precludes drawing conclusions about the 
nature or direction of these relationships.  
While the use of coping scales such as the COPE (Carver et al., 1989), its abbreviated 
version (the Brief-COPE) (Carver, 1997), and other measures have been widely used in 
research, coping scales have been criticised for not all representing similar coping 
constructs and strategies, which makes comparing results from studies using differing 
scales difficult (Skinner, Edge, Altman, & Sherwood, 2003).  Furthermore, scales that 
measure specific coping strategies often do not account for the adaptive nature and 
dynamic context in which the strategies are used, and there are various antecedents and 
contextual considerations that are not accounted for (Skinner et al., 2003; Taylor & 
Stanton, 2007).   
It is important to explore the range of coping strategies that appear to be significant 
in PFI, however, it is necessary to hold that this would not provide a full understanding of 
coping in PFI. A better understanding of the role of coping strategies might help explain 
the relationship between illness perceptions and outcome, as coping potentially has a 
mediating role, as posed by the CSM (Leventhal, 1984).  Further, an initial understanding 
of coping in PFI can contribute to an informed psychological intervention by elucidating 
additional components necessary to include in intervention.  
1.3.6 Health-Related Behaviours 
Research suggests that individuals with PFI experience distress and somatic 
symptoms in relation to their intolerance, and it is possible that this might contribute to 
reported changes in health-related behaviours. Those with PFI are more likely to self-
diagnose, alter their eating habits, avoid specific foods or food groups, or completely 
eliminate perceived triggering foods (Biesiekierski et al., 2014; Blackett, Shamsunder, 
Reilly, Green, & Lebwohl, 2018; Fitzgerald & Frankum, 2017; Knibb et al., 2000; McGowan 




study, Knibb et al. (2000) found that individuals with PFI were more likely to take time off 
work and change their eating habits by avoiding or reducing the offending food than 
controls, and were less likely to have been professionally advised about altering their diet. 
Further, in a sample of individuals reporting PFI, McGowan and Gibney (1993) reported 
that 34% diagnosed themselves, and 57% reported that they nearly always avoid the 
food(s) in question. Undertaking restrictive and/or avoidant diets may impact general 
health including nutrient deficiencies and their sequelae (McGowan & Gibney, 1993). 
Further, the experience of PFI and the potential for consequential food avoidance may 
negatively impact on relationships with food (Böhn et al., 2013), lead to excessive concern 
and worry relating to food, and could potentially influence the development of disordered 
eating behaviours. Preliminary research has found mixed evidence for associations 
between PFI and orthorexia nervosa (McComb & Mills, 2019; Missbach et al., 2015), and 
an association between PFI and avoidant/restrictive food intake disorder (Fitzgerald & 
Frankum, 2017). The tendency for individuals with PFI to self-diagnose and engage in 
restrictive/avoidant behaviours as a result of their PFI provides insight into how these 
individuals self-manage their condition. There is evidence that PFI is associated with 
poorer QoL (Arslan et al., 2004), however, we do not know how individuals with PFI 
perceive their food-related QoL (FR-QoL).  Food and meals, and psychosocial aspects 
surrounding food and meals are an important component of daily living and may be 
associated with distress for those with PFI, who may have to be more careful about what 
they eat and where they can eat (for example, meals out, eating meals ‘on-the-go’, when 
travelling, or at friends or relatives houses), and may be more worried about the impact 
of food and meals on symptoms. 
Research exploring FR-QoL in PFI, to the authors knowledge, does not exist, though 
FA QoL scales for children and parents have been developed and validated (Factor, 
Mendelson, Lee, Nouman, & Lester, 2012).  Following oral desensitisation in children with 
peanut allergy, Factor et al. (2012) described improved FR-QoL including in emotional 
impact, food-related anxiety, social and dietary limitations, dietary restriction, and risk of 




food-related symptoms had poor QoL. Guadagnoli et al. (2019) found that individuals who 
undertook dietary treatments (including food elimination and avoidance) had decreased 
FR-QoL, and additionally reported that individuals with IBS had poorer FR-QoL than 
individuals with Inflammatory Bowel Disease (IBD), which refers to chronic and 
inflammatory GI conditions including Crohn’s disease and ulcerative colitis. In IBD, FR-QoL 
is a considered a significant patient-related outcome, and a specific FR-QoL measure has 
been developed and validated (Hughes et al., 2016). Recent qualitative evidence from 
individuals with IBD indicates that various psychosocial aspects of life impact FR-QoL, and 
patients often use trial-and-error to alter their diets in the hopes of improving the impact, 
though often without success (Czuber‐Dochan et al., 2020). It is important to consider 
that PFI and IBD are very different conditions, though food plays a significant role in 
patient-related outcome in IBD (Hughes et al., 2016), and as food is believed to be a 
significant cause of symptoms in PFI, it is possible that FR-QoL is important in PFI. 
Further, it is plausible that illness perceptions and coping impact FR-QoL as an 
outcome. The beliefs an individual with PFI holds about their intolerance and resulting 
coping strategies used in the context of food or meal-related situations may affect FR-
QoL, though this is not known. Food avoidance and restriction can be targeted through a 
behavioural component of a psychological intervention (Berstad et al., 2005), but better 
understanding the impact and contributors of PFI in FR-QoL will determine if this is a 
necessary component of an intervention. 
 
1.4 Summary 
PFI is a distressing yet largely unexplained condition that affects a significant 
proportion of the population (when compared with FA) and is often reported by women. 
Although there is a substantial body of literature examining the pathophysiological, 
psychological, and health related factors associated with FA, factors associated with the 
maintenance of PFI are understudied and remain largely unknown, despite the 




It is likely that PFI is the result of multiple interactions between biological 
mechanisms, psychological, cognitive and psychosocial factors. Alongside enzymatic, 
pharmacologic and additional undefined mechanisms, it is possible that infection, 
changes in intestinal physiology, and the stress response may contribute to factors 
associated with the onset of PFI. Research investigating psychological characteristics in 
PFI concludes individuals with PFI report frequent and severe somatic symptoms, and it 
is possible that that sensitisation mechanisms proposed to underlie related persistent 
physical symptoms may additionally be implicated in PFI. Previous research additionally 
reports increased distress as compared to those without PFI. Distress may be influenced 
by factors such as illness perceptions, coping, self-management behaviours and 
consequences of PFI, though this requires further investigation   
 
1.5 Rationale and Aims 
There is a need to further examine psychological and additional PFI-related factors 
in adults with PFI, to better understand how these factors may interact to influence 
cognitive appraisals, coping, affect and outcome. Given the strength of the CSM in 
identifying an individual’s beliefs about their illness, and its recent substantiation in 
allergy populations, we are interested in whether the CSM is an appropriate model to 
apply in a PFI population. It is important to identify modifiable factors that may contribute 
to the maintenance of PFI over time, in order to develop a targeted and multifaceted 
psychological intervention to improve outcome. Future intervention could be based on 
Cognitive Behaviour Therapy (CBT), which aims to help an individual identify unhelpful 
beliefs and behaviours and challenge assumptions, or Acceptance and Commitment 
Therapy (ACT), a contextual form of CBT which aims to increase psychological flexibility 
and engage in values-directed actions. Both have the anticipated outcome of managing 
distress, increasing use of flexible coping strategies and improving functioning. 
Research to date is mixed, with several methodological issues. Data are 
predominantly cross-sectional and conducted at the bivariate level, which does not 




precludes casual inferences about the factors associated with PFI. The present study was 
a longitudinal exploratory study that aimed to explore whether applying the CSM provides 
a theoretical framework that can help advance this research, and further, to identify 
significant and modifiable factors that could be targeted in an intervention. We 
investigated whether PFI-related illness perceptions and coping strategies influenced 
negative affect and FR-QoL and explored additional factors that contribute to PFI. The 
results of this study will help to improve understanding of the lived experience of food 
intolerance, which additionally may provide health care professionals with information 
that can be helpful for their patients, and in their own understanding of their patient’s 
complaints.  Additionally, we aimed to identify modifiable factors that may maintain 
distress in PFI, in order to work towards the development of a model and related 
psychological intervention to improve outcome 
 
1.6 Hypotheses 
The study is exploratory, and thus all hypotheses (PH) and aims (PA) are exploratory. 
 
Primary Hypotheses: 
• PH1) To explore and identify any illness perceptions associated with negative affect 
(anxiety and distress) and poor FR-QoL, using bivariate and multivariate analyses. 
o Based on previous research in IBS (Rutter & Rutter, 2002) and allergy (Knibb & 
Horton, 2008), we expect illness representations including illness identity, 
emotional representations, and consequences beliefs to be associated with 
negative affect (anxiety and distress) and poorer FR-QoL, and improved illness 
coherence and control beliefs to be associated with improved affect (anxiety 
and distress) and FR-QoL. 
• PH2) To explore and identify coping strategies associated with negative affect (anxiety 
and distress) and poor FR-QoL, using bivariate and multivariate analyses. 
o Based on previous research in IBS (Rutter & Rutter, 2002) and allergy (Knibb & 




reinterpretation and planning will be associated with improved affect (anxiety 
and distress) and FR-QoL, and that strategies including self-blame and 
disengagement will be associated with decreased affect (anxiety and distress) 
and poorer FR-QoL.  
• PH3) To explore and identify additional psychological and PFI-related factors 
associated with negative affect (anxiety and distress) and poor FR-QoL, including 
perceived stress, symptom severity, functional impairment, and severity of PFI 
(measured by the number of offending foods reported), using bivariate and 
multivariate analyses.   
 
Primary Exploratory Aims:  
To assess the stability of illness perceptions, coping strategies and impact of PFI over time, 
in order to: 
• PA1) To explore the mediating relationship of illness perceptions (T1) and coping (T1), 
on negative affect and poor FR-QoL at T2, to determine whether the CSM is an 
appropriate model to apply to PFI.  
• PA2) To explore the mediating relationship of additional psychological and PFI-related 
factors (T1), illness perceptions (T1) and coping responses (T1), on negative affect and 
poor FR-QoL at T2. 
 
Secondary Exploratory Aim:  
• SA1) To explore the lived experience of PFI, using content analysis from information 









An observational longitudinal design was employed, and data were collected at 
three timepoints; baseline (T1), 3-months post-baseline (T2), and 6-months post-baseline 
(T3). A within-groups design was used to assess illness perceptions, coping strategies, 
negative affect, FR-QoL, perceived stress, functional impairment, and symptom severity, 
to understand if these remain relatively stable, or fluctuate over time.  
To assess primary hypotheses and aims,  the primary dependent variables included 
anxiety as measured by the HADS-A, total distress (HADS-T)  (Zigmond & Snaith, 1983), 
and FR-QoL as measured by the Satisfaction with Food Related Life Scale (SWFL) (Grunert, 
Dean, Raats, Nielsen, & Lumbers, 2007). The primary independent variables were (PH1) 
CSM constructs as measured by the IPQ-R (Moss-Morris et al., 2002), (PH2) coping 
responses as measured by the Brief-COPE (Carver, 1997), and (PH3) additional 
psychological and PFI-related factors including scores from outcome measures (see 2.5.2) 
and severity of PFI (number of foods intolerant to).  
The study was conducted entirely online, involving administering a purpose-
designed questionnaire on the platform Qualtrics (https://www.qualtrics.com/uk/), 
which was completed at three timepoints; baseline (T1), 3-month follow-up (T2), and 6-
month follow-up (T3).  Covariates will include age and gender if significant.   
 
2.2 Power Analysis 
A power analysis was conducted in GPower (Faul, Erdfelder, Lang, & Buchner, 
2007).  Power was set at 0.8, α = 0.05, and indicated a sample size of 150 patients was 
required to detect a moderate effect size of .30, if we were to use all variables entered 
into a regression model (distress, Brief-COPE domains, and IPQ-R constructs). To account 
for 40% attrition over time, the aim was to recruit a sample of N = 210, to ensure the 
study would be sufficiently powered to detect significant predictors, assuming all Brief-




only Brief-COPE domains and IPQ-R factors demonstrating significance from correlational 
analysis.  
 
2.3 Ethical Approval 
Ethical approval for this study (HR-18/19-8576) was granted by the King’s College 
London Psychiatry, Nursing and Midwifery Research Ethics Subcomittee on 27th February, 
2019 (see Appendix I). As this project required participants to consider whether they have 
experienced low mood or anxiety, information regarding sources of support was provided 
in the study information sheet (see Appendix II), which participants were asked to read 
before they were able to proceed to accessing the study consent form (see Appendix III). 
An amendment to add the Perceived Stress Scale (Cohen, Kamarck, & Mermelstein, 1994) 
was approved on 07/05/2019, prior to data collection.  
 
2.4 Participants and Setting 
Participants were adults living in the United Kingdom and were recruited online via 
targeted advertisements via social media, and an advert in the King’s College London (KCL) 
Research Ethics Committee fortnightly circular recruitment email. Three hundred and 
forty-nine adults provided consent to participate study, and of these, three hundred and 
thirty-three completed the questionnaire at baseline.  
2.4.1 Inclusion and Exclusion Criteria 
Potential participants were eligible if they were over the age of 18; fluent in 
English; had access to the internet to complete a survey; and self-reported PFI 
(participants were not subjected to an oral food challenge to confirm their PFI). Potential 
participants were excluded if they had a medically-diagnosed FA only; were acting as a 
proxy for a child’s symptoms; were under the age of 18; and were not fluent in English.  
Exclusion criteria were determined based on the study aim to investigate the individual’s 
subjective experience of PFI in the general population, and as a parent or carer’s 
interpretation of an individual’s experience are not equivalent to the individuals 




over a web-based survey, and for convenience and comprehension purposes the decision 
was made to only include adults fluent in English.  
 
2.5 Study Questionnaire 
2.5.1 Demographic and Clinical Information 
A purpose-designed questionnaire was built (see Appendix IV) including i) basic 
demographic information; age, identified gender, ethnicity (ONS categories), ii) PFI-
related information; a list of 10 clinically recognised common PFI foods, a list of symptoms 
typically reported in PFI, how PFI was diagnosed, age at which symptoms appeared, iii) 
FA-related information; list of 10 clinically recognised allergenic foods, list of symptoms 
typically reported in FA, how FA was diagnosed, use of epi pen, age symptoms appeared, 
iv) additional health information; diagnosis of IBS, Coeliac Disease, and any atopic 
condition. A free text box was included for participants to discuss how PFI affects their 
life. Items were drafted using careful consideration for question type, wording and layout, 
matching response options to questions and applicability of the survey questions to the 
study objective and the participants and was assessed by a focus group of service-users 
to obtain feedback prior to study recruitment (see 2.7). 
 
2.5.2 Outcome Measures 
The Revised Illness Perception Questionnaire (IPQ-R) (Moss-Morris et al., 2002). 
The IPQ-R is a validated measure of an individual’s illness perceptions across 8 subscale 
factors, including identity, consequences, personal control, treatment control, timeline 
acute/chronic beliefs, timeline cyclical beliefs, illness coherence and emotional 
representations. Illness identity is measured by the sum-score of items where an 
individual indicates whether they believe symptoms are related to their illness. The 
remaining subscale factors are measured through a 38 items questionnaire, rated on a 
five-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). The IPQ-R 
additionally measures beliefs about the cause of the condition. Items are considered 




the word ‘illness’ was replaced with ‘intolerance’, and a symptom of ‘brain fog’ was 
added, as it has been reported in PFI. In the current sample, reliability analysis on the 38-
item scale demonstrated acceptable internal consistency (α = .77), and analyses on 
subscale factors of consequences (α = .86), personal control (α = .80), treatment control 
(α = .80), timeline acute/chronic (α = .88), timeline cyclical (α = .88), illness coherence (α = 
.92) and emotional representations (α = .91) demonstrated good internal consistency. 
The Brief COPE Inventory (Brief-COPE) (Carver, 1997). The Brief COPE is a validated 
28-item questionnaire to measure a range of coping responses and is an abbreviated 
version of the original 60-item COPE Inventory. The Brief-COPE consists of 14 subscales, 
which each reflect different coping responses, including self-distraction, active coping, 
denial, substance use, use of emotional support, use of instrumental support, behavioural 
disengagement, venting, positive reframing, planning, humour, acceptance, religion, and 
self-blame. All 28 items are scored on a four-point Likert scale from 1 (‘I haven’t been 
doing this at all) to 4 (I’ve been doing this a lot), and 2 items are combined to compute 
each of the 14 subscale factors. In the current sample, reliability analyses on all scale items 
demonstrated good internal consistency (α = .88), however, internal consistency of the 
subscales varied, ranging from (α = .44) ‘substance-use’ to (α = .89 ) ‘use of instrumental 
support’.  
The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983). The 
HADS is a 14-item reliable and validated scale to assess anxiety (HADS-A) and depressive 
(HADS-D) symptoms, with 7 items allocated to each subscale. Item responses are unique 
to the question and scored on a four-point scale from 0 to 4, with higher scores being 
indicative of increased severity of anxiety or depression symptoms. Clinical cut-off scores 
for both subscales are set at a score of ≥8. The total score (HADS-T) is the sum of all 14 
items. In populations with persistent physical symptoms, the HADS-T has been 
demonstrated to be a particularly useful way to measure general psychological distress 
(Norton, Cosco, Doyle, Done, & Sacker, 2013). Further, the HADS is often used in clinical 
populations as few items reference somatic symptoms in order to provide a reliable 




fatigue, pain or insomnia (Bjelland, Dahl, Haug, & Neckelmann, 2002; Johnston, Pollard, 
& Hennessey, 2000; Norton et al., 2013; Zigmond & Snaith, 1983).    In the current sample, 
reliability on the anxiety and depression subscales demonstrated good internal 
consistency (α = .872) and (α = .856) respectively, and reliability of all scale items (HADS-
T) demonstrated strong internal consistency (α = .90). 
The Satisfaction with Food-Related Life (SWFL) (Grunert et al., 2007). The SWFL 
scale is a short, unidimensional, and valid 5-item measure of food related QoL. All items 
are scored on a seven-point Likert scale from 1 (strongly disagree) to 7 (strongly agree), 
for a maximum sum score of 35 (indicative of being extremely satisfied with food-related 
life). In the current sample, reliability analysis on all scale items demonstrated good 
internal consistency (α = .88). 
The Perceived Stress Scale (PSS) (Cohen et al., 1994). The perceived stress scale is 
a reliable and validated 10-item measure of the degree to which an individual perceives 
events as stressful. Items are rated on a 5-point scale from 0 (never) to 4 (very often), for 
a maximum sum score of 40. Higher scores are indicative of increased perceived stress. A 
review concluded the psychometric properties of the 10-item PSS is superior to those of 
the 14-item and 4-item PSS, with good internal consistency reported (Lee, 2012). In the 
current sample, reliability analyses demonstrated poor internal consistency (α = .20). 
The Work and Social Adjustment Scale (WSAS) (Mundt, Marks, Shear, & Greist, 
2002). The WSAS is a reliable and validated 5-item scale measuring functional 
impairment, to assess the impact of an individual’s difficulties across five domains; work, 
home management, social leisure activities, private leisure activities, and relationships. 
Items are rated on a nine-point Likert scale from 0 (not at all impaired) to 8 (very severely 
impaired), for a maximum sum score of 40. Clinical cut-off on the WSAS is established 
≥10, corresponding to significant functional impairment. In the current sample, reliability 
analysis demonstrated strong internal consistency (α = .94). 
The Patient Health Questionnaire (PHQ-15) (Kroenke, Spitzer, & Williams, 2002). 
The PHQ-15 is a self-administered reliable and valid questionnaire used to assess the 




all) to 2 (bothered a lot). Cut-off scores of 5, 10 and 15 have been set to represent low, 
medium and high symptom severity. In the current sample, reliability analysis 
demonstrated good internal consistency (α = .86).  
The Birmingham IBS Symptom Questionnaire (IBS-SQ) (Roalfe, Roberts, & Wilson, 
2008). The Birmingham IBS Symptom Questionnaire is an 11-item validated scale based 
on Rome-II criteria to assess the severity of IBS symptoms. Items are scored on a 6-point 
Likert scale ranging from 0 (‘none of the time) to 5 (‘all of the time’), which derives a sum 
scale score, and score for three subscales measuring specific symptoms of ‘diarrhea’, 
‘pain’, and ‘constipation’. Scores are calculated specifically for each subscale the total sum 
score, which provide a score out of 100. Previous research has demonstrated has 
acceptable reliability and good test-retest reliability, and reliability in the currently sample 
demonstrated good internal consistency (α = .85).  
 
2.6 Procedure 
The Qualtrics platform was used to collect data from the purpose-built 
questionnaire. The questionnaire was comprised of four sections; 1) participant 
information sheet, 2) eligibility criteria, 3) consent form and 4) the study questionnaire, 
which included a section on demographic and clinical information (see 2.5.1), followed by 
all outcome measures. At the end of the questionnaire, a free text box was included for 
participants to write anything about their PFI that they wished to share. The main study 
questionnaire was only accessible to those who completed the consent form and met all 
eligibility criteria. The questionnaire was developed and shared with a recruited focus-
group, comprised of service-users with PFI (see 2.7). 
Over a one-month period, individuals over the age of 18 were recruited through 
internal KCL REC research recruitment emails, and through online social media sources 
including Facebook, Reddit, and/or Twitter, via REC approved advertisements. Individuals 
were able to respond to advertisements by clicking a link that led them to the study 
webpage, at their own convenience. The study webpage contained a brief description for 




Following the participant information sheet, interested individuals were able to continue 
to a page to assess eligibility criteria. If participants were not eligible, they were exited 
from the webpage. Individuals who met eligibility criteria were taken to the consent form, 
where they were able to provide consent, by selecting a tick box and initialing beside each 
consent criteria, followed by writing their full name, date and email, and creating a unique 
identifier code. Participants who provided consent were taken to the baseline 
questionnaire, which took an average of 34.4 minutes to complete, including reading the 
information sheet, providing consent, assessing eligibility, and completing the study 
questionnaire. Three-months following baseline data collection, participants received an 
email informing them that the 3-month follow-up data collection period was to occur over 
a two-week period, and included a link to complete the T2 survey, which took an average 
of 19.3 minutes to complete. Six-months following baseline data collection, participants 
received an email informing them that the 6-month follow-up data collection period was 
to occur over a two-week period, and included a link to complete the T3 survey, which 
took an average of 22.4 minutes to complete.  
 
2.7 Service-User Focus Group 
Service-users with PFI were involved in a focus group to provide feedback on the 
study questionnaire prior to recruitment via an advertisement was posted online on 
People in Research (https://www.peopleinresearch.org). Service-users who responded 
were invited to read the study information sheet and provide consent to participate in 
the focus group. Participants were offered £10 for their feedback upon completion of the 
study questionnaire and feedback survey. Service-users were asked the following 
questions; (1) did the wording of the questionnaires used make sense to you?; (2) How 
easy was it for you to understand our survey?; (3) How long did it take you to complete 
the survey?; (4) Is there anything we did not include on the survey that you think we need 
to include?; (5) How readable is the font, including size and colour?; (6) Did you have any 




Six service-users participated in the focus group. Following recommendations, the 
survey was altered to make the font darker and larger, and a feature was added to 
enhance continuity of scrolling so that Likert-scale responses were held at the top of the 
screen for readability. Participants indicated the wording and questionnaires made sense, 
and indicated they appreciated the inclusion of a ‘free text’ box at the end of the survey 
to write anything else about their food intolerance that was not asked. On average, the 
participants reported the survey took 20 minutes to complete.  
 
2.8 Data Analysis 
 
Qualitative Analysis 
 Qualitative data was collected to explore the lived experience of PFI and 
content analysis was used to draw themes from their text (Bengtsson, 2016). Participants 
were given the option to freely enter text in response to the question “is there anything 
else that you would like to tell us about your food intolerance or your experience with food 
intolerance?”. The aim was to gather information that may have not been captured 
through included scales in order to better understand the impact and consequences of 
PFI in daily life. Further, the hope was to use the qualitative data to completement and 
provide context to the findings from quantitative analyses if possible. Participant free-text 
responses were analysed for content, and categories and subcategories were identified 
(Hsieh & Shannon, 2005) using a deductive (bottom-up) approach, rather than an 
inductive (top-down) approach in order to illustrate the quantitative findings.  The aim of 
the current study was not to use an inductive approach, though a paper using thematic 
analyses from semi-structured interviews in a sample of participants (N = 6) from the 
current study was completed by another student for a separate project.  
 
Statistical Analysis 
All statistical analyses were carried out using the statistical software package SPSS 
(IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: 




Variables were created to assess sample characteristics and outcome measure 
scores (including sum and subscale scores) at baseline and across T1, T2 and T3. Variables 
created included age category (18-44 or 45+), identified gender (identifies female or does 
not identify female), ethnicity (white or BME), PFI characteristics (PFI-only, PFI+FA, 
severity of PFI, diagnosis of PFI, reported foods and reported symptoms), and additional 
clinical characteristics (diagnoses of IBS, Coeliac Disease and/or Atopic Disease). Outcome 
measure scores included illness perceptions (IPQ-R) including, illness identity, emotional 
representations, timeline acute/chronic, timeline cyclical, personal control, treatment 
control, and illness coherence; coping domains (Brief-COPE) including self-distraction, 
active coping, denial, substance use, use of emotional support, use of instrumental 
support, behavioural disengagement, venting, positive reframing, planning, humour, 
acceptance, religion, and self-blame; FR-QoL (SWFL); anxiety (HADS-A); total distress 
(HADS-T); functional impairment (WSAS); perceived stress (PSS); GI symptom severity 
(Birmingham IBS-SQ) and extraintestinal symptom severity (PHQ-15). For multivariate 
analyses, a variable from the PHQ-15 was created which included all but the three items 
responsible for GI symptoms, to allow for examining GI and extraintestinal symptom 
severity separately. This new variable to measure extraintestinal symptom severity is 
referred to as (PHQ).  
The data were checked for normality (Appendix V). Univariate and bivariate 
analyses including average scores, frequencies, independent and paired samples t-tests, 
chi-square tests for independence, and repeated measures analysis of variance (ANOVAs) 
were used to calculate sample and clinical characteristics. Bivariate correlation and 
multivariate regression and mediation analyses were used to explore associations and 
mediators of ‘outcome’. Outcome was measured in two domains across three outcomes; 
negative affect (including i) anxiety (HADS-A), ii) distress (HADS-Total)) and iii) FR-QoL 
(SWFL). Previous research supports the use of the HADS-T as a measure of distress 
(Norton et al., 2013; Norton, Sacker, Young, & Done, 2011), and in the current study the 
HADS subscales were correlated (r = .61), suggesting good concurrent validity. Further, it 




to anxiety, and additionally that are unique to distress, when HADS-D scores are included 
in the outcome of “distress”.  
Pearson bivariate correlations were conducted to investigate relationships between 
illness perceptions, coping strategies, and additional psychological and PFI-related factors 
and outcome. Due to the large number of correlations reported, alpha was set at 0.01 to 
reduce Type 1 errors. Multivariate analyses including multiple linear regression and 
mediation were used to explore factors that were associated with outcome and those 
that mediated outcome (Figure 1 a,b). 
Multiple regression analyses (using the forced entry and hierarchical method) were 
used to examine the total effect of associations of illness perceptions (PH1), coping 
strategies (PH2) and outcome, and to explore the total effect of additional psychological 
and PFI-related factors (PH3) and outcome. The regression model is demonstrated in 
Figure 1a, which illustrates the total effect (c path) of the independent variable (X) on the 
dependent variable (Y). Preliminary analyses were conducted to ensure no violations of 
normality, linearity and multicollinearity, Analyses of residuals from the model were 
performed to assess model fit and check for outliers.   
Mediation analysis was conducted using the PROCESS v3.4 (Hayes, 2017) macro for 
SPSS, to assess direct and indirect mediation effects of illness perceptions, coping 
responses, and additional factors on outcome. The mediation model is demonstrated in 
Figure 1b, which illustrates the indirect effects (c’ path) of X on Y through a mediating 
variable (M). A 95% bootstrap-confidence interval (5,000 samples) was used to determine 
statistical significance.   





3.1 Participant Flow 
Recruitment and participation flow information is presented in Figure 2.  During the 
recruitment phase, 349 individuals met criteria and consented to participate in the study.  
Baseline data (T1) were collected from (May 22, 2019 until June 5, 2019), and 255 
individuals comprised the baseline sample (see Figure 2).  
Three-month follow up data (T2) were collected from August 22, 2019 – September 
5, 2019. Complete questionnaires were submitted by 170 participants, and following T2, 
156 participants completed all T1 and T2 outcome measures (see Figure 2). 
Six-month follow-up data (T3) were collected between November 22, 2019 to 
December 6, 2019. Complete questionnaires were submitted by 110 participants and 
following T3, matched and complete data at all three time points were obtained for 84 
participants (see Figure 2).  
Due to the number of participants that were lost to follow up, the decision was 
made to not include data from T3 in the final mediation model in analysis and will be 









3.2 Presentation of Results 
Results are presented following the study hypotheses and aims. Sample 
characteristics were calculated using univariate descriptive and inferential statistical 
analyses. To assess PH1, PH2, and PH3 separately and as a whole model, cross-sectional 
baseline correlations and linear regression analyses were conducted for three outcome 
variables including anxiety, distress and FR-QoL. To assess primary exploratory aims, 
paired t-tests and repeated measure ANOVA’s were calculated to measure the stability of 
scores on outcome measures over time (T1 – T2 and T1 – T3) in order to inform 
subsequent longitudinal mediation analyses. To assess PA1 and PA2, temporally ordered 
mediation analyses were conducted to identify mediating mechanisms that contribute to 
outcome, which can aid in developing an effective multifaceted intervention. To assess 
the secondary exploratory aim, content-analysis was used for the qualitative data.  
3.3 Sample Characteristics 
At the start of analysis, the sample was split to compare characteristics of individuals 
who identify female (N = 236; 92.5%) and individuals who do not identify female (N = 19; 
7.5%). The significant size difference in these two groups precluded further group 
analysis, and the results are presented in Appendix VI. The sample was then split to 
compare characteristics of individuals who self-reported PFI only (N = 194; 76.1%) to 
individuals who self-reported both PFI and FA (N = 61; 23.9%), and results are presented 
in Appendix VII. There were no significant demographic differences between groups. PFI-
only were more likely to self-report IBS (2 = 7.71, p = .006), and there was a trend for PFI-
only to be more likely to self-report Coeliac Disease (2 = 3.69, p = .055). There were no 
significant differences in baseline scores on outcome measures, or in the proportion of 
individuals that met HADS subscales caseness threshold.  
The sample was split a third time, in order to compare characteristics of participants 
who reported they had IBS in addition to PFI, against participants who had PFI only. PFI 
and IBS have considerable demographic and symptom overlap, and it is possible that 
these groups share other important similarities, or group differences. The results are 




ethnicity. A larger proportion of individuals with IBS+ PFI had only PFI and no other 
identified FA. Furthermore, individuals with IBS were more likely to report intolerance to 
an increasing number of foods, with 32% of individuals with IBS+PFI reporting intolerance 
to more than 4 foods. Individuals with IBS + PFI reported significantly increased symptom 
severity on the IBS-SQ and the PHQ-15, and furthermore, reported significantly increased 
WSAS scores, indicative of functional impairment, as compared to individuals with PFI 
only.  There were no group differences in anxiety, depression, perceived stress, or FR-
QoL, indicating IBS does not further elevate psychological distress. 
The study aim was to explore factors in PFI, and all following results are for the 
sample as a whole. There seem to be important differences between individuals with PFI 
as compared to individuals with both IBS and PFI, which will be touched on in the 
discussion. The characteristics of the entire sample are presented in Table 1 & Table 2. 
3.3.1 Demographic, PFI-Related and Clinical Characteristics 
255 individuals completed T1. The sample ranged from 18 – 74 years, with an 
average age of 37.7 (15.0), 92.5% identified female, and 90.2% identified Caucasian (Table 
1). Age categories were collapsed to examine differences between participants 18-44 and 
45+, as has been done previously (see Chapter 1). Information regarding education or 
employment was not collected and will be discussed under Study Limitations.  
The median duration of PFI was 11.6 years, and PFI was primarily self-diagnosed 
(61.5%).  Individuals with PFI reported symptoms in response to more than one food 
(71.7%) (see Table 1). Additional GI and atopic conditions were reported by participants, 
including IBS, asthma, environmental allergies and skin-related atopy such as urticaria. 
Mean scores (Table 2) on the FR-QoL, WSAS, PHQ-15, and the PSS were within the 
‘moderate’ range. No clinical cut-offs are set for the Birmingham IBS-SQ.  Mean HADS 
scores on the depression subscale were below clinical threshold (≥8), however, average 
scores on the HADS-A subscale were above clinical threshold (≥8). Across the sample, 
59.6% were above clinical cut-off on the HADS-A and considered to meet ‘caseness’ 




Table 1  
Participant Demographic Characteristics 
T1 (N = 255)  
Demographic Characteristics M (SD) / N (%)  
Age  37.7 (15.0) 
Identify Female 236 (92.5%) 
Caucasian 230 (90.2%) 
18-44 162 (63.5%) 
PFI & Clinical Characteristics Mdn [IQR] / N (%)  
Duration of PFI    11.6 [9.0 – 20.5]      
PFI Only 194 (76.1%) 
PFI & FA 61 (23.9%) 
PFI Diagnosis  
             Self-Diagnosed 153 (61.5%) 
             Medical Professional 76 (30.5%) 
             CAM Practitioner 20 (8.0%) 
Number of Offending Foods   
             1 food 72 (28.3%) 
             2 foods 59 (23.5%) 
             3 foods 55 (21.7%) 
             4+ foods 67 (26.5%) 
Irritable Bowel Syndrome  122 (47.8%)  
Coeliac Disease  19 (7.5%)    
Atopic Conditions  
             Asthma 69 (27.1%) 
             Skin-Related 63 (24.7%) 
             Hay-fever/Rhinitis/Allergy 122 (47.8%) 
             Medication Allergy 66 (25.9%) 
Table 2  
 
Participant Outcome Measure Scores 
 
Outcome Measure Scores T1 (N = 255) T2 (N = 170) T3 (N = 110) 
 M (SD) M (SD) M (SD) 
SWFL  23.1 (7.0) 23.8 (7.2) 23.3 (7.7) 
HADS Anxiety  9.0 (4.9) 9.0 (5.2) 8.8 (5.7) 
HADS Depression  5.9 (4.4) 5.8 (4.5) 5.8 (4.7) 
HADS Total 15.0 (8.0) 14.8 (8.7) 14.3 (9.4) 
WSAS 10.2 (9.1) 9.1 (9.5) 8.9 (9.0) 
PHQ-15 11.7 (5.9) 11.0 (5.5) 10.7 (5.6) 
IBS-SQ Sum Score 28.7 (17.4) 26.6 (18.1) 26.6 (18.1) 




3.3.2 Additional PFI Characteristics 
Commonly Reported Offending Foods 
The most commonly reported intolerance was dairy (including milk and cheese), 
reported by 57.3% of the sample, followed by gluten and wheat (42.3%) (see Table 3). 
The 91 and 77 participants who responded that they were intolerant to ‘fruits, vegetables 
and/or legumes’ and ‘other’ respectively, were asked to indicate which items specifically, 
and results are displayed in Figure 3 and Figure 4.  
 
Commonly Reported Symptoms 
GI symptoms including bloating (24%), stomach pain (21%), and constipation or 
diarrhea (15%), accounted for 60% of reported symptoms. Extraintestinal symptoms 
including fatigue (10%), mood changes (8%), brain fog (7%), headache (6%), joint pain 
(6%) and hives/itching skin (3%), comprised 40% of complaints.  The foods most 
frequently reported to cause both GI symptoms and extraintestinal symptoms were dairy, 






Table 3  
Commonly Reported Offending Foods 
  
  N % of sample 
Dairy (including milk, cheese and lactose intolerance) 153 57.3% 
Gluten and/or Wheat Intolerance  113 42.3% 
Fruits, Vegetables, Legumes 91 34.1% 
Other 77 28.8% 
Egg 40 15% 
Nuts and Seeds 34 12.7% 
Fructose Intolerance 31 11.6% 
Soya 30 11.2% 












































Causal Attributions of PFI 
The three most endorsed causes of PFI on the IPQ-R were heredity (47.2%), 
chance/bad luck (46.5%), and diet/eating habits (45.7%) (see Table 4). Psychological 
attributions were reported by 39.4%.  In the free-text section of the IPQ-R participants 
included their own causal beliefs, and causes relating to gut health, previous health 
conditions, and medication were frequently described (see Appendix IX). 
Table 4  
 
Causal Attributions of PFI 
Cause N % of sample 
Hereditary 126 47.2% 
Chance or bad luck 124 46.5% 
Diet or eating habits 122 45.7% 
Stress or worry 105 39.4% 
My own behaviour 80 30% 
Emotional State 76 28.4% 
Aging 67 25.1% 
Pollution in environment 57 21.4% 
Germ or virus 44 16.5% 
Poor past medical care 39 14.6% 
My mental attitude 39 14.6% 
Overwork 37 13.8% 
Family problems or worries 34 12.8% 
Alcohol 29 10.9% 
Smoking 25 9.3% 
My Personality 23 8.6% 
Altered Immunity 20 7.5% 
Accident or Injury 13 4.9% 
 
3.4 Cross-Sectional Results (PH1, PH2): Illness Perceptions, Coping and Outcome 
3.4.1 Correlational Analysis 
Pearson bivariate correlations were conducted to investigate relationships between 
illness perceptions, coping strategies and outcome. Only correlations significant at α = 





IPQ-R and HADS-A: Five IPQ-R domains including emotional representations, identity, 
consequences, cyclical timeline, and illness coherence were significantly associated with 
anxiety. The strongest correlation was between emotional representations and anxiety (r 
= .36), followed by illness identity (r = .24) and cyclical timeline beliefs (r = .23). Beliefs 
about consequences were less strongly correlated to anxiety (r = .17). Stronger illness 
coherence beliefs, representative of an understanding of PFI, was correlated with lower 
anxiety (r = -.18).  
 
IPQ-R & HADS-T: Illness perceptions that were correlated with anxiety were significantly 
associated with the HADS-T as an outcome of distress.  The strongest correlation was 
between emotional representations and distress (r = .40). Illness identity (r = .27), 
consequences (r = .24) and cyclical timeline beliefs (r = .21) were also associated with 
distress. Stronger illness coherence was correlated with decreased distress (r = -.19).  
 
IPQ-R & SWFL: Four IPQ-R domains correlated with SWFL. The strongest correlation was 
between consequences and poor SWFL  (r = -.43),  followed by emotional representations 
(r = -.41), illness identity (r = -.36), and cyclical timeline beliefs (r = -.21).  
 
IPQ-R & Brief COPE: Four Brief-COPE strategies of denial, disengagement, and self-blame 
were significantly correlated with illness perceptions.  Denial was correlated with illness 
identity (r = .25) and emotional representations (r = .17). Self-blame was correlated with 
emotional representations (r  = .22) and illness identity (r =.19). Disengagement was 
correlated with emotional representations (r =.29) and illness identity (r = .25) but less 
strongly correlated with consequences (r = .21) and cyclical timeline (r =.18). Lower scores 
on disengagement were correlated with stronger beliefs of personal control (r = -.19), 
treatment control (r = -.20) and illness coherence (r = -.17).  
 
Brief-COPE & HADS-A: Seven coping responses including self-distraction, denial, 
substance use, disengagement, venting, positive reframing and self-blame significantly 
correlated with anxiety. The strongest association was between self-blame and anxiety (r 




were less correlated with anxiety include self-distraction (r = .28), substance use (r = .19), 
and venting (r = .18). Positive reframing was the only coping mechanism significantly 
correlated with decreased anxiety (r = -.18).  
Brief-COPE & HADS-T: Coping responses that were significantly correlated with anxiety 
were significantly correlated distress, however, acceptance was additionally correlated. 
The strongest associations were between self-blame and distress (r = .56), followed by 
disengagement (r = .56), and denial (r = .36). Coping mechanisms that correlated to a 
lesser degree include self-distraction (r = .29), substance use (r = .22), and venting (r = 
.20). Positive reframing (r = -.22) and acceptance (r = -.16) were correlated with decreased 
distress. Of note, it appears that once depression is included in the measure of distress, 
acceptance is associated with lower distress.  
 
Brief-COPE & SWFL: Three coping responses correlated with SWFL.  The strongest 
association was between disengagement and SWFL (r = -.28), followed by self-blame (r = 
-.27). Positive reframing was correlated with increased SWFL (r = .21). 
 
3.4.2 Multivariate Linear Regression  
To assess the strength of associations between IPQ-R and Brief-COPE dimensions 
and outcome at baseline, multivariate linear regression analyses were conducted using 
the hierarchical method with factors only significant from correlational analyses.   
 
IPQ-R & COPE on HADS-A as Outcome 
Age was included in Step 1 of this model as older age was correlated with 
decreased anxiety (r = - .210). The model explained 42.4% of the variance in anxiety (see 
Table 5).  At Step 1, age contributed significantly F(1,207) = 9.50, p = 0.002 and accounted 
for 3.9% of the variation in anxiety. In Step 2, introducing illness perceptions explained an 
additional 18% of the variance, and this change in R² was significant, ∆F(5,202) = 10.52, p 
< 0.001. In Step 3, adding coping domains to the model explained an additional 20.5% of 




The results showed that illness identity, emotional representations, and coping using self-
blame are associated with increased anxiety. Older age and positive reframing are 
associated with decreased anxiety. The strongest contributor to anxiety in PFI is 
emotional representations (β = .381) and self-blame (β = .358). 
 
Table 5   
Cross-Sectional Hierarchical Regression of IPQ-R and Brief-COPE: HADS-A as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .209 .039 .044** 
Age -2.275 .683 -.226** -3.330 .005    
Step 2      .491 .219 .198*** 
Identity .430 .117 .254*** 3.663 <.001    
Consequences -.165 .081 -.184 -2.035 ns    
Illness Coherence -.042 .069 -.043 -.615 ns    
Emotional Rep. .316 .076 .381*** 4.177 <.001    
Timeline Cyclical .055 .085 .045 .645 ns    
Step 3      .678 .424 .195*** 
Denial .428 .268 .105 1.594 ns    
Disengagement .307 .220 .100 1.400 ns    
Venting -.200 .212 -.061 -.944 ns    
Positive Reframing -.406 .158 -.153* -2.566 .011    
Self-Blame .855 .173 .358*** 4.934 <.001    
Self-Distraction .126 .186 .044 .677 ns    
Substance Use -.008 .189 -.003 -.044 ns    
* p < 0.05, ** p < 0.01, *** p < 0.001, ns = nonsignificant, R² is adjusted 
 
IPQ-R & COPE on HADS-T as Outcome 
 The model explained 47% (adjusted R²) of the variance in distress (see Table 6). 
At Step 1, illness perceptions explained 18.7% of the variance, and this was significant, 
F(5,203) = 10.6, p < 0.001. In Step 2, adding coping domains to the model explained an 
additional 28.3% of the variation and this change in R² was significant, ∆F(8,195) = 14.6, 
p < 0.001. The results revealed that illness identity, emotional representations of PFI, and 
coping domains of disengagement and self-blame are associated with increased distress, 
whereas positive reframing is associated with decreased distress.  The strongest 
contributors of increased distress in PFI is strong emotional representations (β = .390) 





Table 6   
Cross-Sectional Hierarchical Regression of IPQ-R and Brief-COPE: HADS-T as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .454 .187 .206*** 
Identity .637 .204 .211** 2.957 .002    
Consequences -.199 .141 -.130 -1.368 ns    
Illness Coherence -.121 .120 -.072 -.977 ns    
Emotional Rep. .552 .131 .390*** 4.086 <.001    
Timeline Cyclical .019 .147 .009 .136 ns    
Step 2      .709 .470 .297*** 
Acceptance -.483 .283 -.099 -1.706 ns    
Denial .725 .443 .104 1.635 ns    
Disengagement 1.30 .358 .248*** 3.634 <.001    
Venting -.435 .343 -.078 -1.271 ns    
Positive Reframing -.593 .277 -.131* -2.142 .033    
Self-Blame 1.127 .284 .277*** 3.974 <.001    
Self-Distraction .477 .303 .099 1.573 ns    
Substance Use -.033 .311 -.006 -.106 ns    
* p < 0.05, ** p < 0.01, *** p < 0.001, ns = nonsignificant, R² is adjusted 
 
IPQ-R & COPE on SWFL as Outcome 
 The model explained 26.7% of the variance in poor FR-QoL (see Table 7). In Step 
1, illness perceptions explained 22.3%, and this was significant, F(4,206) = 16.08, p < 
0.001. In Step 2, coping domains explained an additional 4.4% of the variation in poor FR-
QoL and this change in R² was significant, ∆F(3,203) = 5.15, p = 0.002. The results imply 
that illness identity and emotional representations of PFI are associated with poorer FR-
QoL, whereas positive reframing is associated with improved FR-QoL. The strongest 
contributor of poor FR- QoL are strong emotional representations of PFI (β = -.214). 
Table 7  
Cross-Sectional Hierarchical Regression of IPQ-R and Brief-COPE: SWFL as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .488 .223 .238*** 
Identity -.409 .163 -.173** -2.513 .013    
Consequences -.203 .113 -.162 -1.804 ns    
Emotional Rep. -.247 .102 -.214** -2.426 .016    
Timeline Cyclical -.177 .111 -.104 -1.588 ns    
Step 2      .540 .267 .054** 
Disengagement -.107 .327 -.025 -.328 ns    
Positive Reframing .665 .225 .179** 2.954 .004    
Self-Blame -.443 .244 -.132 -1.818 ns    




3.5 Cross-Sectional Results (PH3): Additional Psychological and PFI-related Factors on 
Outcome 
3.5.1 Correlational Analyses 
Pearson bivariate correlation coefficients were conducted to investigate 
relationships between additional factors and outcome (refer to Appendix XI for the 
correlation matrix). Only correlations significant at α = 0.01 are reported.  
 
HADS-A: Elevated anxiety was significantly correlated with increased scores of scales of 
perceived stress (PSS), (r = 0.70), extraintestinal symptom severity (PHQ) (r = .56), GI 
symptom severity (IBS-SQ) (r = .38), functional impairment (WSAS), (r = .36), poorer FR-
QoL (SWFL) (r = -.33), and increased severity of PFI (r = .18).  
 
HADS-T: Elevated distress was significantly correlated with increased scores of stress (r = 
.76), extraintestinal symptoms (r = .59), GI symptoms (r = .38) functional impairment (r = 
.47), poorer FR-QoL (r = -.39).  
 
SWFL: Poor FR-QoL was significantly correlated with scores of increased anxiety (HADS-
A) (r = -.33), distress (HADS-T) (r = -.39), perceived stress (r = -.42), extraintestinal 
symptoms (r = -.41), GI symptoms (r  = -.43),  functional impairment  (r = -.39), and 
increased severity of PFI (r = -.32).  
 
3.5.2 Multivariate Linear Regression 
Hierarchical multivariate linear regression was used to assess the strength of 
associations between additional psychological and PFI-related factors and outcome at 
baseline, only using factors significant from correlational analyses. In the anxiety and 
distress models, the PSS score was entered separately to control for its effects, as stress, 





HADS-A as Outcome 
The model explained 54.2% of the variance in anxiety (see Table 8). Age was 
entered to control for its effect at Step 1, and contributed significantly to the model, 
F(1,210) = 10.52, p = 0.001, accounting for 4.3% of the variance. In Step 2, PSS scores 
explained an additional 43.9% and this change in R² was significant, ∆F(1,209) = 179.14, p 
< 0.001. In Step 3, additional factors and PFI severity explained a further 6% of the 
variance, and this change in R² was significant, ∆F(5,204) = 6.48, p < 0.001. Increased 
stress (PSS) and extraintestinal symptom severity (PHQ) are associated with elevated 
anxiety, whereas older age is associated with decreased anxiety. Apart from stress, the 
strongest contributor to elevated anxiety are extraintestinal symptoms (β = .279). 
Table 8   
Cross-Sectional Hierarchical Regression of Additional Factors Associated with PFI: HADS-A as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .218 .043 .048*** 
Age -2.180 .672 -.229*** -3.273 .001    
Step 2      .698 .482 .440*** 
PSS .419 .033 .675*** 12.754 <.001    
Step 3      .747 .542 .070*** 
SWFL -.018 .040 -.025 -.450 ns    
WSAS .022 .029 .046 .773 ns    
PHQ .238 .060 .279*** 3.964 <.001    
IBS-SQ -.006 .018 .022 .344 ns    
PFI Severity .062 .153 .021 .404 ns    
* p < 0.05, ** p < 0.01, *** p < 0.001, ns = nonsignificant, R² is adjusted 
 
 
HADS-T as Outcome 
The model explained 63.2% of the variance in distress (see Table 9). At Step 1, PSS 
scores explained 55.7% of variation in distress, F(1,213) = 270.20, p < 0.001. In Step 2, 
introducing outcome measures explained a further 7.5% of the variance, and this change 
in R² was significant, ∆F(4,209) = 11.99, p < 0.001. The results indicate that increased 
stress (PSS), extraintestinal symptom severity (PHQ), and functional impairment (WSAS) 
are significantly associated with distress. Apart from stress, the strongest contributor to 





SWFL as Outcome 
The model explained 27.8% of the variance in poor FR-QoL (see Table 10), F(7,203) 
= 12.55,  p < 0.001. Increased stress (PSS), increased GI symptom severity (IBS-SQ), and 
increased severity of PFI, indicated by a greater number of offending foods are 
significantly associated with poorer FR-QoL. Perceived stress was the strongest 
contributor to poor FR-QoL (β = -.229) 
Table 10  
Cross-Sectional Hierarchical Regression of Additional Factors Associated with PFI: SWFL As Outcome  
Variable b SE b β t p R R2 ∆R2 
      .550 .278 .302*** 
HADS-A .009 .128 .006 .072 ns    
HADS-D -.188 .139 -.117 -1.347 ns    
WSAS -.076 .051 -.113 -1.481 ns    
PHQ .042 .111 .035 .374 ns    
PSS -.201 .077 -.229** -2.610 .010    
IBS-SQ -.082 .032 -.203** -2.590 .010    
PFI Severity -.793 .269 -.190** -2.950 .004    
* p < 0.05, ** p < 0.01, *** p < 0.001, ns = nonsignificant, R² is adjusted 
 
 
3.6 Cross-sectional Results (PH1 +PH2 +PH3): Illness Perceptions, Coping and 
Additional Factors on Outcome 
 
Results from the cross-sectional regression analyses revealed specific illness 
perceptions, coping and additional factors associated with anxiety, distress and FR-QoL.  
To explore the impact of illness perceptions (PH1) and coping responses (PH2) on 
outcome while controlling for additional factors (PH3), complete hierarchical regression 
Table 9  
Cross-Sectional Hierarchical Regression of Additional Factors Associated With PFI: HADS-T as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .748 .557 .589*** 
PSS .788 .047 .748*** 16.438 <.001    
Step 2      .801 .632 .082*** 
SWFL -.040 .053 -.033 -.671 ns    
WSAS .116 .042 .142** 2.756 .006    
PHQ .384 .089 .268*** 4.306 <.001    
IBS-SQ -.031 .027 -.065 -1.144 ns    




models were analysed using variables that were significant from previous regressions. In 
the anxiety and distress models, PSS was not entered, as stress, anxiety and distress are 
highly correlated. All R² reported are adjusted.  
 
HADS-A as Outcome 
The model explained 46.3% of the variance in anxiety (see Table 11). At Step 1, 
age was entered to control for its effect, and contributed significantly to the model 
F(1,212) = 10.24,  p < 0.01, accounting for 4.2% of the variance. In Step 2, PHQ scores 
explained an additional 28.5% of variation in anxiety and this change in R² was significant, 
∆F(1,211) = 90.70,  p < 0.001. In Step 3, illness perceptions explained a further 1.8% of 
the variance, and this change in R² was significant, ∆F(2,209) = 4.16,  p < 0.05. In Step 4, 
coping responses explained an additional 11.8% of the variance, and this change in R² was 
significant, ∆F(2,207) = 24.06, p < 0.001. Increased severity of extraintestinal symptoms 
(PHQ), emotional representations and self-blame are associated with elevated anxiety, 
whereas older age and positive reframing are associated with decreased anxiety. The 
strongest contributors to increased anxiety are extraintestinal symptoms (β = .542) and a 
coping response of self-blame (β = .345). 
Table 11  
Cross-Sectional Hierarchical Regression of Additional Factors, IPQ-R, And Brief-COPE: HADS-A as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .215 .042 .046** 
Age -2.169 .678 -.215** -3.200 .002    
Step 2      .577 .327 .287*** 
PHQ .452 .047 .542*** 9.52 <.001    
Step 3      .598 .345 .024* 
Illness Identity .004 .113 .002 .031 ns    
Emotional Rep. .144 .052 .174** 2.797 .006    
Step 4         
Self-Blame .828 .134 .345*** 6.188 <.001 .691 .463 .121*** 
Positive Reframing -.394 .135 -.148** -2.910 .004    






 HADS-T as Outcome 
The model explained 53.4% of the variance in distress (see Table 12). At Step 1, 
increased PHQ and WSAS scores were significant contributors, F(2,209) = 69.78,  p < 
0.001, accounting for 39.5% of the variance. In Step 2, illness perceptions explained only 
0.4% of the variance, and this was not significant, ∆F(2,207) = 1.87,  p = 0.170. In Step 3, 
coping responses explained an additional 13.5% of the variance, and this change in R² was 
significant, ∆F(3,204) = 20.94,  p < 0.001. The results suggest that increased severity of 
extraintestinal symptoms (PHQ), functional impairment (WSAS), and coping responses of 
self-blame and disengagement are associated with elevated distress, whereas positive 
reframing is associated with decreased distress. The strongest contributors to distress are 
extraintestinal symptom severity (β = .410) and self-blame (β = .268). 
Table 12   
Cross-Sectional Hierarchical Regression of Additional Factors, IPQ-R, And Brief-COPE: HADS-T as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .633 .395 .400*** 
PHQ .579 .093 .410*** 6.236 <.001    
WSAS .248 .054 .300*** 4.564 <.001    
Step 2      .641 .399 .010 
Illness Identity -.211 .184 -.074 -1.150 ns    
Emotional Rep. .141 .090 .100 1.571 ns    
Step 3      .741 .534 .139*** 
Self-Blame 1.091 .240 .268*** 4.550 <.001    
Positive Reframing -.625 .218 -.139** -2.869 .005    
Disengagement .897 .334 .171** 2.686 .008    
* p < 0.05, ** p < 0.01, *** p < 0.001, ns = nonsignificant, R² is adjusted 
 
SWFL as Outcome 
The model explained 32.6% of the variance in FR-QoL (see Table 13). At Step 1 
increased PSS and IBS scores, and PFI severity contributed significantly to the model, 
F(3,202) = 37.31,  p < 0.001, accounting for 27.8% of the variance. In Step 2, illness 
perceptions explained a further 3.3% of the variance, and this change in R² was significant, 
∆F(2,200) = 5.68,  p < 0.05. In Step 3, coping responses explained an additional 1.5% of 
the variance, and this change in R² was significant, ∆F(1,199) = 5.44,  p < 0.05. The results 
indicate stress (PSS), severity of GI symptoms (IBS-SQ), PFI severity, illness identity, and 




is associated with improved FR-QoL. The strongest contributors to FR-QoL are stress (β = 
- .328) and GI symptom severity (β = - .233). 
 
Table 13   
Cross-Sectional Hierarchical Regression of Additional Factors, IPQ-R, And Brief-COPE:  SWFL as Outcome 
Variable b SE b β t p R R2 ∆R2 
Step 1      .537 .278 .289*** 
PSS -.280 .054 -.328*** -5.231 <.001    
IBS-SQ -.093 .026 -.233*** -3.532 <.001    
PFI Severity -.784 .258 -.191** -3.035 .003    
Step 2      .572 .311 .039** 
Illness Identity -.315 .156 -.130* -2.017 .045    
Emotional Rep. -.190 .078 -.165* -2.436 .016    
Step 3      .588 .326 .018* 
Positive Reframing .521 .223 .139* 2.333 .021    
* p < 0.05, ** p < 0.01, *** p < 0.001, R² is adjusted 
 
 
3.7 Longitudinal Results (PA1, PA2): Change Scores and Mediation Analyses 
 
3.7.1 Change in Scores Over Time 
Change scores were calculated to assess the stability of illness perceptions, coping 
strategies, and additional factors over time. All IPQ-R, Brief-COPE, and additional 
psychological factors were used in change score analyses, but only the IPQ-R and Brief-
COPE factors clinically significant from regression analyses are shown in Table 14.  Paired 
samples t-tests were used to examine the difference in scores between T1 – T2, and a 
repeated measures ANOVA was used to examine change scores between T1 – T3. Results 
determined no significant differences in IPQ-R, Brief- COPE, or additional outcome 
measure scores from T1 – T2, or from T1 – T3. These findings demonstrate the relative 
stability of PFI and impact of PFI over time, of illness perceptions related to PFI and use of 
















Paired Mean Scores at T1, T2 and T3 and Change Score Statistics  
Variable T1 
(N = 255) 
T2 
(N = 170) 
Change in scores 
T1 – T2 
T3 
(N = 110) 
Change in scores  
T1 – T3 
 M(SD) M(SD) T-Statistic M(SD) F-Statistic 




t(149) = 0.49, p > .05 23.7  
(7.1) 
F(2, 158) = 0.06, p > .05 




t(140) = -0.77, p > .05 9.0  
(5.6) 
F(1.8, 135.6) = 1.18, p > .05 




t(140) = -1.17, p > .05 5.7  
(4.6) 
F(2, 150) = 0.56, p > .05 




t(140) = -1.13, p > .05 14.8  
(9.2) 
F(2, 150) = 1.09, p > .05 




t(138) = -0.93, p > .05 8.9  
(9.0) 
F(1.8, 133.6) = 1.71, p > .05 




t(138) = -0.90, p > .05 10.7  
(5.6) 
F(1.8, 130.5) = 1.48, p > .05 




t(133) = 0.24, p > .05 26.0 
(19.1) 
F(1.8, 130.2) = 0.60, p > .05 




t(135) = 0.70, p > .05 19.1 
(8.6) 







t(140) = 0.81, p > .05 4.2  
(3.0) 








t(153) = -1.09, p > .05 16.1 
(6.0) 
F(2, 166) = 0.00, p > .05 
 




t(133) = -0.81, p > .05 3.0  
(1.5) 
F(2, 150) = 0.56, p > .05 
 




t(135) =0 .61, p > .05 3.8  
(1.9) 







t(134) = 0.69, p > .05 4.0  
(1.8) 
F(2, 142) = 0.09, p > .05 
 
* p < 0.05, ** p < 0.01, *** p < 0.001 
Note: mean scores described in Table 14 are paired means only, as these provide the basis for 




3.7.2 Mediation Analysis 
 Temporally ordered mediation analyses were carried out to determine the direct 
and indirect effects of illness perceptions, coping responses, and additional psychological 
and PFI-related factors at T1 on outcome at T2, using factors significantly related from 
regression analyses. Models were tested using bootstrapping, which determines indirect 
effect sizes and additionally produces a bias-corrected bootstrap (BCB) 95% confidence 
interval. An indirect effect is assumed to be significant if the BCB confidence interval does 
not include zero (Hayes, 2009). Due to considerable attrition from T1 – T3, T2 outcome 
scores at T2 were used in mediation analyses.  
 
3.7.2.1 Illness Perceptions, Coping and Outcome (PA1) 
To test the suitability of the CSM, mediation analyses were conducted to explore the 









HADS-A as Outcome 
Four models were tested to explore the direct and indirect effects of illness 
identity, emotional representations, positive reframing, and self-blame on anxiety. The 
results are presented in Table 15, and Figure 6 shows the full (6a) and partial (6b) 
mediation models. Positive reframing was not a significant mediator of anxiety (see 
Appendix XII). Self-blame completely mediated the effects of illness identity (b = .27) 
Figure 6a, and partially mediated the effects of emotional representations (b = .21) Figure 




6b, on anxiety. Examining path effect sizes revealed that self-blame had a stronger 
influence on anxiety (b path) than the total effect of illness perceptions (C path). 
 
HADS-T as Outcome 
Six models (see Table 15) investigating distress as an outcome were tested to 
explore the direct and indirect effects of illness identity, emotional representations, 
positive reframing, self-blame, and disengagement. Figure 7(a,b,c) presents the partial 
mediation models.  Positive reframing was not a significant mediator (see Appendix XII). 
Self-blame (Figure 7(a,b)) partially mediated the effects of illness identity (b = .58) and 
6a 6b 








emotional representations (b = .40), and disengagement (Figure 7c) partially mediated 
the effects of illness identity (b = .52). Path effect sizes demonstrate that self-blame and 
disengagement had a stronger influence on distress than the total effect of illness 
perceptions. 
 
SWFL as Outcome 
Two models examining FR-QoL as an outcome were tested to investigate the 
direct and indirect effects of illness identity, emotional representations and positive 
reframing (see Table 15). There was no significant indirect effect of illness perceptions on 
FR-QoL through coping (see Appendix XII). Examining path effect sizes revealed that 
illness perceptions had a stronger influence on FR-QoL than coping domains. 
 
3.7.2.2 Additional Factors, Coping and Outcome (PA2) 
Mediation analyses explored possible mediating roles of additional factors, coping 
(negative affect models) and illness perceptions (FR-QoL models) on outcome.  Figures 
for not significant models can be found in Appendix XIII. 
 
HADS-A as Outcome 
Two models were tested to explore the direct and indirect effects of 
extraintestinal symptom severity (PHQ) and coping responses of self-blame and positive 
reframing on anxiety. The results are presented in Table 16. Coping responses did not 
mediate the effect of extraintestinal symptoms on anxiety (see Appendix XIII). 
 
HADS-T as Outcome 
Seven models were tested to explore the direct and indirect effects of 
extraintestinal symptom severity (PHQ) and functional impairment (WSAS), coping 
responses of self-blame, positive reframing, and disengagement on distress. The results 
are presented in Table 16, and Figure 8 shows the partial (8 a,b) and full (8c) mediation 




strategies were not significant mediators of extraintestinal symptoms (see Appendix XIII). 
Self-blame (b =.27) and disengagement (b =.29) partially mediated the effects of 
functional impairment (Figure 8a, and 9b, respectively). Extraintestinal symptom severity 
fully mediated (Figure 9c) the effect of functional impairment on distress (b = .06). 
 
SWFL as Outcome 
Seven models were tested to explore whether stress, GI symptom severity, and 
PFI severity directly impacted FR-QoL, or whether illness identity and emotional 
representations mediated this, and additionally to explore whether GI symptom severity 
mediated the effect of stress in FR-QoL. The results are presented in Table 16, and Figure 
9 shows the and partial (9 a,b,c,d) and full (9 e,f) mediation models. Figures for non-
significant models can be found in Appendix XIII. A stronger illness identity of PFI partially 
mediated the effects of increased stress (b = -.27) on FR-QoL (Figure 9a). Emotional 
representations of PFI partially mediated the effects of stress (b = -.18)  and GI symptom 
severity (b = -.16)  on FR-QoL (Figure 9 b, c).  Increased GI symptom severity partially 
mediated the effect of stress (b = - .15), Figure 9d. The effects of increased PFI severity 
8c 





(Figure 9e,f) were fully mediated by illness identity (b = -.40) and emotional 



























Table 15  
 















X → Y 
Indirect 
Effect 
(95% BCB CI*) 
Illness 
Identity 
b = .18*** 
p < .001 
Self-
Blame 
b = .68*** p 
< .001 
Anxiety ◊◊b = .27  
p = ns 
b = .39*** 
p < .001 




b = -.01 
p = ns 
Pos. 
Reframe 
b = -.31 
p = ns 
Anxiety b = .39*** 
p < .001 
b = .40*** 
p < .001 
b = .00  
(-.04 - .05) 
Emotional 
Rep. 
b = .09*** 




b = .55** 
p = .01 
 
Anxiety ◊b = .21*** 
p < .001 
 
b = .26*** 
p < .001 
 




b = -.03 
p = ns 
Pos. 
Reframe 
b = -.24 
p = ns 
Anxiety b =.26*** 
p < .001 
b = .27*** 
p < .001 
b = .01 
 (-.01, .03) 
Illness 
Identity 
b = .18*** 
p < .001 
Self-
Blame 
b = 1.22*** 
p < .001 
Distress ◊b = .58* 
p = .02 
b = .80*** 
p < .001 




b = -.01 




p = .02 
Distress b =.81 *** 
p < .001 
b = .81*** 
p < .001 
b = .01  
(- .11, .13) 
Illness 
Identity 
b = .16*** 
p < .001 
Disengag
ement 
b = 1.80*** 
p < .001 
Distress ◊b = .52* 
p = .04 
b = .80*** 
p < .001 
b = .28 
 (.07, .54) 
Emotional 
Rep. 
b = .09*** 
p < .001 
Self-
Blame 
b = 1.06*** 
p < .001 
Distress ◊b = .40*** 
p < .001 
b = .50*** 
p < .001 




b = -.03 
p = ns 
Pos. 
Reframe 
b = -.73* 
p = .04 
Distress b = .48*** 
p < .001 
b = .50*** 
p < .001 




b = .00 
p = ns 
Disengag
ement 
b = 2.82*** 
p < .001 
Distress b = .50*** 
p < .001 
b = .49*** 
p < .001 




b = .00 
p = ns 
Pos. 
Reframe 
b = .69* 
p = .02 
Fr-QoL b = -.77*** 
p < .001 
b = -.77*** 
p < .001 




b = -.04 
p = ns 
Pos. 
Reframe 
b = .47 
p = ns 
FR-QoL b = -.48*** 
p < .001 
b = -.50*** 
p < .001 
b = -.02  
(-.06, .01) 
* p < 0.05, ** p < 0.01, *** p < 0.001, BCB-CI* = bias-corrected bootstrap confidence intervals, ◊ 































X → Y 
Indirect 
Effect 
(95% BCB CI*) 
PHQ b = .16*** 
p < .001 
Self-Blame b = .26 
p = .22 
Anxiety b = .33*** 
p < .001  
b = .37*** p 
< .001 
b = .04  
(- .02, .12) 
PHQ b = -.001 
p = .862 
Pos. 
Reframe 
b = -.31 
p = .12 
Anxiety b = .37*** p 
< .001 
b = .37*** p 
< .001 
b = .00  
(- .02, .02) 
PHQ b = .16*** 
p < .001 
Self-Blame b = .41  
p = .23 
Distress b = .68*** p 
< .001 
b = .74*** p 
< .001 
b = .07  
(- .03, .19) 
PHQ b = -.001 




p = .006 
Distress b =.74***  
p < .001 
b = .75*** p 
< .001 
b = .00  
(- .04, .04) 
PHQ b = .12*** 
p < .001 
Disengag. b = .73 
p = .12 
Distress b = .65*** p 
< .001 
b = .74*** p 
< .001 
b = .09 
(- .03, .23) 
WSAS b = .06** 
p = .002 
Self-Blame b = 1.06** 
p = .002 
Distress ◊b = .27*** 
p < .001 
b = .33*** p 
< .001 
b = .06  
(.01, .13) 
WSAS b = -.01 
p = ns 
Pos. 
Reframe 
b = -.79* 
p = .02 
Distress b = .35*** p 
< .001 
b = .36*** p 
< .001 
b = .01  
(-.02, .05) 
WSAS b = .07*** 
p < .001 
Disengage b = 1.31** 
p = .01 
Distress ◊b = .29*** 
p < .001 
b = .39*** p 
< .001 
b = .09 
(.02, .20) 
WSAS b = .37*** 
p < .001 
PHQ b = .68*** 
p < .001 
Distress ◊◊b = .06 
p = .46 
b = .31*** 
p < .001 
b = .25 
(.13, .40) 
PSS b = .10** 
p = .003 
Illness 
Identity 
b =- .56** 
p = .004 
Fr-QoL ◊b = -.27*** 
p < .001 
b = -.33*** 
p < .001 
b = - .05  
(-.12, -.01) 
PSS b = .37*** 
p < .001 
Emotional 
Repres. 
b = - .40*** 
p < .001 
FR-QoL ◊b = -.18* 
p = .02 
b = -.33*** 
p < .001 
b = -.15  
(-.25, -.07) 
PSS b = .17*** 
p < .001 
IBS-SQ b = - .18*** 
p < .001 
FR-QoL ◊b  - .15* 
p = .04 
b =- .34*** 
p < .001 
b = -.18*** 
(-.27, -.10) 
IBS-SQ b = .07*** 
p < .001 
Illness 
Identity 
b = -.41* 
p = .04 
FR-QoL b = -.18*** 
p < .001 
b = .21*** p 
< .001 
b = - .03  
(-.06, .003) 
IBS-SQ b = .17*** 
p < .001 
Emotional 
Repres. 
b = -.32*** 
p < .001 
Fr-QoL ◊b =- .16*** 
p < .001 
b = .21*** p 
< .001 




b = .55** 
p < .001 
Illness 
Identity 
b = -.69*** 
p < .001 
Fr-QoL ◊◊b = -.40 
p = .30 
b = - .78* 
p = .05 




b = .97** 
p = .004 
Emotional 
Repres. 
b = - .52*** 
p < .001 
FR-QoL ◊◊b = -.30 
p = .40 
b = - .80* 
p = .04 
b = -.50  
(-.92, -.13) 
* p < 0.05, ** p < 0.01, *** p < 0.001, BCB-CI* = bias-corrected bootstrap confidence intervals,  ◊ denotes 




3.8 Content Analysis Results: Lived Experience of PFI 
The secondary aim was to explore the lived experience of PFI, specifically, to 
communicate the personal, social and societal consequences of PFI, and the health-
related behaviours individuals implement to manage PFI. A deductive approach to the 
content analysis of participants free-text responses was taken, four major themes were 
identified, some with related subthemes, including; 
 
1) Personal Psychological Impact of PFI, which describes the personal psychological 
impact of PFI, and included subthemes of; Attitude towards PFI; Coping & 
Adjustment; Impact on mood; Understanding PFI (see Table 17). The subtheme 
‘Attitude towards PFI’ includes content regarding how participants described their 
thoughts or beliefs towards their PFI, including factors such as motivation, 
determination, apathy or willpower. The subtheme ‘Coping & Adjustment’ includes 
content where participants specifically described coping responses, their thoughts or 
feelings towards coping or content regarding their adjustment to PFI. The subtheme 
‘Impact on mood’ includes content whereby participants specifically described or 
mentioned a change in mood or impact on mood, including feeling low, anxious, 
distressed, upset, or conversely described a change in how they feel or think about 
themselves. The subtheme ‘Understanding PFI’ includes content whereby 
participants described how they think about and understand their PFI.  
2) Social Impact of PFI, which describes the psychological and emotional impact PFI in a 
social context, such as relating to how PFI impacts social gatherings or perceptions 
from friends and family (see Table 17). This theme includes content whereby 
participants mentioned perceptions from another person, or thoughts or emotions 
they may experience in or in relation to social situations.  
3)  Societal Impact of PFI, which describes the impact of having PFI in larger society and 
included subthemes of; Grocery shopping and Convenience meals / Eating at 
restaurants (see Table 17). The subtheme ‘Grocery shopping’ includes content 




experiences when grocery shopping with a PFI, whereas the subtheme ‘Convenience 
meals / Eating at restaurants’ includes content where participants described their 
experience or the impact of eating food ‘on-the-go’ or at restaurants.  
4) Diagnosis and Management of PFI, which describes how individuals with PFI 
diagnosed and manage PFI, such as their treatment strategies and approaches  and 
included subthemes of; Contact with Medical Practitioners; Diagnosis; 
Avoidance/Restriction; Supplements; Cooking at home; Checking / Being careful (see 
Table 17). The subtheme ‘Contact with Medical Practitioners’ includes content where 
participants mentioned any experience when contacting or seeking help from a 
medical practitioner, including having input, advice, treatment plans, diagnosis or a 
greater understanding of PFI from a medical practitioners’ involvement.  The 
subtheme ‘Diagnosis’ includes content where participants described how they came 
about having their PFI diagnosed, whether this was self-diagnosed or diagnosed by 
any other person or test. The subtheme ‘Avoidance/Restriction’ includes responses 
and content regarding managing PFI through avoiding or restricting the offending 
food(s). The subtheme ‘Supplements’ includes any mention of using supplements to 
help manage PFI and its related somatic symptoms. The subtheme ‘Cooking at home’ 
includes content where participants identified cooking meals at home in order to 
manage PFI. The subtheme ‘Checking / Being careful’ included responses whereby 
participants described using management strategies to help prevent a reaction that 
involved checking (checking ingredients, checking with restaurant staff, checking 
menus or washroom locations ahead of time), and being careful (using food diaries, 
timing meals). 
 
A sample of the content analysis is included in Table 17, and all quotes are fully 
anonymised. The quotes from participants have been separated according to the themes 




Table 17  























Attitude towards PFI 
“It takes a lot of willpower and determination” 
 
“Sometimes I just give up and sometimes I am very determined” 
 
Coping & Adjustment 
“You learn to live with it, but it does affect your ability to cope especially during a flare up” 
 
“I accept my condition. Though I get annoyed when my symptoms flare up… shouldn't, 
but overall I know I can't change it and have lived with [the symptoms] for so long 
that it is 'normal” 
 
“I have lived with [it] since my teens, I am now 63, I have learned to control it”. 
 
“It was harder to cope with pain and some symptoms during teenage years than today” 
 
Impact on Mood 
“It exacerbates my anxiety” 
 
“I feel my emotions are quite flat on the happy/joy side since I developed the intolerance” 
 
“It's getting me down that I have to avoid so many foods and that I face consequences 
if I don't” 
 
“or I think I might 'get away' with [the food]. Then I regret it and feel stupid!” 
 
Understanding PFI 
“Understanding is limited, and I generally have to plan down time afterwards [eating 
an offending food]” 
 
“The most difficult part is not knowing precisely what food (or what amount of food) 
















“…makes me feel like an attention seeker” 
 
“explaining over and over that you are trying to avoid it often draws annoying reactions 
from other people” 
 
“now people are more accepting that I have food intolerances and don't think that I am 
just being "weird and picky" about what I eat” 
 
“I feel embarrassed sometimes refusing the food people have kindly prepared” 
“It can be quite stressful and create anxiety when trying to organise things with  friends 















“Shopping takes longer because I have to read labels…even of known products as some 
brands change the ingredients of regular products…also deciphering …technical terms… 
and trying to decide if I'll take a chance or not” 
 
Convenience Meals / Eating at Restaurants 
“when I have to rely on convenience foods…I know I am taking a chance” 
 
“I get a bit anxious whenever I eat out.” 
 
“constant need to make sure the restaurant can prepare the right food and that there 
are toilets available” 
 




















Contact with Medical Practitioners 
“Lack of understanding by doctors is a big limiting factor to getting effective 
medication” 
 
“I have never expected my Doctor to find a solution” 
 
“There isn’t any input from [health professionals] to help check you’re getting everything 
you need nutrient wise or recommend alternatives” 
 
Diagnosis 
“It took me a few years to realise what was wrong. I did food elimination and did get a 
blood test done too.” 
 
“From my own understanding/research I feel I have this food intolerance but have not been 
























“I avoid foods that cause me problems but at times it doesn’t make any difference as 
I’m still ill” 
 
“It requires abstaining from certain foods but it’s worth the effort” 
 
”I tend to rely on self-directed elimination diets” 
 
Supplements 
“I can take lactase pills whenever I would like to eat dairy” 
 
Cooking at Home 
“It is much easier to eat at home or not eat when outside to avoid symptoms” 
 
Checking / Being Careful 
“I use “logistics” to minimise the chances of an episode, e.g. always choosing a ‘safe’ 
option from the menu, timing meals…go home straight after eating etc.” 
 




The results from the content analysis highlight challenges and consequences related 
to PFI, as detailed by individuals with PFI.  Participants described the personal 
psychological impact of PFI, including that PFI is something that requires ‘determination’ 
and ‘willpower’ to manage, and this can be difficult to adhere to. Of interest, negative 
emotional effects of food avoidance were identified; individuals reported difficulty in 
maintaining strict avoidance, and that when offending foods are eaten, there are reports 
of feeling ‘annoyed’, ‘stupid’, and ‘down’, which is in line with the quantitative findings of 
a tendency towards response of self-blame and disengagement.  Individuals discussed the 
social implications of PFI, including ‘drawing reactions from other people’, feelings of 
‘anxiety’ in the face of social plans, and ‘embarrassment’ if food that others prepare is 
refused. Participants described how eating meals out was precarious, and associated with 
‘taking a chance’, feeling ‘anxious’, and a ‘constant need’ to check and plan ahead. The 
sample described a ‘lack of understanding’ and lack of ‘input’ from medical professionals, 




described self-directed treatment by food elimination and avoidance, which nearly all 
respondents reported.      
  Of interest, an understanding of PFI may be related to how effective management 
is.  Participants described limitations of their own understanding of PFI, which meant 
needing to plan for ‘downtime’ and not knowing ‘precisely what food or what amount to 
avoid to avoid symptoms’, whereas another participant described being able to take a 
lactase pill whenever they wanted to eat dairy products.  
Across themes, behaviours including avoidance (of food, of social situations, of 
restaurants) and planning ahead (planning for downtime, planning restaurants that have 
a toilet available, timing meals, planning to go home straight after), arose as common 
ways individuals self-manage PFI to reduce symptoms. Of note, the only participants that 
shared that they had found a way to successfully manage PFI with no unintended 
consequences were individuals who reported lactose-intolerance managed through 



















This paper describes the first longitudinal study conducted to explore psychological 
factors reported by individuals with PFI over time, and the role of these factors in 
outcomes including negative affect (anxiety, distress) and poor FR-QoL. The current 
dissertation aimed to assess the applicability of the CSM in PFI, and quantitatively 
investigated the direct and mediating roles of illness perceptions, coping responses, and 
additional psychological and PFI-related factors associated with poor outcome in PFI. An 
additional aim was to qualitatively analyse the content and themes on the lived 
experience of PFI from free text data.  
 
4.1 Summary of Findings 
Our results lend support to our hypotheses that illness representations and coping 
contribute to outcome in PFI. Coping responses of self-blame and disengagement were 
important contributors to anxiety and distress and had mediating roles on the effect of 
illness perceptions. The role of illness perceptions including illness identity and emotional 
representations were significant contributors to poor FR-QoL, and mediators of stress, PFI 
severity, and symptom severity. Furthermore, findings indicate extraintestinal and GI 
symptom severity contributes to negative affect and poor FR-QoL, respectively. 
Identifying modifiable correlates of PFI is necessary in order to develop an intervention 
to improve outcome, and the findings have allowed for consideration of an evidence-
informed intervention. The following discussion of findings will be presented with sample 
characteristics, followed by results separated by outcome (negative affect and FR-QoL).  
 
4.2 Summary of Sample Characteristics 
A considerable proportion of the sample were female (92.5%), which is consistent 
with previous research demonstrating PFI is more often reported by women (see Chapter 
1). This suggests that although our sample is representative of PFI, as it is predominantly 




are in line with findings described in Chapter 1, and additional previous research 
(Biesiekierski et al., 2014; Knibb et al., 2000; McGowan & Gibney, 1993; Nelson & Ogden, 
2008; Nettleton et al., 2010); our sample predominantly reported symptoms in response 
to more than one food (71.7%), described GI and extraintestinal symptoms including 
bloating, stomach pain, bowel changes, fatigue and mood changes, and primarily self-
diagnosed PFI (61.5%). Just under half of the sample self-reported IBS (47.8%), and those 
with IBS+PFI had increased functional impairment, symptom severity, and severity of PFI, 
reporting more offending foods, compared to individuals with PFI alone.  
Self-reported depression was below clinical threshold, though above scores 
previously reported in PFI samples (Lillestøl, Berstad, et al., 2010; Lind, Lied, et al., 2010). 
Research in PFI has rarely reported case-level anxiety, however, in the current study, self-
reported anxiety was above clinical threshold across all three time points. Research in PFI 
samples from Norway have reported average HADS-A scores at 5.3(3.7) (Lillestøl, Berstad, 
et al., 2010) and 4.9(3.5) (Lind, Lied, et al., 2010), compared to the current study T1 = 9.0 
(4.9). The aforementioned research was conducted in smaller clinical samples, whereas 
the current study was formed of a larger non-clinical sample, who reported significantly 
increased anxiety. However, the average age in these two samples, 39.5 (Lillestøl, 
Berstad, et al., 2010) and 39.2 (Lind, Lied, et al., 2010) is similar to the average age in the 
current sample, which was 37.7.  This suggests that results from the current community 
sample might be more generally representative of individuals with PFI, bearing in mind 
the significant proportion of women in the sample. Investigating PFI in IBS populations 
has established HADS-A scores above clinical threshold (Dainese et al., 2014; Nybacka et 
al., 2018). Less than half of the current participants reported IBS, implying that anxiety is 
characteristic of the sample independent of IBS. It appears self-reported anxiety is a 
clinically significant feature of the sample and is higher than has been previously reported 
in PFI populations.  
Illness representations in PFI were related to one another and to subsequent coping 
responses. A strong illness identity, measured by the attribution of symptoms to PFI was 




PFI. Illness identity was additionally related to beliefs that PFI would last a long time and 
also that it is cyclical and unpredictable. Beliefs about consequences of PFI were strongly 
related to emotional representations, illness identity and timeline representations. Beliefs 
about control of PFI were related to improved ideas about how long PFI would last and 
an improved emotional response.  Stronger illness coherence beliefs, relating to a better 
understanding of PFI, was associated with weaker emotional representations, and 
improved timeline cyclical beliefs, suggesting that the more someone understands PFI, 
the less upsetting and unpredictable they perceive it. Illness representations were 
understandably related to coping responses. High illness identity and emotional 
representations scores were related to avoidant coping responses including denial, 
behavioural disengagement and self-blame. Beliefs about the consequences and 
unpredictability of PFI were associated with behavioural disengagement, whereas 
stronger control and coherence beliefs were related to less disengagement.  
 
4.3 Outcome Summary: Negative Affect  
The results support our primary hypotheses, and established that illness 
perceptions, coping responses and additional psychological and PFI-related factors have 
direct associations to negative affect in PFI. The data established that this effect is stable 
over a 6-month period in the current sample, and the exploratory aim to use temporally 
ordered mediation analyses to assess suitability of the CSM was supported. 
Illness perceptions including emotional representations and illness identity were 
most strongly associated with negative affect, including anxiety and distress, followed by 
beliefs about consequences, a cyclical timeline and illness coherence, at a bivariate level, 
which was expected and in line with research in IBS populations (Rutter & Rutter, 2002, 
2007). Coping responses were more strongly correlated with anxiety and distress than 
illness perceptions. Coping responses of self-blame, disengagement, denial and self-
distraction were associated with elevated anxiety and distress, whereas responses of 




Baseline multivariate linear regression models, which accounted for 42.4% - 46.3% 
of the variance in anxiety, and 47% - 63.2% of the variance in total distress, provided 
confirmation for some of the exploratory findings. However, significant findings for beliefs 
related consequences, illness coherence and a cyclical timeline, and a coping response of 
acceptance were not retained, and will be discussed. Illness perceptions of emotional 
representations and illness identity, and coping responses of self-blame (anxiety and 
distress) and disengagement (distress only) were significantly associated with negative 
affect, whereas positive reframing was associated with improved affect. Results 
additionally revealed that functional impairment (distress only) and extraintestinal 
symptom severity increases negative affect.  
Age was included as a covariate in the anxiety models, and results from regression 
analyses established that a younger age was significantly associated with increased 
anxiety.  Though this was not specifically explored in the current study, there are potential 
hypotheses to account for age effects supported by the findings from content analysis, 
which suggest a role of age and adjustment in helping to cope with PFI.  Research 
exploring the concept of illness intrusiveness, or the illness-related disruptions in valued 
activities, interests and lifestyles (Dancey, Hutton-Young, Moye, & Devins, 2002; Devins 
et al., 1996), has demonstrated that younger-age adults appear to experience more 
significant distress and decreased well-being (Devins, Bezjak, Mah, Loblaw, & Gotowiec, 
2006; Devins et al., 1996). It is possible that participants over 45 have lived with PFI for a 
longer time; analysis from the current sample indicates that participants over 45 have had 
PFI for an average of 22.5 years, compared to 12.4 years for participants under 45. A 
longer lived-experience with PFI may have equipped these participants with a better 
understanding of their symptoms and intolerances, or more flexible ways to cope with or 
adjust to lifestyle changes in PFI, though this has not been confirmed. Further, research 
has established that older-age adults are better able to adjust or disengage from goals 
and tasks that may be unattainable, and that this can be protective for well-being (Dunne, 
Wrosch, & Miller, 2011). In PFI this may mean that older participants are better able to 




Results from the content analysis suggests that participants who had lived with symptoms 
since they were teenagers had ‘learned to control it’ now and found ‘it was harder to cope 
with pain and some symptoms’ when they were younger. These findings would be 
important to explore in future qualitative research. 
Mediation analyses established that coping responses of self-blame and 
disengagement had a mediating role in the relationship between illness perceptions and 
negative affect, providing support for a study aim of testing the CSM in PFI. Path analyses 
revealed that  coping had a stronger influence on outcome than illness perceptions, and 
an accumulation of evidence has established that coping responses contribute to 
psychological distress (Burker, Evon, Loiselle, Finkel, & Mill, 2005; Carver et al., 1993; 
Carver & Scheier, 2002; Carver et al., 1989; Doering et al., 2004; Snow-Turek, Norris, & 
Tan, 1996; Wu et al., 2013), though the outcome of any coping strategy can said to be 
adaptive or maladaptive depending on factors such as the context in which it is used and 
the intent of the strategy used (Moss‐Morris et al., 1996). Positive reframing was the only 
coping response associated with improved affect significant from regression analyses, yet 
showed no mediating effects, which is consistent with previous research that has found 
that avoidant coping responses are more strongly associated with poor outcome and 
distress (Brown et al., 2007; Burker et al., 2005; Carver et al., 1993; Compas et al., 2006; 
Doering et al., 2004; Drossman et al., 2000; Moss‐Morris et al., 1996; Murberg & Bru, 
2001; Scharloo et al., 1998; Snow-Turek et al., 1996; Trivedi et al., 2009).   
A significant effect was found for behavioural disengagement and functional 
impairment specific to distress, suggesting that these were important only once the 
depression subscale was included in the measure of total distress. Research in clinical 
health populations have demonstrated an association between disengagement, 
depression, poor outcome, and functional impairment in clinical health populations 
(Brown et al., 2007; Carver et al., 1993; Compas et al., 2006; Moss‐Morris et al., 1996; 
Murberg & Bru, 2001; Rutter & Rutter, 2002, 2007; Trivedi et al., 2009). Disengagement 
was associated with distress, however, as most participants had PFI for a median of 11.6 




been experienced for a number of years and influences disengagement. In the distress 
mediation models, self-blame and disengagement partially mediated the effects of 
functional impairment, however, a subsequent model confirmed functional impairment 
was fully mediated by extraintestinal symptom severity.  In IBS samples, depression 
(Ballou & Keefer, 2017; Frändemark, Törnblom, Jakobsson, & Simrén, 2018; Koloski, 
Boyce, Jones, & Talley, 2012) and non-GI symptoms (Frändemark et al., 2018; Koloski et 
al., 2012) have been associated with impaired mental and physical functioning and work-
related productivity. Again, it is not possible to know the direct causality of the current 
findings, though future prodromal or prospective studies could address this.  
Extraintestinal symptom severity appears to be an important factor in negative 
affect.  Results from mediation analyses demonstrated significant total effects of 
extraintestinal symptom severity and that this was not mediated by any coping response, 
highlighting the significant impact of non-GI symptoms on negative affect in PFI. It is 
possible that extraintestinal symptoms such as fatigue, mood changes, headache, brain 
fog and joint pain are more distressing for individuals as they are not often an expected 
reaction to food and so individuals may be worried about the cause and meaning of the 
symptoms. Additionally, these symptoms may have a more significant impact on daily life, 
interfering with school, work, relationships and leisure activities. Prior research in 
persistent physical symptom populations have demonstrated that non-GI symptoms are 
often associated with psychological distress, functional limitations, less adaptive coping 
and poorer health outcome (Ballou & Keefer, 2017; Edwards, Dworkin, Sullivan, Turk, & 
Wasan, 2016; Frändemark et al., 2018; Koloski et al., 2012).  The results provide support 
for a role of extraintestinal symptoms as associated with negative affect and functional 
impairment, but it is important to explore this further in future research to disentangle 
the mechanisms through which these relationships occur, and if there are other factors 
which contribute to increased extraintestinal symptom severity.  
The data suggests that coping responses of self-blame and disengagement have a 
mediating role on the effect illness perceptions in negative affect, providing support for 




significant contributor to negative affect, and not mediated by coping. A future 
intervention should address how self-blame and disengagement are used in PFI, and how 
extraintestinal symptoms are perceived and responded to, as these contribute to affect 
and functional impairment. It would be important to provide individuals with PFI coping 
skills and strategies to help self-manage symptoms and PFI-related consequences, to 
contribute to improved outcome.  
 
4.4 Outcome Summary: Food Related Quality of Life 
The results established that illness perceptions, coping responses and additional 
psychological and PFI-related factors have direct associations to FR-QoL in PFI, supporting 
our hypotheses. Suitability of the CSM in an outcome of FR-QoL using the SWFL as a 
measure was not supported. 
Correlation coefficients determined illness perceptions including consequences, 
emotional representations and illness identity held stronger correlations to FR-QoL than 
coping responses. Self-blame and disengagement negatively impact FR-QoL, whereas 
positive reframing a situation or response was related to improved FR-QoL.  
Baseline multivariate linear regression models to test the three primary 
hypotheses and accounted for 26.7% - 32.6% of the variance in FR-QoL. Illness identity 
and stronger emotional representations of PFI accounted for a higher proportion of the 
variance than coping responses. Positive reframing was the only coping response 
associated with improved FR-QoL. Results established that perceived stress, GI symptom 
severity and severity of PFI were additionally significantly associated with poor FR-QoL.  
Mediation analyses demonstrated no significant mediating effect of positive 
reframing on illness representations, indicating that the hypothesised mediating role of 
coping in the CSM may not be suitable in FR-QoL, when using the SWFL as a measure of 
FR-QoL.  Additional mediation models demonstrated the effects of stress were partially 
mediated by illness perceptions and additionally by GI symptom severity. Further, PFI 
severity was fully mediated by illness perceptions. Finally, the effects of increased GI 




evidence suggests that illness identity, emotional representations, stress and GI 
symptoms severity are important modifiable factors to address in a future intervention to 
improve FR-QoL. 
The experience of GI symptoms in IBS has been reported to be associated with 
anticipation of an unpredictable symptom episode, shame associated with losing control 
of bowel function, and limitations in daily life (Chang et al., 2006). In PFI, GI symptoms 
(which includes uncomfortable symptoms and distressing consequences) were partially 
mediated by emotional representations, indicating that the emotional impact of PFI 
influences GI symptom severity. It is possible that experience of GI symptoms negatively 
impacts FR-QoL as through conditioning, food and meals may become associated with a 
potential symptom episode and related consequences. Furthermore, a negative 
association between food and the experience of GI symptoms could contribute to 
increased stress surrounding food and meals. This is of interest, as evidence suggests that 
the stress response can independently modulate gut function and GI motility through gut-
brain interaction, which contributes to GI symptomatology, and has been implicated in 
IBS and FGID (Mayer, 2000, 2011; Mayer, Craske, & Naliboff, 2001; Mayer, Naliboff, et al., 
2001; Mayer & Raybould, 1990). Therefore, it is possible that seeing or thinking about 
offending foods or meals alone could induce a stress response and related changes in GI 
function, resulting in the physical and emotional experience of GI symptoms, which can 
impact an individual’s FR-QoL. It would be important to explore these hypotheses further.  
The current results provide evidence for a role of illness perceptions, stress and 
GI symptom severity in FR-QoL. Mediation was confirmed in other analyses, and it is 
possible that the CSM hypotheses were not supported in FR-QoL as a result of the 
measure chosen, which will be discussed. In a future psychological intervention, 
incorporating psychoeducation on the role of stress, stress management, and the gut-
brain axis in GI symptomatology, as well strategies to manage how symptoms are 





4.5 Results Summary & Theoretical Implications 
The results support our hypotheses that illness perceptions and coping both directly 
influence outcome, and partially support the applicability of the CSM in PFI. Overall, the 
findings of the study have important implications for theory, practice and future research. 
Over a 6-month follow-up period, there were no changes in illness perceptions, coping 
responses, psychological distress, FR-QoL, somatic symptom severity, perceived stress or 
level of functional impairment. This demonstrates the relative stability and impact of PFI 
over time and may imply that in our sample, the experience of PFI is not largely influenced 
by external stressors. Further, the results imply that how individuals think about PFI and 
its related symptoms and subsequently cope, may contribute to sustained poor outcome.  
An aim of the study was to determine whether the CSM is an appropriate model to 
apply to PFI. The results established that coping responses of self-blame and 
disengagement had significant partial and complete mediating roles in the link between 
illness identity and emotional representations and negative affect. Previous research 
testing the CSM in allergy (Knibb & Horton, 2008) and IBS (Knowles et al., 2017; Rutter & 
Rutter, 2002, 2007) populations have found that coping has mediating effects between 
illness perceptions and psychological distress. However, coping responses did not have a 
significant mediating role in an outcome of FR-QoL, and illness perceptions contributed 
to more variance than coping. Overall, the hypothesis that coping is a mediating factor 
between illness representations and outcome could only partially be confirmed, and the 
CSM can be appropriately applied to negative affect.  
Subsequent mediation models testing additional factors in PFI highlighted that 
coping responses had no mediating effect on extraintestinal symptom severity in anxiety 
or distress. An IPQ-R domain of emotional representations partially mediated the effects 
of GI symptom severity in FR-QoL, indicating that the emotional distress in relation to GI 
symptoms was an important factor in poor FR-QoL. Overall, the findings provided 
evidence that a hallmark feature of PFI, somatic symptoms, are a contributor of poor 
outcome. The experience of extraintestinal symptoms appear to be particularly important 




is surprising as though the experience of extraintestinal symptoms are frequently 
reported in PFI (see Chapter 1), research has not yet demonstrated that extraintestinal 
symptoms are a more significant contributor to negative affect than GI symptoms. Future 
research should explore this to further elucidate this relationship.  
Symptom severity has been demonstrated to contribute to poor outcome and 
reduced QoL in IBS samples (Ballou & Keefer, 2017; Böhn et al., 2013; De Gucht, 2015; 
Fond et al., 2014; Frändemark et al., 2018; Jerndal et al., 2010; Knowles et al., 2017; 
Koloski et al., 2012; Lackner, Gudleski, Ma, et al., 2014; Lackner, Gudleski, Thakur, et al., 
2014; Phillips, Wright, & Kent, 2013, 2014; Rutter & Rutter, 2002, 2007; Wolitzky-Taylor, 
Craske, Labus, Mayer, & Naliboff, 2012). It is worth considering why somatic symptoms 
specifically are an important contributor to poor outcome in PFI. Though this was not 
directly investigated, results from the qualitative analysis describe the direct personal 
consequences of PFI symptoms, including ‘I don’t want to go into embarrassing details of 
what it does to me’, ‘when I do eat something with wheat I wake up next day with a low 
mood’,  ‘and I think to myself why do I put myself through these symptoms just for that 
meal of pizza or pasta?’, and further described social consequences such as discomfort 
with social meals and eating at restaurants, and/or perceptions of judgement from friends 
and family. If symptoms are negatively appraised and associated with adverse 
consequences, individuals may be more likely to be vigilant towards the signs of 
symptoms. This is consistent with hypotheses of cognitive-emotional sensitisation 
(Brosschot, 2002; Eriksen & Ursin, 2002; Eriksen & Ursin, 2004; Ursin & Eriksen, 2001), 
somatosensory amplification (Barsky, 1979; Barsky et al., 1988; Barsky et al., 1990; Jones 
& Ebert, 2003; Jones et al., 2004), and visceral sensitivity (Labus et al., 2004; Labus et al., 
2007). The role of visceral sensitivity in GI symptoms as contributing to poor outcome has 
been demonstrated in IBS (Garland et al., 2012; Knowles et al., 2017; Wolitzky-Taylor et 
al., 2012), and there is preliminary evidence of visceral sensitivity in PFI (Lind, Lied, et al., 
2010). In addition to symptom vigilance, it is also possible that individuals may avoid 
contexts associated with symptoms, as is characteristic in IBS (Rønnevig, Vandvik, & 




such as food avoidance. In a 2017 study by Fitzgerald and Frankum (2017), the authors 
determined that intolerance was the most commonly reported reason for food avoidance 
and/or restriction, along with concerns that the food(s) makes me feel sick. Findings from 
the qualitative analysis of the current study revealed that individuals with PFI are likely to 
restrict and avoid the offending food(s) to help manage PFI. However, behaviours or goals 
that are difficult to adhere to, such as food avoidance, may be associated with distress if 
it is not successfully implemented or if there are repeated failures at an attempt to adhere 
to it (Dunne et al., 2011). Results from the qualitative analyses demonstrated the 
challenges of food avoidance, and surprisingly highlighted examples of self-blame and 
disengagement experienced if unable to adhere, including ‘‘I think I might 'get away' with 
a bit of bread or cake. Then I regret it and feel stupid!’; ‘sometimes I just give up’; and ‘I 
think to myself why, do I put myself through these symptoms just for that meal’.  Though 
not directly measured, results of content analysis revealed that participants experience 
distress in relation to symptoms and symptom-related dietary and lifestyle changes, 
which were additionally associated with negative personal and social consequences.  
The impact of consequences or control beliefs were not established at a 
multivariate level in the current study, which have been demonstrated to be significant 
in IBS (Rutter & Rutter, 2002, 2007),  or illness coherence beliefs, as has been found in 
allergy (Knibb & Horton, 2008). Consequences of PFI were described in the qualitative 
component, but surprisingly, were not a significant factor from the IPQ-R. This finding is 
unexplained and may have had to do with the wording in the scale, however, reliability 
analyses demonstrated good internal consistency in the ‘consequences’ subscale. It is 
possible that the wording on scale does not activate representations about a significant 
impact of PFI on daily life, or perhaps participants do not view PFI as serious or harmful 
condition, or with financial consequences. It is also possible that individuals do not 
perceive very many consequences about PFI, as symptoms are often cyclical, but the few 
consequences reported are more severe. However, when participants had the chance to 
reflect on the impact of PFI, consequences were an important part of their narrative of 




which may reflect that currently PFI is not particularly well understood, nor does it have 
an established treatment. However, results from the content analysis suggest that self-
directed changes in dietary habits appear to be the most common form of self-treatment 
that individuals maintain. Results from content analysis additionally highlighted that 
individuals struggle to understand the nature of their intolerance in terms of which foods 
specifically are symptomatic, how much of a food can they tolerate, and if are there 
situational or contextual factors that impact symptom experiences. The qualitative 
content did not align with the constructs as measured on the IPQ-R. It is possible that the 
wording on the scale could be adapted with better specificity for PFI in future research.  
Hypothesised coping strategies of acceptance and planning, which have been 
associated with improved outcome in IBS and allergy (Knibb & Horton, 2008; Rutter & 
Rutter, 2002), were not established, though were described in the content analysis., 
including “I accept my condition. Though I get annoyed when my symptoms flare 
up…overall I know I can't change it and have lived with [the symptoms] for so long that it 
is 'normal”’ and “I use “logistics” to minimise the chances of an episode, e.g. always 
choosing a “safe” option from the menu, timing meals so we go home straight after 
eating”.  It is likely that the coping scale used did not capture or reflect how coping 
responses can be flexibly used or adapted depending on the specific context they are used 
in, and the wording of the questions did not specify a context for which coping occurs. 
The measurement of coping strategies has been critiqued (Skinner et al., 2003; Taylor & 
Stanton, 2007), and Skinner et al. (2003) identified over 400 coping behaviours measured 
in the literature, demonstrating challenges trying to capture the construct of coping 
through lower-order strategies used. It is important to identify specific coping behaviours, 
but perhaps to organise these according to higher-order function of the action (Skinner 
et al., 2003). This would be important to frame in specific PFI-related contexts, however, 
to better understand coping, it is likely that this information may be best attained through 





The CSM posits a dynamic framework, whereby individuals update representations 
in line with new information, experiences and coping outcomes (Leventhal et al., 2016). 
However, the current findings established that illness representations and coping 
responses remained stable across all three time points, suggesting that participants did 
not update or change their formed illness perceptions and subsequent coping. It is 
possible that the number of years participants have had PFI influences these findings, and 
the median duration of PFI was 11.6 years. Future longitudinal research should recruit 
individuals with PFI at symptom onset, and measure illness perceptions, coping and 
related factors from this point forward, to explore whether these variables are sensitive 
to change around the period of adjustment.   
The results additionally demonstrated that in PFI, symptoms appear to persist 
despite management and coping efforts. The experience of persistent symptoms is 
distressing and additionally contributes to poor outcome and may mean that as a result, 
the only information acquired, namely, the continued experience of somatic symptoms, 
serves to reinforce existing illness representations. The data perhaps implies some rigidity 
in how individuals perceive PFI and in the coping responses used, which may contribute 
to sustained poor outcome. It is also possible that self-management behaviours such as 
food avoidance, are used as it gives individuals a sense of control, however, results of the 
content analysis imply this also does not appear to improve outcome or reduce symptoms 
and may contribute to further distress, and this has also been reported in IBS (Guadagnoli 
et al., 2019; Jamieson, Fletcher, & Schneider, 2007). It is likely that these illness 
representations and coping responses used will continue to remain unchanged, unless 
they are targeted directly in an evidence-informed intervention. 
 
4.6 Clinical Implications 
Evidence from regression and mediation analyses suggest that specific, perhaps 
inflexibly held illness representations and coping responses of self-blame and 
disengagement could be addressed in a psychological intervention with the anticipated 




symptoms are a strong contributor of impaired functioning, psychological distress, and 
poor FR-QoL. PFI and IBS share sociodemographic and clinical features including anxiety 
and somatisation, and individuals with IBS often report PFI and vice versa (see Chapter 1). 
Results from the current study suggest that  participants with PFI+IBS have elevated 
symptom severity and PFI severity and increased functional impairment, and it is possible 
that components of psychological interventions aimed at managing symptoms that have 
been successfully implemented in IBS populations may additionally be beneficial to 
include in any future PFI intervention. GI symptom severity in IBS is associated with poor 
outcome, often related to unhelpful symptom appraisals, symptom-specific  and illness-
related worries, avoidance behaviours including avoidance of food, and food-related, 
social, work, and travel situations (Rønnevig et al., 2009), and related personal and social 
consequences of symptoms. 
A formulated cognitive-behavioural model of IBS (Spence & Moss-Morris, 2007) has 
allowed for the development of psychological interventions in IBS. These interventions 
often include psychoeducation as well as both cognitive and behavioural components to 
address the specific unhelpful beliefs and thoughts that are proposed to contribute to the 
maintenance of somatic symptoms, distress, and avoidant behaviour patterns and 
resultant ‘vicious circle’, and further, some have incorporated ‘third-wave’ approaches 
including mindfulness and acceptance (Chilcot & Moss-Morris, 2013; Ferreira, Eugenicos, 
Graham Morris, & Gillanders, 2011; Ferreira, Gillanders, Morris, & Eugenicos, 2018; 
Garland et al., 2012; Gillanders, Ferreira, Angioni, Carvalho, & Eugenicos, 2017; Ljótsson 
et al., 2010; Sebastián Sánchez, Gil Roales-Nieto, Ferreira, Gil Luciano, & Sebastián 
Domingo, 2017; Windgassen et al., 2017). It is possible that components of effective 
interventions in IBS may prove successful in PFI, including psychoeducation, teaching 
situationally functional and adaptive coping skills to help self-manage symptoms, distress 
and consequences of symptoms experienced in PFI, addressing specific thoughts, beliefs  
and avoidant behaviour patterns that may act as maintaining factors, and incorporating 




Together, this may point to the benefit of a transdiagnostic approach, within which 
components of an intervention could be applied as necessary, with an aim to enhance 
flexibility in an individuals’ response to PFI and its sequelae, as well as flexibility in 
choosing what skill to use in various situations. In light of this, Acceptance and 
Commitment Therapy (ACT) might be an appropriate transdiagnostic framework 
(Brassington et al., 2016), which is a contextual form of CBT that aims to improve quality 
of life by enhancing psychological flexibility, “the ability to contact the present moment 
more fully as a conscious human being and, based on what the situation affords, to 
change or persist in behaviour in order to serve valued ends” (p.24) (Luoma, Hayes, & 
Walser, 2017). 
The results of the current study highlighted the impact of somatic symptoms in 
contributing to negative affect and poor FR-QoL in PFI, and the use of self-blame and 
disengagement as coping strategies as contributing to anxiety and distress. ACT proposes 
that suffering is maintained through six core “inflexibility processes” (p.16) (Luoma et al., 
2017) including experiential avoidance, which is an unwillingness to contact difficult 
thoughts, emotions and sensations, often leading to effort in trying to eliminate, avoid, 
or change these private experiences, and resulting in inflexible behaviour patterns than 
take people away from what matters most (Hayes & Strosahl, 2004). In the current 
sample, it is possible that an unwillingness to experience distressing symptoms, emotions 
and/or thoughts can influence the use of self-blame or disengagement and avoidance 
patterns, potentially maintaining poor outcome. For example, if an individual is worried 
about experiencing symptoms at a restaurant or social gathering, they might choose to 
avoid the plans all together; and as a participant described “I feel devastated when I 
[become symptomatic] in public, and it does make me want to avoid going out for a long 
while after an episode“. As another example, if an individual becomes symptomatic after 
eating, that person might blame themselves for eating that meal in the first place; this 
was described by a participant as “I think I might 'get away' with a bit of bread or cake. 
Then I regret it and feel stupid!”. In the first example, the decision to avoid or cancel plans 




embarrassment following GI distress, and avoidance effectively eliminates the chance of 
a distressing experience around others, however, by doing so, avoiding plans (through 
disengagement) may mean limitations on social and leisure activities. In the second 
example, self-blame provides an ‘answer’ for the distressing experience, though using 
self-blame as a problem-solving strategy can cause further unintended distress, 
frustration, and guilt.  
Previous research in IBS using a CBT intervention identified cognitive change as a 
significant mediator of outcome (Chilcot & Moss-Morris, 2013), including changes in 
catastrophising and fear avoidance.  In a traditional CBT intervention, the content of 
distorted thoughts would be restructured to reflect more realistic thoughts (Naliboff, 
Frese, & Rapgay, 2008). However, ACT proposes, through Relational Frame Theory 
(Barnes-Holmes & Roche, 2001) that changing how one relates to the content of their 
thoughts, or changing the context of how the thought is experienced, can be more 
effective cognitive change than attempting to change the literal content of thoughts 
(Hayes, 2016) (note; a discussion of relational frame theory is outside the scope of this 
paper, see (Barnes-Holmes & Roche, 2001; Hayes, 2016)). Specific cognitive practices and 
strategies taught in an ACT intervention can influence how sensations, thoughts, and 
emotions are noticed, perceived and flexibly responded to. This can change how an 
individual relates to their experiences and can influence functional behaviours such as 
contextually adaptive coping responses and re-engagement with what is valued, even in 
the face of difficulty, which can further drive cognitive change. An ACT intervention uses 
cognitive, experiential and exposure-based exercises, metaphors and between-session 
work focused on six flexibility processes; present moment awareness (non-judgmental 
contact with the here-and-now), values (clarifying chosen qualities that contribute to a 
personally meaningful life), committed action (acting in line with chosen values to support 
living a meaningful life), self-as-context (observer stance to see oneself as separate from 
the content of experiences and instead as the frame from which events are experienced), 




emotions and sensations, as an alternative to attempting to avoid, control or alter them) 
(Luoma et al., 2017).  
ACT has been successfully evidenced in conditions with persistent physical 
symptoms including chronic pain (McCracken & Velleman, 2010; McCracken, Vowles, & 
Eccleston, 2005; Scott & McCracken, 2015; Vowles, Sowden, & Ashworth, 2014), IBS 
(Ferreira et al., 2011; Ferreira et al., 2018; Gillanders et al., 2017; Sebastián Sánchez et 
al., 2017), chronic fatigue (Ferreira et al., 2011; Jacobsen, Kallestad, Landrø, Borchgrevink, 
& Stiles, 2017), and in a group of adults with various long-term conditions (Brassington et 
al., 2016). Furthermore, ACT additionally incorporates elements of self-compassion 
throughout the six flexibility processes, which has been shown to contribute to improved 
outcome in chronic pain patients (Vowles et al., 2014).  
Though the current study was not designed with an ACT framework in mind, and as 
a result did not include any ACT-specific outcome measures (Bond et al., 2011; 
McCracken, 2013; McCracken, Vowles, & Eccleston, 2004; Vowles, McCracken, McLeod, 
& Eccleston, 2008), a focus on acceptance of extraintestinal and GI symptoms, enhancing 
self-compassion, increasing flexibility in coping strategies used, and engaging in what is 
valued and meaningful as an alternative to avoidance fit within an ACT framework. In line 
with the current findings, the author proposes an ACT-based 4-session (each 90 minutes, 
for a total 6 hours) self-administered intervention, with therapist support. This method 
was selected as both a 4-session a self-administered (Lackner et al., 2008) and online-
delivered (Ljótsson et al., 2010) CBT intervention has contributed to improved outcome 
in IBS, and there is preliminary evidence for internet-based ACT (Lappalainen et al., 2014; 
Simister et al., 2018), though not in an IBS population. Further, a self-administered and 
internet-based interventions are more convenient to both deliver and access and is an 
important consideration in light of the current social distancing recommendations. The 
proposed intervention would aim to improve the quality of life alongside difficulties, 
instead of trying to change difficulties, and include components evidenced in ACT-
consistent interventions in IBS (Ferreira et al., 2011; Ferreira et al., 2018; Ljótsson et al., 




representations of PFI, illness identity, self-blame, disengagement, noticing and 
responding to symptoms, and doing what matters in the context of PFI-related distress.  
For a detailed intervention plan, please see Appendix XIV. 
1) Psychoeducation & Exploration – including psychoeducation on the stress response, 
gut-brain interactions, the role of food avoidance, symptom hypervigilance, the 
connection between symptoms and cognitive and emotional reactions to symptoms, 
and exploration of the role and experience with experiential avoidance.  
2) Present Moment Awareness – including mindfulness practices of (e.g. mindful eating, 
mindfulness around thoughts of meal and context of meals, Lovingkindness), to 
facilitate mindful awareness and a self-as-context (observer) position.  
3) Defusion – including experiential exercises to facilitate change in how individuals 
relate to their thoughts instead of being fused with the content or meaning of their 
thoughts and stories; aiming to help individuals be able to take a step back from their 
thoughts and choose how they would ideally like to act in a valued direction.  
4) Self-as-Context – including discussions, metaphors and exercises to help individuals 
see themselves as separate from the content of their experiences, from identities, 
labels or symptoms they assign to themselves, and from stories that define 
themselves based on PFI experiences. 
5) Acceptance – including willingness to tolerate difficult thoughts, emotions, sensations 
and situations related to PFI; of symptoms if/when they show up and trying not to 
fight or control them; and of challenge in order to work towards change. 
6) Values – including identifying and clarifying what is personally meaningful to them, 
and how they want to act in line with values, even in the face of difficulty. 
7) Committed Action – including setting structured and meaningful goals and 
committing to values-based action, including exposure to challenging situations; 
discussing who can help on their journey and what else can help bring them towards 
what matters most; discussing skills such as problem-solving to overcome barriers. 
8) Self-Compassion – including discussions, exercises and metaphors to facilitate a sense 




or uncomfortable symptoms; and self-compassion to continue to engage in values-
based actions in light of challenges.  
 
4.7 Strengths and Limitations 
4.7.1 Strengths 
The present study is strengthened by a longitudinal design. It is the first to 
investigate PFI and related psychological factors at multiple time points to establish 
unique contributors to PFI and the relative stability of the individual impact of PFI. 
Furthermore, the addition of the qualitative component of the study allowed for 
capturing a sample of the lived experience of PFI, to better understand the psychological, 
physical and social impact. The current sample was not clinical, thereby enhancing the 
generalisability of the findings to a female community population. Samples drawn from 
allergy, gastroenterological and medical clinics are often used in research studying 
individuals with PFI, which provides important information regarding other existing 
clinical comorbidities and allows for validating PFI, however, these samples are usually 
smaller in size. The study benefitted from a relatively large baseline sample (N = 255), and 
as the aims were exploratory, a large sample size adequately powered the study to be 
able to simultaneously examine multiple psychological and PFI-related factors that may 
be relevant to outcome. To date, research exploring PFI has primarily been at a bivariate 
and cross-sectional level, precluding drawing a causal relationship. In the current study, 
data was analysed at a bivariate and multivariate level; exploratory correlational analyses 
informed later regression models, which identified predictors to be used in confirmatory 
mediation models. Further, this study is strengthened by using temporally ordered data 
in the mediation models, which has been recommended in CSM research to better 
capture the dynamic processes proposed in the framework (DeLongis & Morstead, 2019).  
The current study is the first to apply the CSM as a psychological framework to the 
experience of PFI. The results of the study provide preliminary evidence of the role of 
illness perceptions and coping responses as contributing to negative affect and poor FR-




understanding PFI and related management behaviours. Furthermore, the study 
identified the unique role of the experience of extraintestinal and GI symptoms and 
established that these are not only a significant contributor to poor outcome, but also are 
not readily influenced through investigated coping responses. The results were 
considered in the context of research in the well-studied condition IBS, in order to 
propose a psychological intervention with an aim to improve outcome. The findings of 
the current study help to advance the current understanding of PFI, and provide basis for 
further research, discussed under Recommendations for Future Research.  
4.7.2 Limitations 
There are several limitations; 
First, though an adequate baseline sample was recruited, there was significant 
attrition from T1 to T3, precluding the use of T3 outcome data in temporally ordered 
mediation analyses. It is possible that a low incentive for participation or the sampling 
methodology used to recruit participants online through social media sites contributed to 
poor retention. Furthermore, some participants provided non-functional email addresses 
at baseline, and therefore it was impossible to contact them for follow-up data collection. 
Second, there was missing data at each time point, resulting in data exclusion from 
that participant. Of interest, there were no significant differences in age or the proportion 
reporting IBS between those who completed all three time points, and those who did not. 
However, those who only completed the T1 questionnaire had significantly elevated 
anxiety, total distress, extraintestinal symptom severity, and GI symptom severity. The 
exclusion of data was not enough to significantly impact study power, data analyses or 
results. It is possible that this could have been rectified by the use of forced responses in 
the questionnaire. The decision was made to alert participants of unanswered questions, 
though not force a response, as some research has demonstrated that forced-response 
questionnaires are subject to a reactance effect and survey dropout (Stieger, Reips, & 
Voracek, 2007; Vicente & Reis, 2010).  
Third, online questionnaires and self-report measures are subject to various 




outcome measures used however, results from paired t-tests and repeated measure 
ANOVA’s demonstrated consistency in paired scores over time, suggesting relative 
stability of responses. Further, conducting a structured diagnostic interview would not 
have been feasible for the current study, or warranted given its exploratory nature, and 
additionally, somatic symptoms in PFI are subjectively experienced, and would be 
challenging for an interviewer or observer to measure.  
Fourth, the measures used in the current study should be evaluated for future 
research, specifically A) the PSS, B) the HADS, C) a measure of FR-QoL, D) a measure of 
coping, and E) a measure of IBS. A) The PSS in our sample had very low internal 
consistency, and results from the PSS should be interpreted with caution. This finding was 
surprising, as the 10-item PSS, which was the measure used in the current study has 
demonstrated good internal consistency in previous research (Lee, 2012).  B) The decision 
was made to use the HADS (Zigmond & Snaith, 1983), as it does not contain somatic items, 
the HADS-T has been demonstrated to be a good measure of distress (Norton et al., 2013) 
and the HADS has been used in previous research with PFI samples (see Chapter 1). Due 
to the large number of measures included, it was important to not increase participant 
burden with additional measures. However, some have argued that the HADS does not 
reliably differentiate between anxiety and depression (Coyne & van Sonderen, 2012; 
Norton et al., 2013), and that measures specifically designed to capture anxiety and 
depression, such as the GAD-7 (Spitzer, Kroenke, Williams, & Löwe, 2006) and PHQ-9 
(Spitzer, Kroenke, Williams, & Group, 1999) respectively, are recommended. Research 
comparing the HADS-A and GAD-7 (Baker et al., 2018; Esser et al., 2018), and the HADS-
D and PHQ-9 (Cameron, Crawford, Lawton, & Reid, 2008; Hansson, Chotai, Nordstöm, & 
Bodlund, 2009) has found that all scales have fair psychometric properties though often 
differed in the severity of cases captured, suggesting clinical threshold levels differ 
between measures. C) The SWFL was used to assess FR-QoL and provided only a general 
measure of how satisfied an individual is with their FR-QoL but may not have captured 
the specific contributors to FR-QoL in PFI. A measure for PFI specifically does not currently 




Brief-COPE did not capture the context, specificity or range of coping responses and styles 
in PFI and should not be considered to represent a full understanding of coping in PFI.  E) 
The IBS measure used (Roalfe, Roberts, & Wilson, 2008) does not have established cut-
off points, so it is difficult quantify symptom severity, and scoring inconsistences reported 
in literature citing this measure preclude comparison of current findings. 
Sixth, the questionnaire did not include important patient-level characteristics 
that were found to be potentially significant in a recent systematic review (see Chapter 
1), such as level of education and employment, or a measure of visceral sensitivity (Labus 
et al., 2004), and this was due to the current study and questionnaire being designed and 
built prior to attaining results of the systematic review.  
Seventh, the sample was 92.5% female, limiting the generalisability of study 
findings to men and children. Results from previous research supports the finding that PFI 
is predominantly reported in women, however, it is not known if this is due to 
underreporting in men or additional psychosocial or physiological differences that 
influence the subjective experience of PFI.  
Finally, surprisingly, GI symptoms were not significantly associated with anxiety or 
distress. It is possible that GI symptom severity in PFI is not as significant of a sequela as 
it is reported in FGID including IBS, however, this is not possible to know from the basis 
of this study alone and must be explored further.  
 
4.8 Recommendations for Future Research 
Future research should explore factors that influence the onset of PFI using 
prospective longitudinal designs, and whether there are specific social factors that 
increase the risk of someone self-diagnosing a food intolerance, such as those found in 
the systematic review (see Chapter 1) including education level, employment history, and 
early living conditions. It would also be interesting to capture whether external 
information influences PFI, as the CSM posits that information from mass media or friends 
and family can influence illness perceptions (Leventhal et al., 2016). The popularisation of 




social media blogs and platforms focused on nutrition and healthy eating offer mixed and 
often unsubstantiated claims, and may contribute to an individual perceiving food 
intolerance, though this has not been specifically studied in PFI.  A  qualitative analysis by 
Hamshaw, Barnett, Gavin, and Lucas (2019) explored perceptions of expertise in social 
media in both FH adults and parents of children with FH, but this was regarding 
information seeking following diagnosis.   
It is possible that the CSM has future applicability in PFI, perhaps using structured 
equation modelling to further explore all factors relevant in the miniatous of PFI. Future 
research should consider using the Visceral Sensitivity Index (VSI) (Labus et al., 2004), 
which has been demonstrated to predict symptom severity in individuals with PFI (Lind, 
Lied, et al., 2010), and could provide the basis to target visceral sensitivity specifically in 
an intervention. Outcome could be measured using the GAD-7 and PHQ-9 as an 
alternative to the HADS, and it would be interesting to see if any differences exist in 
reported negative affect or in the proportion of the sample to reach clinical threshold if 
different measures of anxiety and depression are used. 
Research should consider measuring specific PFI-related self-management 
behaviours, coping styles and adherence to these efforts, and additionally explore PFI-
specific FR-QoL. However, to do so, it is important to develop and validate a specific PFI-
related FR-QoL measure, as has been done in FA (Flokstra-de Blok et al., 2008), and IBD 
(Hughes et al., 2016) populations, to specifically capture what about PFI impacts FR-QoL. 
It would be important to recruit individuals with PFI for qualitative interviews, in order to 
generate items that would be specific to PFI. Interviews could consider aspects such as 
the impact of limited food options, having to read food labels at grocery stores, the social 
impact of PFI with friends and family members, the impact when dining out or when 
travelling, beliefs about the potential for or any existing nutrient deficiencies, and the 
impact of food restriction, though it would be important for participants to share aspects 
that may not have been considered. It would be helpful to know what individuals do as a 




of these behaviours, and how they contribute to outcome. This would be important to 
explore in qualitative research using structured and semi-structured interviews.  
Finally, further research could include specific ACT measures of psychological 
flexibility and other core components of the ACT model such as experiential avoidance 
and acceptance, using validated measures including the  Acceptance and Action 
Questionnaire (AAQ-II) (Bond et al., 2011) or alternatively the IBS Acceptance and Action 
Questionnaire (Ferreira, Eugenicos, Morris, & Gillanders, 2013), a modified Chronic Pain 
Acceptance Questionnaire (CPAQ)  (McCracken et al., 2005; Vowles et al., 2008) and 
Committed Action Questionnaire (McCracken, 2013), to test the applicability of an of ACT 
framework in PFI, and to test the hypothesised ACT-based intervention.   
 
4.9 Conclusions 
This study was the first to longitudinally investigate psychological and PFI-related 
factors in individuals with self-reported food intolerance and explore how these factors 
uniquely impact outcomes of mood and FR-QoL. The present study provides evidence 
that psychological factors including illness perceptions and coping responses, and related 
factors of stress and symptom severity have a role in explaining poor outcome. Of the 
psychological variables included in the study, coping responses of self-blame and 
disengagement are important contributors to anxiety and distress, whereas illness 
perceptions including illness identity and emotional representations contribute to poor 
FR-QoL.  The experience of extraintestinal and GI symptoms are associated with distress 
and poor FR-QoL, respectively, and are a defining feature of the food intolerance reaction. 
A psychological intervention that aims to enhance flexibility, address illness perceptions, 
promote contextually adaptive coping responses and incorporate acceptance of 
discomfort and values-based goal setting, such as one based on an ACT framework,  may 
be of benefit to individuals  with PFI who  experience psychological and symptom-related 





Aaron, L. A., & Buchwald, D. (2001). A review of the evidence for overlap among 
unexplained clinical conditions. Annals of Internal medicine, 134, 868-881.  
Arslan, G., Lind, R., Olafsson, S., Florvaag, E., & Berstad, A. (2004). Quality of Life in 
Patients with Subjective Food Hypersensitivity: Applicability of the 10-Item Short 
Form of the Nepean Dyspepsia Index. Digestive Diseases and Sciences, 49, 680-
687. doi:10.1023/B:DDAS.0000026318.81635.3b 
Baker, A. M., Holbrook, J. T., Yohannes, A. M., Eakin, M. N., Sugar, E. A., Henderson, R. J., 
. . . Mathews, A. M. (2018). Test performance characteristics of the air, GAD-7, 
and HADS-Anxiety screening questionnaires for anxiety in chronic obstructive 
pulmonary disease. Annals of the American Thoracic Society, 15(8), 926-934.  
Ballou, S., & Keefer, L. (2017). The impact of irritable bowel syndrome on daily 
functioning: Characterizing and understanding daily consequences of IBS. 
Neurogastroenterology & Motility, 29(4), e12982.  
Barnes-Holmes, S. C. H. D., & Roche, B. (2001). Relational frame theory: A post-
Skinnerian account of human language and cognition: Springer Science & 
Business Media. 
Barsky, A. J. (1979). Patients who amplify bodily sensations. Annals of Internal medicine, 
91(1), 63-70.  
Barsky, A. J., Goodson, J. D., Lane, R. S., & Cleary, P. D. (1988). The amplification of 
somatic symptoms. Psychosomatic Medicine, 50(5), 510-519.  
Barsky, A. J., Orav, E. J., & Bates, D. W. (2005). Somatization increases medical utilization 
and costs independent of psychiatric and medical comorbidity. Archives of 
general psychiatry, 62(8), 903-910.  
Barsky, A. J., Wyshak, G., & Klerman, G. L. (1990). The somatosensory amplification scale 
and its relationship to hypochondriasis. Journal of psychiatric research, 24(4), 
323-334.  
Bengtsson, M. (2016). How to plan and perform a qualitative study using content 
analysis. NursingPlus Open, 2, 8-14.  
Berstad, A., Arslan, G., Lind, R., & Florvaag, E. (2005). Food hypersensitivity—
immunologic (peripheral) or cognitive (central) sensitisation? 
Psychoneuroendocrinology, 30, 983-989. doi:10.1016/J.PSYNEUEN.2005.04.010 
Berstad, A., Undseth, R., Lind, R., & Valeur, J. (2012). Functional bowel symptoms, 
fibromyalgia and fatigue: A food-induced triad? Scandinavian Journal of 
Gastroenterology, 47(8-9), 914-919. 
doi:http://dx.doi.org/10.3109/00365521.2012.690045 
Biesiekierski, J. R., Newnham, E. D., Shepherd, S. J., Muir, J. G., & Gibson, P. R. (2014). 
Characterization of adults with a self-diagnosis of nonceliac gluten sensitivity. 





Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the Hospital 
Anxiety and Depression Scale: an updated literature review. Journal of 
Psychosomatic Research, 52(2), 69-77.  
Blackett, J. W., Shamsunder, M., Reilly, N. R., Green, P. H. R., & Lebwohl, B. (2018). 
Characteristics and comorbidities of inpatients without celiac disease on a 
gluten-free diet. European Journal of Gastroenterology and Hepatology, 30(4), 
477-483. doi:http://dx.doi.org/10.1097/MEG.0000000000001071 
Böhn, L., Störsrud, S., Törnblom, H., Bengtsson, U., & Simrén, M. (2013). Self-Reported 
Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated 
With More Severe Symptoms and Reduced Quality of Life. The American Journal 
of Gastroenterology, 108, 634-641. doi:10.1038/ajg.2013.105 
Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., . . . 
Zettle, R. D. (2011). Preliminary psychometric properties of the Acceptance and 
Action Questionnaire–II: A revised measure of psychological inflexibility and 
experiential avoidance. Behavior therapy, 42(4), 676-688.  
Boyce, J. A., Assa'ad, A., Burks, A. W., Jones, S. M., Sampson, H. A., Wood, R. A., . . . 
Arshad, S. H. (2011). Guidelines for the diagnosis and management of food 
allergy in the United States: summary of the NIAID-sponsored expert panel 
report. Journal of the American Academy of Dermatology, 64(1), 175-192.  
Brassington, L., Ferreira, N. B., Yates, S., Fearn, J., Lanza, P., Kemp, K., & Gillanders, D. 
(2016). Better living with illness: A transdiagnostic acceptance and commitment 
therapy group intervention for chronic physical illness. Journal of Contextual 
Behavioral Science, 5(4), 208-214.  
Bratten, J. R., Spanier, J., & Jones, M. P. (2008). Lactulose breath testing does not 
discriminate patients with irritable bowel syndrome from healthy controls. 
American Journal of Gastroenterology, 103(4), 958-963.  
Brosschot, J. F. (2002). Cognitive‐emotional sensitization and somatic health complaints. 
Scandinavian Journal of Psychology, 43(2), 113-121. Retrieved from 
https://onlinelibrary.wiley.com/doi/abs/10.1111/1467-
9450.00276?sid=nlm%3Apubmed 
Brown, C., Battista, D. R., Sereika, S. M., Bruehlman, R. D., Dunbar-Jacob, J., & Thase, M. 
E. (2007). Primary care patients' personal illness models for depression: 
relationship to coping behavior and functional disability. General Hospital 
Psychiatry, 29(6), 492-500.  
Bueno, L., Fioramonti, J., Delvaux, M., & Frexinos, J. (1997). Mediators and 
pharmacology of visceral sensitivity: from basic to clinical investigations. 
Gastroenterology, 112(5), 1714-1743.  
Burker, E. J., Evon, D., Loiselle, M. M., Finkel, J., & Mill, M. (2005). Planning helps, 
behavioral disengagement does not: coping and depression in the spouses of 
heart transplant candidates. Clinical transplantation, 19(5), 653-658.  
Cameron, I. M., Crawford, J. R., Lawton, K., & Reid, I. C. (2008). Psychometric 
comparison of PHQ-9 and HADS for measuring depression severity in primary 




Carr, S., Chan, E., Lavine, E., & Moote, W. (2012). CSACI position statement on the 
testing of food-specific IgG. Allergy, Asthma & Clinical Immunology, 8(1), 12.  
Carver, C. S. (1997). You want to measure coping but your protocol's too long: Consider 
the Brief COPE. International Journal of Behavioral Medicine, 4, 92-100.  
Carver, C. S., Pozo, C., Harris, S., Noriega, V., Scheier, M., Robinson, D., . . . Clark, K. 
(1993). How coping mediates the effect of optimism on distress: a study of 
women with early stage breast cancer. Journal of personality and social 
psychology, 65(2), 375.  
Carver, C. S., & Scheier, M. F. (2002). Coping processes and adjustment to chronic 
illness. Christensen AJ, Antoni MH. Chronic physical disorders: Behavioral 
medicine’s perspective. The Blackwell series in health psychology & behavioral 
medicine. Malden, MA, US: Blackwell Publishing, 47-68.  
Carver, C. S., Scheier, M. F., & Weintraub, J. K. (1989). Assessing coping strategies: a 
theoretically based approach. Journal of personality and social psychology, 56(2), 
267.  
Chalder, T., & Willis, C. (2017). “Lumping” and “splitting” medically unexplained 
symptoms: is there a role for a transdiagnostic approach? In: Taylor & Francis. 
Chang, L., Toner, B. B., Fukudo, S., Guthrie, E., Locke, G. R., Norton, N. J., & Sperber, A. 
D. (2006). Gender, age, society, culture, and the patient’s perspective in the 
functional gastrointestinal disorders. Gastroenterology, 130(5), 1435-1446.  
Chilcot, J., & Moss-Morris, R. (2013). Changes in illness-related cognitions rather than 
distress mediate improvements in irritable bowel syndrome (IBS) symptoms and 
disability following a brief cognitive behavioural therapy intervention. Behaviour 
Research and Therapy, 51(10), 690-695.  
Cohen, S., Kamarck, T., & Mermelstein, R. (1994). Perceived stress scale. Measuring 
stress: A guide for health and social scientists, 10.  
Compas, B. E., Boyer, M. C., Stanger, C., Colletti, R. B., Thomsen, A. H., Dufton, L. M., & 
Cole, D. A. (2006). Latent variable analysis of coping, anxiety/depression, and 
somatic symptoms in adolescents with chronic pain. Journal of consulting and 
clinical psychology, 74(6), 1132.  
Coyne, J. C., & van Sonderen, E. (2012). No further research needed: abandoning the 
Hospital and Anxiety Depression Scale (HADS). Journal of Psychosomatic 
Research, 72(3), 173.  
Czuber‐Dochan, W., Morgan, M., Hughes, L., Lomer, M., Lindsay, J., & Whelan, K. (2020). 
Perceptions and psychosocial impact of food, nutrition, eating and drinking in 
people with inflammatory bowel disease: a qualitative investigation of food‐
related quality of life. Journal of Human Nutrition and Dietetics, 33(1), 115-127.  
Dainese, R., Casellas, F., Marine-Barjoan, E., Vivinus-Nebot, M., Schneider, S. M., 
Hebuterne, X., & Piche, T. (2014). Perception of lactose intolerance in irritable 
bowel syndrome patients. European Journal of Gastroenterology and 
Hepatology, 26(10), 1167-1175. 
doi:http://dx.doi.org/10.1097/MEG.0000000000000089 
Dainese, R., Galliani, E. A., Lazzari, F., Leo, V., & Naccarato, R. (1999). Discrepancies 




bowel syndrome patients. The American Journal of Gastroenterology, 94, 1892-
1897. doi:10.1111/j.1572-0241.1999.01226.x 
Dancey, C., Hutton-Young, S., Moye, S., & Devins, G. (2002). Perceived stigma, illness 
intrusiveness and quality of life in men and women with irritable bowel 
syndrome. Psychology, Health & Medicine, 7(4), 381-395.  
De Gucht, V. (2015). Illness perceptions mediate the relationship between bowel 
symptom severity and health-related quality of life in IBS patients. Quality of Life 
Research, 24(8), 1845-1856. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493794/pdf/11136_2015_Arti
cle_932.pdf 
DeLongis, A., & Morstead, T. (2019). Bringing the social context into research using the 
common sense model. Health psychology review, 13(4), 481-483.  
Devins, G. M., Bezjak, A., Mah, K., Loblaw, D. A., & Gotowiec, A. P. (2006). Context 
moderates illness‐induced lifestyle disruptions across life domains: a test of the 
illness intrusiveness theoretical framework in six common cancers. Psycho‐
Oncology: Journal of the Psychological, Social and Behavioral Dimensions of 
Cancer, 15(3), 221-233.  
Devins, G. M., Styra, R., O'connor, P., Gray, T., Seland, T., Klein, G., & Shapiro, C. (1996). 
Psychosocial impact of illness intrusiveness moderated by age in multiple 
sclerosis. Psychology, Health & Medicine, 1(2), 179-191.  
Doering, L. V., Dracup, K., Caldwell, M. A., Moser, D. K., Erickson, V. S., Fonarow, G., & 
Hamilton, M. (2004). Is coping style linked to emotional states in heart failure 
patients? Journal of cardiac failure, 10(4), 344-349.  
Dreborg, S. (2015). Debates in allergy medicine: food intolerance does not exist. World 
Allergy Organization Journal, 8(1), 1-6.  
Drossman, D. A., Leserman, J., Li, Z., Keefe, F., Hu, J. B., & Toomey, T. C. (2000). Effects 
of Coping on Health Outcome Among Women With Gastrointestinal Disorders. 
Psychosomatic Medicine, 62, 309 - 317.  
Dunne, E., Wrosch, C., & Miller, G. E. (2011). Goal disengagement, functional disability, 
and depressive symptoms in old age. Health Psychology, 30(6), 763.  
Edwards, R. R., Dworkin, R. H., Sullivan, M. D., Turk, D. C., & Wasan, A. D. (2016). The 
role of psychosocial processes in the development and maintenance of chronic 
pain. The Journal of Pain, 17(9), T70-T92.  
Elieson, L. M., Domotor, Z., & Koteles, F. (2017). Health anxiety mediates the connection 
between somatosensory amplification and self-reported food sensitivity. 
Ideggyogyaszati Szemle, 70(9-10), 307-314. 
doi:http://dx.doi.org/10.18071/isz.70.0307 
Eriksen, H., & Ursin, H. (2002). Sensitization and subjective health complaints. 
Scandinavian Journal of Psychology, 43(2), 189-196. Retrieved from 
https://onlinelibrary.wiley.com/doi/abs/10.1111/1467-
9450.00286?sid=nlm%3Apubmed 
Eriksen, H., & Ursin, H. (2004). Subjective health complaints, sensitization, and sustained 





Esser, P., Hartung, T. J., Friedrich, M., Johansen, C., Wittchen, H. U., Faller, H., . . . Schulz, 
H. (2018). The Generalized Anxiety Disorder Screener (GAD‐7) and the anxiety 
module of the Hospital and Depression Scale (HADS‐A) as screening tools for 
generalized anxiety disorder among cancer patients. Psycho‐oncology, 27(6), 
1509-1516.  
Factor, J. M., Mendelson, L., Lee, J., Nouman, G., & Lester, M. R. (2012). Effect of oral 
immunotherapy to peanut on food-specific quality of life. Annals of Allergy, 
Asthma & Immunology, 109(5), 348-352. e342.  
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G* Power 3: A flexible statistical 
power analysis program for the social, behavioral, and biomedical sciences. 
Behavior research methods, 39(2), 175-191.  
Ferreira, N., Eugenicos, M., Graham Morris, P., & Gillanders, D. (2011). Using acceptance 
and commitment therapy in irritable bowel syndrome. Gastrointestinal Nursing, 
9(9), 28-35.  
Ferreira, N. B., Eugenicos, M. P., Morris, P. G., & Gillanders, D. T. (2013). Measuring 
acceptance in irritable bowel syndrome: preliminary validation of an adapted 
scale and construct utility. Quality of Life Research, 22(7), 1761-1766.  
Ferreira, N. B., Gillanders, D., Morris, P. G., & Eugenicos, M. (2018). Pilot study of 
acceptance and commitment therapy for irritable bowel syndrome: A 
preliminary analysis of treatment outcomes and processes of change. Clinical 
Psychologist, 22(2), 241-250.  
Fitzgerald, M., & Frankum, B. (2017). Food avoidance and restriction in adults: a cross-
sectional pilot study comparing patients from an immunology clinic to a general 
practice. Journal of eating disorders, 5(1), 30.  
Flokstra-de Blok, B. M., DunnGalvin, A., Vlieg-Boerstra, B. J., Elberink, J. N. O., 
Duiverman, E. J., Hourihane, J. O. B., & Dubois, A. E. (2008). Development and 
validation of the self-administered Food Allergy Quality of Life Questionnaire for 
adolescents. Journal of Allergy and Clinical Immunology, 122(1), 139-144. e132.  
Folkman, S., & Lazarus, R. S. (1985). If it changes it must be a process: study of emotion 
and coping during three stages of a college examination. Journal of personality 
and social psychology, 48(1), 150.  
Folkman, S., Lazarus, R. S., Dunkel-Schetter, C., DeLongis, A., & Gruen, R. J. (1986). 
Dynamics of a stressful encounter: cognitive appraisal, coping, and encounter 
outcomes. Journal of personality and social psychology, 50(5), 992.  
Fond, G., Loundou, A., Hamdani, N., Boukouaci, W., Dargel, A., Oliveira, J., . . . Boyer, L. 
(2014). Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a 
systematic review and meta-analysis. European archives of psychiatry and clinical 
neuroscience, 264(8), 651-660. Retrieved from 
https://link.springer.com/content/pdf/10.1007%2Fs00406-014-0502-z.pdf 
Foster, N. E., Bishop, A., Thomas, E., Main, C., Horne, R., Weinman, J., & Hay, E. (2008). 
Illness perceptions of low back pain patients in primary care: what are they, do 
they change and are they associated with outcome? PAIN, 136(1-2), 177-187.  
Fox, M., Mugford, M., Voordouw, J., Cornelisse-Vermaat, J., Antonides, G., de la Hoz 




allergy in Europe: a patient-based cost of illness study. The European Journal of 
Public Health, 23(5), 757-762.  
Frändemark, Å., Törnblom, H., Jakobsson, S., & Simrén, M. (2018). Work productivity 
and activity impairment in irritable bowel syndrome (IBS): a multifaceted 
problem. American Journal of Gastroenterology, 113(10), 1540-1549.  
Frissora, C. L., & Koch, K. L. (2005). Symptom overlap and comorbidity of irritable bowel 
syndrome with other conditions. Current gastroenterology reports, 7(4), 264-
271.  
Garland, E. L., Gaylord, S. A., Palsson, O., Faurot, K., Mann, J. D., & Whitehead, W. E. 
(2012). Therapeutic mechanisms of a mindfulness-based treatment for IBS: 
effects on visceral sensitivity, catastrophizing, and affective processing of pain 
sensations. Journal of Behavioral Medicine, 35(6), 591-602. Retrieved from 
https://link.springer.com/content/pdf/10.1007%2Fs10865-011-9391-z.pdf 
Gillanders, D., Ferreira, N. B., Angioni, E., Carvalho, S. A., & Eugenicos, M. P. (2017). An 
implementation trial of ACT-based bibliotherapy for irritable bowel syndrome. 
Journal of Contextual Behavioral Science, 6(2), 172-177.  
Gocki, J., & Bartuzi, Z. (2016). Role of immunoglobulin G antibodies in diagnosis of food 
allergy. Advances in Dermatology and Allergology/Postȩpy Dermatologii i 
Alergologii, 33(4), 253.  
Golley, S., Corsini, N., Topping, D., Morell, M., & Mohr, P. (2015). Motivations for 
avoiding wheat consumption in Australia: Results from a population survey. 
Public Health Nutrition, 18(3), 490-499. doi:10.1017/S1368980014000652 
Grunert, K. G., Dean, M., Raats, M. M., Nielsen, N. A., & Lumbers, M. (2007). A measure 
of satisfaction with food-related life. Appetite, 49, 486-493. 
doi:10.1016/j.appet.2007.03.010 
Guadagnoli, L., Mutlu, E. A., Doerfler, B., Ibrahim, A., Brenner, D., & Taft, T. H. (2019). 
Food-related quality of life in patients with inflammatory bowel disease and 
irritable bowel syndrome. Quality of Life Research, 28(8), 2195-2205.  
Gupta, R. S., Warren, C. M., Smith, B. M., Jiang, J., Blumenstock, J. A., Davis, M. M., . . . 
Nadeau, K. C. (2019). Prevalence and Severity of Food Allergies Among US 
Adults. JAMA network open, 2(1), e185630-e185630. Retrieved from 
https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2720064/gupta
_2019_oi_180240.pdf 
Gwee, K.-A. (2010). Post-infectious irritable bowel syndrome, an inflammation-
immunological model with relevance for other IBS and functional dyspepsia. 
Journal of Neurogastroenterology and Motility, 16(1), 30. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879823/pdf/jnm-16-30.pdf 
Hamshaw, R. J. T., Barnett, J., Gavin, J., & Lucas, J. S. (2019). Perceptions of Food 
Hypersensitivity Expertise on Social Media: Qualitative Study. Interactive journal 
of medical research, 8(2), e10812.  
Hansson, M., Chotai, J., Nordstöm, A., & Bodlund, O. (2009). Comparison of two self-





Hayes, A. F. (2009). Beyond Baron and Kenny: Statistical mediation analysis in the new 
millennium. Communication monographs, 76(4), 408-420.  
Hayes, A. F. (2017). Introduction to mediation, moderation, and conditional process 
analysis: A regression-based approach: Guilford publications. 
Hayes, S. C. (2016). Acceptance and commitment therapy, relational frame theory, and 
the third wave of behavioral and cognitive therapies–republished article. 
Behavior therapy, 47(6), 869-885.  
Hayes, S. C., & Strosahl, K. D. (2004). A practical guide to acceptance and commitment 
therapy: Springer Science & Business Media. 
Hazeldine, M., Worth, A., Levy, M. L., & Sheikh, A. (2010). Follow-up survey of general 
practitioners' perceptions of UK allergy services. Primary Care Respiratory 
Journal, 19(1), 84. Retrieved from 
https://www.nature.com/articles/pcrj20102.pdf 
Hetterich, L., & Stengel, A. (2020). Psychotherapeutic interventions in irritable bowel 
syndrome. Frontiers in Psychiatry, 11, 286.  
Hsieh, H.-F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. 
Qualitative Health Research, 15(9), 1277-1288.  
Hughes, L. D., King, L., Morgan, M., Ayis, S., Direkze, N., Lomer, M. C., . . . Whelan, K. 
(2016). Food-related quality of life in inflammatory bowel disease: development 
and validation of a questionnaire. Journal of Crohn's and Colitis, 10(2), 194-201.  
Jacobsen, H. B., Kallestad, H., Landrø, N. I., Borchgrevink, P. C., & Stiles, T. C. (2017). 
Processes in acceptance and commitment therapy and the rehabilitation of 
chronic fatigue. Scandinavian Journal of Psychology, 58(3), 211-220.  
Jakobsen, M. D., Braaten, T., Obstfelder, A., & Abelsen, B. (2016). Self-Reported food 
hypersensitivity: Prevalence, Characteristics, and Comorbidities in the norwegian 
women and cancer study. PLoS ONE, 11(12). 
doi:http://dx.doi.org/10.1371/journal.pone.0168653 
Jamieson, A. E., Fletcher, P. C., & Schneider, M. A. (2007). Seeking control through the 
determination of diet: a qualitative investigation of women with irritable bowel 
syndrome and inflammatory bowel disease. Clinical Nurse Specialist, 21(3), 152-
160.  
Jerndal, P., Ringström, G., Agerforz, P., Karpefors, M., Akkermans, L., Bayati, A., & 
Simrén, M. (2010). Gastrointestinal‐specific anxiety: an important factor for 
severity of GI symptoms and quality of life in IBS. Neurogastroenterology & 
Motility, 22(6), 646-e179.  
Johansson, S., Hourihane, J. B., Bousquet, J., Bruijnzeel‐Koomen, C., Dreborg, S., 
Haahtela, T., . . . Van Cauwenberge, P. (2001). A revised nomenclature for 
allergy: an EAACI position statement from the EAACI nomenclature task force. 
Allergy, 56(9), 813-824. Retrieved from 
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1398-9995.2001.00002.x-
i1?sid=nlm%3Apubmed 
Johnston, M., Pollard, B., & Hennessey, P. (2000). Construct validation of the hospital 
anxiety and depression scale with clinical populations. Journal of Psychosomatic 




Jones, C. J., Smith, H. E., Frew, A. J., Toit, G. D., Mukhopadhyay, S., & Llewellyn, C. D. 
(2014). Explaining adherence to self-care behaviours amongst adolescents with 
food allergy: A comparison of the health belief model and the common sense 
self-regulation model. British Journal of Health Psychology, 19, 65-82. 
doi:10.1111/bjhp.12033 
Jones, M. P., & Ebert, C. C. (2003). Bloating and somatosensory amplification in 
functional dyspepsia (FD). The American Journal of Gastroenterology, 98(s9), 
S263.  
Jones, M. P., Schettler, R. A., Olden, K., & Crowell, M. D. (2004). Alexithymia and 
somatosensory amplification in functional dyspepsia. Psychosomatics, 45(6), 
508-516.  
Jones, S. M., & Burks, A. W. (2017). Food allergy. New England Journal of Medicine, 
377(12), 1168-1176. Retrieved from 
https://www.nejm.org/doi/pdf/10.1056/NEJMcp1611971?articleTools=true 
Kaptein, A. A., Klok, T., Moss-Morris, R., & Brand, P. L. (2010). Illness perceptions: impact 
on self-management and control in asthma. Current Opinion in Allergy and 
Clinical Immunology, 10(3), 194-199.  
Kelsay, K. (2003). Psychological aspects of food allergy. Current Allergy and Asthma 
Reports, 3, 41-46.  
Knibb, R. C., Armstrong, A., Booth, D. A., Platts, R. G., Booth, I. W., & MacDonald, A. 
(1999). Psychological characteristics of people with perceived food intolerance in 
a community sample. Journal of Psychosomatic Research, 47(6), 545-554. 
doi:http://dx.doi.org/10.1016/S0022-3999%2899%2900055-0 
Knibb, R. C., Booth, D., Platts, R., Armstrong, A., Booth, I., & Macdonald, A. (1999). 
Episodic and semantic memory in accounts of food intolerance. Applied 
Cognitive Psychology, 13(5), 451-464. 
doi:http://dx.doi.org/10.1002/%28SICI%291099-
0720%28199910%2913:5%3C451::AID-ACP608%3E3.0.CO;2-D 
Knibb, R. C., Booth, D. A., Platt, R., Armstrong, A., Booth, I. W., & McDonald, A. (2000). 
Consequences of perceived food intolerance for welfare, lifestyle and food 
choice practices, in a community sample. Psychology, Health & Medicine, 5, 419-
430. doi:10.1080/713690215 
Knibb, R. C., & Horton, S. (2008). Can illness perceptions and coping predict 
psychological distress amongst allergy sufferers? British Journal of Health 
Psychology, 13(1), 103-119.  
Knowles, S. R., Austin, D. W., Sivanesan, S., Tye-Din, J., Leung, C., Wilson, J., . . . Hebbard, 
G. (2017). Relations between symptom severity, illness perceptions, visceral 
sensitivity, coping strategies and well-being in irritable bowel syndrome guided 
by the common sense model of illness. Psychology, Health & Medicine, 22(5), 
524-534.  
Ko, J., Lee, J. I., Muñoz-Furlong, A., Li, X.-m., & Sicherer, S. H. (2006). Use of 
complementary and alternative medicine by food-allergic patients. Annals of 




Koloski, N. A., Boyce, P. M., Jones, M. P., & Talley, N. J. (2012). What level of IBS 
symptoms drives impairment in health-related quality of life in community 
subjects with irritable bowel syndrome? Quality of Life Research, 21(5), 829-836.  
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2002). The PHQ-15: validity of a new 
measure for evaluating the severity of somatic symptoms. Psychosomatic 
Medicine, 64(2), 258-266.  
Labus, J., Bolus, R., Chang, L., Wiklund, I., Naesdal, J., Mayer, E. A., & Naliboff, B. D. 
(2004). The Visceral Sensitivity Index: development and validation of a 
gastrointestinal symptom-specific anxiety scale. Alimentary Pharmacology and 
Therapeutics, 20, 89-97. doi:10.1111/j.1365-2036.2004.02007.x 
Labus, J., Mayer, E. A., Chang, L., Bolus, R., & Naliboff, B. D. (2007). The central role of 
gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of 
the visceral sensitivity index. Psychosomatic Medicine, 69(1), 89-98.  
Lackner, J. M., Gudleski, G. D., Ma, C.-X., Dewanwala, A., Naliboff, B., & Group, R. t. I. O. 
S. R. (2014). Fear of GI symptoms has an important impact on quality of life in 
patients with moderate-to-severe IBS. The American Journal of 
Gastroenterology, 109(11), 1815.  
Lackner, J. M., Gudleski, G. D., Thakur, E. R., Stewart, T. J., Iacobucci, G. J., Spiegel, B. M., 
& Group, R. t. I. O. S. R. (2014). The impact of physical complaints, social 
environment, and psychological functioning on IBS patients’ health perceptions: 
looking beyond GI symptom severity. The American Journal of Gastroenterology, 
109(2), 224.  
Lackner, J. M., Jaccard, J., Krasner, S. S., Katz, L. A., Gudleski, G. D., & Holroyd, K. (2008). 
Self-administered cognitive behavior therapy for moderate to severe irritable 
bowel syndrome: clinical efficacy, tolerability, feasibility. Clinical 
Gastroenterology and Hepatology, 6(8), 899-906.  
Lappalainen, P., Granlund, A., Siltanen, S., Ahonen, S., Vitikainen, M., Tolvanen, A., & 
Lappalainen, R. (2014). ACT Internet-based vs face-to-face? A randomized 
controlled trial of two ways to deliver Acceptance and Commitment Therapy for 
depressive symptoms: An 18-month follow-up. Behaviour Research and Therapy, 
61, 43-54.  
Lazarus, R. S. (1990). Stress, coping and illness. Personality and disease, 97-120.  
Lazarus, R. S., & Folkman, S. (1984). Stress, appraisal, and coping: Springer publishing 
company. 
Lee, E.-H. (2012). Review of the psychometric evidence of the perceived stress scale. 
Asian nursing research, 6(4), 121-127.  
Leventhal, H. (1984). Illness representations and coping with health threats. 
The common-sense model of self-regulation of health and illness, 22434 42-60 (London: 
Routledge Taylor and Francis Group 2003). 
Leventhal, H., Phillips, L. A., & Burns, E. (2016). The Common-Sense Model of Self-
Regulation (CSM): a dynamic framework for understanding illness self-





Liden, M., Kristjnsson, G., Valtysdottir, S., Venge, P., & Hllgren, R. (2010). Self-reported 
food intolerance and mucosal reactivity after rectal food protein challenge in 
patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 39(4), 
292-298. doi:http://dx.doi.org/10.3109/03009740903379630 
Lied, G. A., Lillestøl, K., Lind, R., Valeur, J., Morken, M. H., Vaali, K., . . . Berstad, A. (2011). 
Perceived food hypersensitivity: A review of 10 years of interdisciplinary 
research at a reference center. Scandinavian Journal of Gastroenterology, 46, 
1169-1178. doi:10.3109/00365521.2011.591428 
Lillestøl, K., Berstad, A., Lind, R., Florvaag, E., Arslan Lied, G., & Tangen, T. (2010). 
Anxiety and depression in patients with self-reported food hypersensitivity. 
General Hospital Psychiatry, 32(1), 42-48. 
doi:http://dx.doi.org/10.1016/j.genhosppsych.2009.08.006 
Lillestøl, K., Helgeland, L., Arslan Lied, G., Florvaag, E., Valeur, J., Lind, R., & Berstad, A. 
(2010). Indications of 'atopic bowel' in patients with self-reported food 
hypersensitivity. Alimentary Pharmacology and Therapeutics, 31(10), 1112-1122. 
doi:http://dx.doi.org/10.1111/j.1365-2036.2010.04261.x 
Lind, R., Arslan, G., Eriksen, H. R., Kahrs, G., Haug, T. T., Florvaag, E., & Berstad, A. 
(2005). Subjective health complaints and modern health worries in patients with 
subjective food hypersensitivity. Digestive Diseases and Sciences, 50(7), 1245-
1251. doi:http://dx.doi.org/10.1007/s10620-005-2767-6 
Lind, R., Berstad, A., Hatlebakk, J., & Valeur, J. (2013). Chronic fatigue in patients with 
unexplained self-reported food hypersensitivity and irritable bowel syndrome: 
Validation of a Norwegian translation of the fatigue impact Scale. Clinical and 
Experimental Gastroenterology, 6(1), 101-107. 
doi:http://dx.doi.org/10.2147/CEG.S45760 
Lind, R., Lied, G. A., Lillestol, K., Valeur, J., & Berstad, A. (2010). Do psychological factors 
predict symptom severity in patients with subjective food hypersensitivity? 
Scandinavian Journal of Gastroenterology, 45(7-8), 835-843. 
doi:http://dx.doi.org/10.3109/00365521003797213 
Lind, R., Lillestol, K., Valeur, J., Eriksen, H. R., Tangen, T., Berstad, A., & Arslan Lied, G. 
(2010). Job stress and coping strategies in patients with subjective food 
hypersensitivity. Scandinavian Journal of Psychology, 51(2), 179-184. 
doi:http://dx.doi.org/10.1111/j.1467-9450.2009.00761.x 
Lipowski, Z. (1986). Somatization: a borderland between medicine and psychiatry. 
CMAJ: Canadian Medical Association Journal, 135(6), 609. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1491312/pdf/cmaj00126-
0035.pdf 
Litleskare, S., Wensaas, K. A., Eide, G. E., Hanevik, K., Kahrs, G. E., Langeland, N., & 
Rortveit, G. (2015). Perceived food intolerance and irritable bowel syndrome in a 
population 3 years after a giardiasis-outbreak: A historical cohort study. BMC 
Gastroenterology, 15 (1) (no pagination)(164). 
doi:http://dx.doi.org/10.1186/s12876-015-0393-0 
Ljótsson, B., Falk, L., Vesterlund, A. W., Hedman, E., Lindfors, P., Rück, C., . . . Andersson, 




irritable bowel syndrome – A randomized controlled trial. Behaviour Research 
and Therapy, 48, 531-539. doi:10.1016/J.BRAT.2010.03.003 
Lomer, M. (2015). The aetiology, diagnosis, mechanisms and clinical evidence for food 
intolerance. Alimentary Pharmacology & Therapeutics, 41(3), 262-275.  
Luoma, J. B., Hayes, S. C., & Walser, R. D. (2017). Learning ACT: An acceptance & 
commitment therapy skills-training manual for therapists: New Harbinger 
Publications. 
Manu, P., Matthews, D. A., & Lane, T. J. (1993). Food intolerance in patients with chronic 
fatigue. International Journal of Eating Disorders, 13(2), 203-209. 
doi:http://dx.doi.org/10.1002/1098-108X%28199303%2913:2%3C203::AID-
EAT2260130208%3E3.0.CO;2-U 
Mayer, E. A. (2000). The neurobiology of stress and gastrointestinal disease. Gut, 47(6), 
861-869. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728136/pdf/v047p00861.pdf 
Mayer, E. A. (2011). Gut feelings: the emerging biology of gut-brain communication. 
Nature reviews. Neuroscience, 12, 453-466. doi:10.1038/nrn3071 
Mayer, E. A., Craske, M., & Naliboff, B. D. (2001). Depression, anxiety, and the 
gastrointestinal system. The Journal of clinical psychiatry, 62, 28-36; discussion 
37.  
Mayer, E. A., Naliboff, B. D., Chang, L., & Coutinho, S. V. (2001). Stress and the 
gastrointestinal tract V. Stress and irritable bowel syndrome. American Journal of 
Physiology-Gastrointestinal and Liver Physiology, 280(4), G519-G524. Retrieved 
from https://www.physiology.org/doi/pdf/10.1152/ajpgi.2001.280.4.G519 
Mayer, E. A., & Raybould, H. E. (1990). Role of visceral afferent mechanisms in functional 
bowel disorders. Gastroenterology, 99(6), 1688-1704. Retrieved from 
https://www.sciencedirect.com/science/article/abs/pii/001650859090475G?via
%3Dihub 
McComb, S. E., & Mills, J. S. (2019). Orthorexia nervosa: A review of psychosocial risk 
factors. Appetite.  
McCracken, L. M. (2013). Committed action: an application of the psychological 
flexibility model to activity patterns in chronic pain. The Journal of Pain, 14(8), 
828-835.  
McCracken, L. M., & Velleman, S. C. (2010). Psychological flexibility in adults with 
chronic pain: A study of acceptance, mindfulness, and values-based action in 
primary care. PAIN, 148, 141-147. doi:10.1016/J.PAIN.2009.10.034 
McCracken, L. M., Vowles, K. E., & Eccleston, C. (2004). Acceptance of chronic pain: 
component analysis and a revised assessment method. PAIN, 107(1-2), 159-166.  
McCracken, L. M., Vowles, K. E., & Eccleston, C. (2005). Acceptance-based treatment for 
persons with complex, long standing chronic pain: a preliminary analysis of 
treatment outcome in comparison to a waiting phase. Behaviour Research and 
Therapy, 43(10), 1335-1346.  
McGowan, M., & Gibney, M. J. (1993). Calcium intakes in individuals on diets for the 
management of cows' milk allergy: a case control study. European journal of 




McKenzie, P. S., Oto, M., Graham, C. D., & Duncan, R. (2011). Do patients whose 
psychogenic non-epileptic seizures resolve,‘replace’them with other medically 
unexplained symptoms? Medically unexplained symptoms arising after a 
diagnosis of psychogenic non-epileptic seizures. Journal of Neurology, 
Neurosurgery & Psychiatry, 82(9), 967-969.  
Missbach, B., Hinterbuchinger, B., Dreiseitl, V., Zellhofer, S., Kurz, C., & König, J. (2015). 
When eating right, is measured wrong! A validation and critical examination of 




Monsbakken, K. W., Vandvik, P. O., & Farup, P. G. (2006). Perceived food intolerance in 
subjects with irritable bowel syndrome-- etiology, prevalence and consequences. 
European Journal of Clinical Nutrition, 60(5), 667-672.  
Moss-Morris, R., & Chalder, T. (2003). Illness perceptions and levels of disability in 
patients with chronic fatigue syndrome and rheumatoid arthritis. Journal of 
Psychosomatic Research, 55(4), 305-308.  
Moss-Morris, R., Weinman, J., Petrie, K., Horne, R., Cameron, L., & Buick, D. (2002). The 
revised illness perception questionnaire (IPQ-R). Psychology and health, 17(1), 1-
16.  
Moss‐Morris, R., Petrie, K. J., & Weinman, J. (1996). Functioning in chronic fatigue 
syndrome: do illness perceptions play a regulatory role? British Journal of Health 
Psychology, 1(1), 15-25.  
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. H. (2002). The Work and Social 
Adjustment Scale: a simple measure of impairment in functioning. The British 
journal of psychiatry : the journal of mental science, 180, 461-464.  
Muraro, A., Werfel, T., Hoffmann‐Sommergruber, K., Roberts, G., Beyer, K., Bindslev‐
Jensen, C., . . . Eigenmann, P. (2014). EAACI food allergy and anaphylaxis 
guidelines: diagnosis and management of food allergy. Allergy, 69(8), 1008-1025. 
Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1111/all.12429 
Murberg, T. A., & Bru, E. (2001). Coping and mortality among patients with congestive 
heart failure. International Journal of Behavioral Medicine, 8(1), 66-79.  
Naliboff, B. D., Frese, M. P., & Rapgay, L. (2008). Mind/body psychological treatments 
for irritable bowel syndrome. Evidence-Based Complementary and Alternative 
Medicine, 5(1), 41-50.  
Nelson, M., & Ogden, J. (2008). An exploration of food intolerance in the primary care 
setting: the general practitioner's experience. Social Science & Medicine, 67(6), 
1038-1045.  
Nettleton, S., Woods, B., Burrows, R., & Kerr, A. (2010). Experiencing food allergy and 
food intolerance: An analysis of lay accounts. Sociology, 44(2), 289-305. 
doi:http://dx.doi.org/10.1177/0038038509357208 
Nimnuan, C., Hotopf, M., & Wessely, S. (2001). Medically unexplained symptoms: an 
epidemiological study in seven specialities. Journal of Psychosomatic Research, 




Norton, S., Cosco, T., Doyle, F., Done, J., & Sacker, A. (2013). The Hospital Anxiety and 
Depression Scale: a meta confirmatory factor analysis. Journal of Psychosomatic 
Research, 74(1), 74-81.  
Norton, S., Sacker, A., Young, A., & Done, J. (2011). Distinct psychological distress 
trajectories in rheumatoid arthritis: findings from an inception cohort. Journal of 
Psychosomatic Research, 71(5), 290-295.  
Nwaru, B., Hickstein, L., Panesar, S., Roberts, G., Muraro, A., Sheikh, A., . . . Group, A. G. 
(2014). Prevalence of common food allergies in Europe: a systematic review and 
meta‐analysis. Allergy, 69(8), 992-1007. Retrieved from 
https://onlinelibrary.wiley.com/doi/full/10.1111/all.12423 
Nybacka, S., Ohman, L., Storsrud, S., Mybeck, M., Bohn, L., Wilpart, K., . . . Simren, M. 
(2018). Neither self-reported atopy nor IgE-mediated allergy are linked to 
gastrointestinal symptoms in patients with irritable bowel syndrome. 
Neurogastroenterology and Motility, 30 (10)(e13379). 
doi:http://dx.doi.org/10.1111/nmo.13379 
Olafsson, S., & Berstad, A. (2003). Changes in food tolerance and lifestyle after 
eradication of Helicobacter pylori. Scandinavian Journal of Gastroenterology, 
38(3), 268-276. Retrieved from 
https://www.tandfonline.com/doi/pdf/10.1080/00365520310000717a?needAcc
ess=true 
Ortolani, C., & Pastorello, E. A. (2006). Food allergies and food intolerances. Best 
Practice & Research Clinical Gastroenterology, 20, 467-483. 
doi:10.1016/j.bpg.2005.11.010 
Parker, S. L., Leznoff, A., Sussman, G. L., Tarlo, S. M., & Krondl, M. (1990). Characteristics 
of patients with food-related complaints. Journal of Allergy and Clinical 
Immunology, 86(4), 503-511.  
Petrie, K., Jago, L. a., & Devcich, D. a. (2007). The role of illness perceptions in patients 
with medical conditions. Current Opinion in Psychiatry, 20, 163-167. 
doi:10.1097/YCO.0b013e328014a871 
Petrie, K., Sivertsen, B., Hysing, M., Broadbent, E., Moss-Morris, R., Eriksen, H. R., & 
Ursin, H. (2001). Thoroughly modern worries: the relationship of worries about 
modernity to reported symptoms, health and medical care utilization. Journal of 
Psychosomatic Research, 51(1), 395-401.  
Petrie, K., & Weinman, J. (2006). Why illness perceptions matter. Clinical Medicine, 6(6), 
536-539. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952762/pdf/536.pdf 
Phillips, K., Wright, B. J., & Kent, S. (2013). Psychosocial predictors of irritable bowel 
syndrome diagnosis and symptom severity. Journal of Psychosomatic Research, 
75, 467-474. doi:10.1016/J.JPSYCHORES.2013.08.002 
Phillips, K., Wright, B. J., & Kent, S. (2014). Irritable bowel syndrome and symptom 
severity: Evidence of negative attention bias, diminished vigour, and autonomic 





Picariello, F., Ali, S., Moss-Morris, R., & Chalder, T. (2015). The most popular terms for 
medically unexplained symptoms: the views of CFS patients. Journal of 
Psychosomatic Research, 78(5), 420-426.  
Porcelli, P., De Carne, M., & Leandro, G. (2014). Alexithymia and gastrointestinal-specific 
anxiety in moderate to severe irritable bowel syndrome. Comprehensive 
psychiatry, 55(7), 1647-1653.  
Reese, I., Ballmer-Weber, B., Beyer, K., Fuchs, T., Kleine-Tebbe, J., Klimek, L., . . . Schäfer, 
C. (2017). German guideline for the management of adverse reactions to 
ingested histamine. Allergo journal international, 26(2), 72-79.  
Renz, H., Allen, K. J., Sicherer, S. H., Sampson, H. A., Lack, G., Beyer, K., & Oettgen, H. C. 
(2018). Food allergy. Nature reviews Disease primers, 4, 17098. Retrieved from 
https://www.nature.com/articles/nrdp201798.pdf 
Roalfe, A. K., Roberts, L. M., & Wilson, S. (2008). Evaluation of the Birmingham IBS 
symptom questionnaire. BMC Gastroenterology, 8, 30. doi:10.1186/1471-230X-
8-30 
Rona, R. J., Keil, T., Summers, C., Gislason, D., Zuidmeer, L., Sodergren, E., . . . Madsen, C. 
(2007). The prevalence of food allergy: A meta-analysis. Journal of Allergy and 
Clinical Immunology, 120, 638-646. doi:10.1016/j.jaci.2007.05.026 
Rønnevig, M., Vandvik, P. O., & Bergbom, I. (2009). Patients’ experiences of living with 
irritable bowel syndrome. Journal of advanced nursing, 65(8), 1676-1685.  
Rosendal, M., Hartman, T. C. O., Aamland, A., Van der Horst, H., Lucassen, P., Budtz-Lilly, 
A., & Burton, C. (2017). “Medically unexplained” symptoms and symptom 
disorders in primary care: prognosis-based recognition and classification. BMC 
family practice, 18(1), 18. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297117/pdf/12875_2017_Arti
cle_592.pdf 
Rutter, C. L., & Rutter, D. R. (2002). Illness representation, coping and outcome in 
irritable bowel syndrome (IBS). British Journal of Health Psychology, 7(4), 377-
391.  
Rutter, C. L., & Rutter, D. R. (2007). Longitudinal analysis of the illness representation 
model in patients with irritable bowel syndrome (IBS). Journal of Health 
Psychology, 12(1), 141-148.  
Scharloo, M., Kaptein, A., Weinman, J., Hazes, J., Willems, L., Bergman, W., & Rooijmans, 
H. (1998). Illness perceptions, coping and functioning in patients with 
rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis. 
Journal of Psychosomatic Research, 44(5), 573-585.  
Schiefert, V. M., & Matteucci, X. (2018). Experiences of tourists suffering from food 
intolerances. Journal of Gastronomy and Tourism, 3(3), 191-202.  
Scott, W., & McCracken, L. M. (2015). Psychological flexibility, acceptance and 
commitment therapy, and chronic pain. Current Opinion in Psychology, 2, 91-96. 
doi:10.1016/J.COPSYC.2014.12.013 
Sebastián Sánchez, B., Gil Roales-Nieto, J., Ferreira, N. B., Gil Luciano, B., & Sebastián 




mindfulness, acceptance and commitment therapy (ACT). Revista Española de 
Enfermedades Digestivas, 109(9), 648-657.  
Sicherer, S., & Sampson, H. (2014). Food allergy: Epidemiology, pathogenesis, diagnosis, 
and treatment. Journal of Allergy and Clinical Immunology, 133, 291-307.e295. 
doi:10.1016/j.jaci.2013.11.020 
Sicherer, S., & Sampson, H. (2018). Food allergy: a review and update on epidemiology, 
pathogenesis, diagnosis, prevention, and management. Journal of Allergy and 
Clinical Immunology, 141(1), 41-58.  
Simister, H. D., Tkachuk, G. A., Shay, B. L., Vincent, N., Pear, J. J., & Skrabek, R. Q. (2018). 
Randomized controlled trial of online acceptance and commitment therapy for 
fibromyalgia. The Journal of Pain, 19(7), 741-753.  
Skinner, E. A., Edge, K., Altman, J., & Sherwood, H. (2003). Searching for the structure of 
coping: a review and critique of category systems for classifying ways of coping. 
Psychological bulletin, 129(2), 216.  
Skypala, I. (2011). Adverse food reactions—an emerging issue for adults. Journal of the 
American Dietetic Association, 111(12), 1877-1891.  
Snow-Turek, A. L., Norris, M. P., & Tan, G. (1996). Active and passive coping strategies in 
chronic pain patients. PAIN, 64(3), 455-462.  
Sommer, I., MacKenzie, H., Venter, C., & Dean, T. (2012). Factors influencing food 
choices of food-allergic consumers: Findings from focus groups. Allergy: 
European Journal of Allergy and Clinical Immunology, 67, 1319-1322. 
doi:10.1111/j.1398-9995.2012.02883.x 
Spence, M. J., & Moss-Morris, R. (2007). The cognitive behavioural model of irritable 
bowel syndrome: a prospective investigation of patients with gastroenteritis. 
Gut, 56(8), 1066-1071.  
Spitzer, R. L., Kroenke, K., Williams, J. B., & Group, P. H. Q. P. C. S. (1999). Validation and 
utility of a self-report version of PRIME-MD: the PHQ primary care study. Jama, 
282(18), 1737-1744.  
Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for 
assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine, 
166(10), 1092-1097.  
Stapel, S. O., Asero, R., Ballmer‐Weber, B., Knol, E., Strobel, S., Vieths, S., & Kleine‐
Tebbe, J. (2008). Testing for IgG4 against foods is not recommended as a 
diagnostic tool: EAACI Task Force Report. Allergy, 63(7), 793-796. Retrieved from 
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1398-9995.2008.01705.x 
Stieger, S., Reips, U. D., & Voracek, M. (2007). Forced‐response in online surveys: Bias 
from reactance and an increase in sex‐specific dropout. Journal of the American 
society for information science and technology, 58(11), 1653-1660.  
Taylor, S. E., & Stanton, A. L. (2007). Coping resources, coping processes, and mental 
health. Annu. Rev. Clin. Psychol., 3, 377-401.  
Teuber, S. S., & Porch-Curren, C. (2003). Unproved diagnostic and therapeutic 
approaches to food allergy and intolerance. Current Opinion in Allergy and 




Teufel, M., Biedermann, T., Rapps, N., Hausteiner, C., Henningsen, P., Enck, P., & Zipfel, 
S. (2007). Psychological burden of food allergy. World Journal of 
Gastroenterology, 13, 3456-3465. doi:10.3748/wjg.v13.i25.3456 
Thabane, M., & Marshall, J. K. (2009). Post-infectious irritable bowel syndrome. World 
journal of gastroenterology: WJG, 15(29), 3591. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721231/pdf/WJG-15-3591.pdf 
Trivedi, R. B., Blumenthal, J. A., O'Connor, C., Adams, K., Hinderliter, A., Dupree, C., . . . 
Sherwood, A. (2009). Coping styles in heart failure patients with depressive 
symptoms. Journal of Psychosomatic Research, 67(4), 339-346.  
Tuck, C. J., Biesiekierski, J. R., Schmid-Grendelmeier, P., & Pohl, D. (2019). Food 
Intolerances. Nutrients, 11(7), 1684.  
Ursin, H., & Eriksen, H. R. (2001). Sensitization, subjective health complaints, and 
sustained arousal. Annals of the New York Academy of Sciences, 933(1), 119-129.  
Vicente, P., & Reis, E. (2010). Using questionnaire design to fight nonresponse bias in 
web surveys. Social science computer review, 28(2), 251-267.  
Vowles, K. E., McCracken, L. M., McLeod, C., & Eccleston, C. (2008). The Chronic Pain 
Acceptance Questionnaire: confirmatory factor analysis and identification of 
patient subgroups. PAIN, 140(2), 284-291.  
Vowles, K. E., Sowden, G., & Ashworth, J. (2014). A comprehensive examination of the 
model underlying acceptance and commitment therapy for chronic pain. 
Behavior therapy, 45(3), 390-401.  
Weinman, J., Petrie, K. J., Moss-Morris, R., & Horne, R. (1996). The illness perception 
questionnaire: a new method for assessing the cognitive representation of 
illness. Psychology and health, 11(3), 431-445.  
Windgassen, S., Moss-Morris, R., Chilcot, J., Sibelli, A., Goldsmith, K., & Chalder, T. 
(2017). The journey between brain and gut: A systematic review of psychological 
mechanisms of treatment effect in irritable bowel syndrome. British Journal of 
Health Psychology, 22, 701-736. doi:10.1111/bjhp.12250 
Wolitzky-Taylor, K., Craske, M. G., Labus, J. S., Mayer, E. A., & Naliboff, B. D. (2012). 
Visceral sensitivity as a mediator of outcome in the treatment of irritable bowel 
syndrome. Behaviour Research and Therapy, 50(10), 647-650.  
Woods, R. K., Abramson, M., Bailey, M., & Walters, E. H. (2001). International 
prevalences of reported food allergies and intolerances. Comparisons arising 
from the European community respiratory health survey (ECRHS) 1991-1994. 
European Journal of Clinical Nutrition, 55(4), 298-304. 
doi:http://dx.doi.org/10.1038/sj.ejcn.1601159 
Woods, R. K., Stoney, R., Raven, J., Walters, E., Abramson, M., & Thien, F. (2002). 
Reported adverse food reactions overestimate true food allergy in the 
community. European Journal of Clinical Nutrition, 56, 31-36. 
doi:10.1038/sj.ejcn.1601306 
Wu, G., Feder, A., Cohen, H., Kim, J. J., Calderon, S., Charney, D. S., & Mathé, A. A. 
(2013). Understanding resilience. Frontiers in behavioral neuroscience, 7, 10.  
Yao, C. K., & Tuck, C. J. (2017). The clinical value of breath hydrogen testing. Journal of 




Yao, C. K., Tuck, C. J., Barrett, J. S., Canale, K. E., Philpott, H. L., & Gibson, P. R. (2017). 
Poor reproducibility of breath hydrogen testing: Implications for its application in 
functional bowel disorders. United European gastroenterology journal, 5(2), 284-
292.  
Yunus, M. B. (2007). Fibromyalgia and overlapping disorders: the unifying concept of 
central sensitivity syndromes. Paper presented at the Seminars in arthritis and 
rheumatism. 
Yunus, M. B. (2008). Central sensitivity syndromes: a new paradigm and group nosology 
for fibromyalgia and overlapping conditions, and the related issue of disease 
versus illness. Paper presented at the Seminars in arthritis and rheumatism. 
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta 
psychiatrica scandinavica, 67(6), 361-370.  
Zopf, Y., Baenkler, H.-W., Silbermann, A., Hahn, E. G., & Raithel, M. (2009). The 
differential diagnosis of food intolerance. Deutsches Ärzteblatt International, 
106, 359-369. doi:10.3238/arztebl.2009.0359 
Zuberbier, T., Edenharter, G., Worm, M., Ehlers, I., Reimann, S., Hantke, T., . . . 
Niggemann, B. (2004). Prevalence of adverse reactions to food in Germany–a 















Appendix II: Study Information Sheet 
 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Ethical Clearance Reference Number: HR-18/19-8576 
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
 
Title of study 
 




I would like to invite you to participate in this research project which forms part of my research for my 
doctorate in Clinical Psychology (DClinPsy). Before you decide whether you want to take part, it is 
important for you to understand why the research is being done and what your participation will involve. 
Please take time to read the following information carefully and discuss it with others if you wish. Ask me 
if there is anything that is not clear or if you would like more information. 
 
What is the purpose of the study? 
 
The purpose of this study is to explore factors, including emotions, thoughts, beliefs and symptoms, 
related to food intolerance, and how food intolerance influences our emotional well-being and our quality 
of life. This study is being conducted fully online with people who have food intolerance and can be 
completed from any computer or device with internet access. We wish to explore if there are any factors 
that might be related to food intolerance and whether these factors may also influence people’s well-
being. We are interested in looking at feelings like anxiety and depression, thoughts and beliefs about 
food intolerance, and how people cope with their condition. We would like to find out whether any of 
these characteristics are associated with food intolerance and if certain issues make people more or less 
likely to experience better or worse well-being.  We hope a better psychological understanding of food 
intolerance will, in the long term, help health care professionals and individuals with food intolerance 
alike better understand and manage food intolerance.   
 
Why have I been invited to take part? 
 
You are being invited to participate in this study because you have identified that you might have food 
intolerance. 
 
What will happen if I take part? 
 
If you choose to take part in the study, following reading this document you may proceed to the consent 
form, where you will be asked to read and sign the mandatory consent questions. When this is complete, 
you may proceed to the survey. The survey will include questions about general information about 
yourself and your experience of food intolerance (e.g. age, gender, additional diagnoses, symptoms of 
food intolerance, aggravating foods), your mood, your beliefs about food intolerance, quality of life, 





Participation will take place in the comfort of your own home or wherever you have access to the 
internet, as this is a fully online study. The survey will take approximately 20 minutes to complete. 
 
This study is longitudinal, which means we would like to see the changes in your experiences of food 
intolerance and well-being over the time. Therefore, we will ask you to complete the same questionnaires 
again 3 months, 6 months, and 12 months after you first completed it. It is very important to complete all 
questionnaires. As part of participation you will be asked to provide your email address. The provided 
email addresses will be only used for sending a reminder emails to remind you about the study.  All data 
you provide will be anonymised and destroyed at the end of the study. 
  
Do I have to take part? 
 
Participation is completely voluntary. You should only take part if you want to and choosing not to take 
part will not disadvantage you in anyway. Once you have read the information sheet, please contact us if 
you have any questions that will help you make a decision about taking part. If you decide to participate 
we will ask you to sign a consent form and you will be given a copy of this consent form to keep. You may 




 As a thank you for your participation, all participants who complete all questionnaires will be entered in a 
draw to win one of two £50 vouchers to www.amazon.co.uk. . 
 
What are the possible risks of taking part? 
 
There are no potential risks of taking part in this study.  If you have a concern about any aspect of this 
study, you should ask to speak to the researchers who will do their best to answer your questions. If you 
think this study has harmed you or caused you psychological stress in any way, you can contact the 
researchers using the contact details at the end of this information sheet in the section “What if I have 
further questions, or if something goes wrong?”. This section also includes the contact information for 
organisations that provide support for emotional distress.  
 
What are the possible benefits of taking part? 
 
There are no direct benefits gained from participating in this research. Your participation will contribute 
to a better understanding of food intolerance, which can help to inform psychological treatment at a later 
stage. 
 
Data handling and confidentiality 
 
Your data will be processed and stored in accordance with the General Data Protection Regulation 2016 
(GDPR). Your data will be stored on a secured password-protected master database at the university. 
Identity in this database will be indicated by a case number, rather than by name, so you cannot be 
identified from it. Your data will not be shared with third parties, and you will not be identified in any 
publication of research results.  Any information you provide will also be kept strictly confidential, as is the 
duty of researchers. Only the researcher (Alessandra De Petrillo) and her supervisors (Dr Emma Godfrey 
and Dr Lyndsay Hughes) will be able to see the provided email addresses. After data collection, 
information linking the case number to your email will be destroyed, which means all the provided 
information will be anonymous and after that point, we will be unable to identify your data.   Anonymous 
data will be securely destroyed in five years.  
 





The data controller for this project will be King’s College London (KCL). The University will process your 
personal data for the purpose of the research outlined above. The legal basis for processing your personal 
data for research purposes under GDPR is a ‘task in the public interest’ You can provide your consent for 
the use of your personal data in this study by completing the consent form that has been provided to you.  
 
You have the right to access information held about you. Your right of access can be exercised in 
accordance with the General Data Protection Regulation. You also have other rights including rights of 
correction, erasure, objection, and data portability. Questions, comments and requests about your 
personal data can also be sent to the King’s College London Data Protection Officer Mr Albert Chan info-
compliance@kcl.ac.uk. If you wish to lodge a complaint with the Information Commissioner’s Office, 
please visit www.ico.org.uk.   
 
What if I change my mind about taking part? 
 
You are free withdraw at any point of the study, without having to give a reason. Withdrawing from the 
study will not affect you in any way. You are able to withdraw your data from the study up until April 1st, 
2020, after which withdrawal of your data will no longer be possible, as all participant emails will be 
destroyed and information linking emails to data, thus anonymising the data. If you choose to withdraw 
from the study we will not retain the information you have given thus far.  
 
What will happen to the results of the study? 
 
The results of the study will form part of a doctoral thesis and could be published in academic journals or 
presented at academic conferences.  A copy of the final report will be available for you at your request by 
emailing the research team. Also, the anonymised data set can be accessed by King’s College London 
students for educational purposes, such as completing their final year project or master’s dissertation for 
up to five years following study completion.  However, they will not be able to access your personal 
information. The anonymous data set will not be shared with any third parties or made publicly available. 
 
Who should I contact for further information? 
If you have any questions or require more information about this study, please contact me using the 
following contact details:  
 
Alessandra De Petrillo 
alessandra.de_petrillo@kcl.ac.uk 
Trainee Clinical Psychologist 
Department of Psychology (PO78) 
Addiction Sciences Building 
Institute of Psychiatry, Psychology & Neuroscience 
King's College London 
SE5 8AF 
 
What if I have further questions, or if something goes wrong? 
 
If this study has harmed you in any way or if you wish to make a complaint about the conduct of the study 
you can contact King's College London using the details below for further advice and information:  
 
Dr Emma Godfrey 
emma.l.godfrey@kcl.ac.uk 
Health Psychology Section, Psychology department,  
IoPPN, King's College London 
5th Floor Bermondsey Wing 





London, SE1 9RT 
020 7188 0178 
 
The following organisations provide support for individuals experiencing distress, however, should not be 
used in a crisis. If you have been experiencing low mood in the last two weeks, please speak to your GP.  
 
NHS 111  
Call: 111  
Advice in England when you need medical help fast but it's not an emergency.  
  
C.A.L.L Mental Health Helpline  
callhelpline.org.uk  
24 hour free helpline: 0800 132 737  
Text: 81066  
Offers emotional support and mental health information for people living in Wales.  
  
CALM (Campaign Against Living Miserably)  
0800 58 58 58 (5pm-midnight)  
thecalmzone.net  
Listening services, information and support for men who feel down or are in crisis.  
  
Samaritans  
Confidential, emotional support 24/7 to those experiencing despair, distress, or suicidal feelings.   
Helpline: 116 123 (24 hours)  
Website: www.samaritans.org.uk  
  
Breathing Space  
A free confidential helpline to call when feeling down or stressed.  

























Appendix III: Study Consent Sheet 
 
 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Please complete this form after you have read the Information Sheet and/or listened to an explanation 
about the research. 
 
Title of Study: Psychological Factors Associated with Perceived Food Intolerance: An Exploratory Study 
 
King’s College Research Ethics Committee Ref: HR-18/19-8576 
 
Thank you for considering taking part in this research. The person organising the research must explain 
the project to you before you agree to take part. If you have any questions arising from the Information 
Sheet or explanation already given to you, please ask the researcher before you decide whether to join in. 
You will be given a copy of this Consent Form to keep and refer to at any time. 
 
I confirm that I understand that by ticking/initialling each box I am consenting to this 
element of the study. I understand that it will be assumed that unticked/initialled boxes 
mean that I DO NOT consent to that part of the study. I understand that by not giving 




 Please tick 
or initial 
1. *I confirm that I have read and understood the information sheet dated Version 2 – 
21/02/2019 for the above study. I have had the opportunity to consider the 






2. I consent voluntarily to be a participant in this study and understand that I can refuse 
to answer questions and I can withdraw from the study at any time, without having to 
give a reason, up until April 1st 2020 
 
 
3. *I consent to the processing of my personal information for the purposes explained 
to me in the Information Sheet.  I understand that such information will be handled in 
accordance with the terms of the General Data Protection Regulation. 
 
 
4. * I understand that my information may be subject to review by responsible 
individuals from the College for monitoring and audit purposes. 
 
 
5. I understand that confidentiality and anonymity will be maintained and it will not be 
possible to identify me in any research outputs. 
 
 
6. I agree that the research team may use my data for future research and understand 
that any such use of identifiable data would be reviewed and approved by a research 
ethics committee. (In such cases, as with this project, data would/would not be 













7. I understand that the information I have submitted will be published as a report 
and I wish to receive a copy of it. (In such cases, as with this project, data 
would/would not be identifiable in any report). 
 
 
8. I understand that I must not take part if I fall under the exclusion criteria as 






__________________               __________________              _________________ 
Name of Participant                 Date          Signature 
 
 
__________________               __________________              _________________ 










Appendix IV: Study Questionnaire with Outcome Measures 
 





Participant ID code 
 
Please input your unique participant ID code that you created at the time of consenting to participate in the 
study 
 
Reminder of code: Your unique participant ID code is a 7 (seven) character code comprised of the following 
1) The first 3 letters of the street you live on 
2) Two-digit birth month 
3) The 2 letters of your Mother's first and last initials  
 
Example: If you live on Sunset Road, were born in December and your mother's name is Jane Smith, your 
unique ID code would be: SUN12JS 
________________________________________________________________ 
 
Please select the gender that best represents you. 
o Female  
o Male  
o Prefer to self-describe ________________________________________________ 
o Prefer not to say  
 
What age are you today? 
_______________________________________________ 
 
What age category best represents you? 
o 18-24  
o 25-34  
o 35-44  
o 45-54  
o 55-64  
o 65-74  
o 75-84  
o 85 +  
 




o Irish  
o Gypsy or Irish Traveller  
o Any other White background  
o White and Black Caribbean  
o White and Black African  
o White and Asian  
o Any other Mixed/Multiple ethnic 
background   
o Indian         
   
o  African  
o  Caribbean  
o Any other Black/African/Caribbean background  
o Arab  
o Any other ethnic group 
o              Pakistani 
o  Bangladeshi 
o  Chinese 
o  Any other Asian background
 
First we would like to ask whether you would describe yourself has having a food intolerance. By this we 
meaning having a negative reaction following eating a particular food. Reactions could include gastrointestinal 
distress (bloating, diarrhoea, cramping, pain), headaches, joint pain or fatigue whenever you ingest the food(s), 
and can occur from 30 min - 48 hours after ingesting the food(s).  
o Yes  
o No  
 
How did you come to realise you had food intolerance(s)? Please select any and all that apply 
▢ Medical Professional or  Allied Health Professional  
▢ Naturopath, Nutritionist or Alternative Health Practitioner  
▢ Results of a double-blind food challenge (if selected, specify from which practitioner under other) 
▢ Results of a blood test (if selected, specify from which practitioner, or self-tested kit under other) 
▢ Results of a breath test  (if selected, specify from which practitioner under other) 
▢ Results of a hair sample test or mail-in test  
▢ Self-diagnosed  
▢ Other ________________________________________________ 
▢ Not applicable  
 
 
Please select any/all of the reactions that you experience following ingestion of the food(s) you are intolerant 





















and/or gas  
▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Diarrhoea  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Cramping  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Stomach 
pain  
▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Headache 
or Migraine  
▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Brain fog  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Fatigue  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  






▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Hives  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  





If the food (s) you react to is not listed, please write the food(s) and reaction(s) below 
________________________________________________________________ 
 
At what age did you develop your food intolerance? 
o 0-18  
o 18-24  
o 25-34  
o 35-44  
o 45-54  
o 55-64  
o 65-74  
o 75-84  
o 85+  




We would now like to ask if you have any diagnosed food allergies (including anaphylaxis) that lead to 
immediate reactions? Reactions could include lip or tongue swelling, throat or chest tightening, difficulty 
breathing or wheezing, skin rashes or hives, rapid heart beat, dizziness or fainting or all of the above after 
consuming the allergenic food(s), and can occur within minutes - two hours after exposure to the food(s).  
o Yes  
o No  
 
 
Do you have an EpiPen?  
o Yes  
o No  
 
 
How were you diagnosed with your food allergy? 
▢ Medical Professional or Allied Health Professional  
▢ Naturopath, Nutritionist or Alternative Health Practitioner  
▢ Results of a double-blind food challenge  
▢ Results of a blood test  
▢ Results of a breath test  
▢ Results of a hair sample test or mail-in test  
▢ Self-diagnosed  
▢ Other ________________________________________________ 





























Skin / Oral 
reactions 
























blood pressure)  
▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
Other  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  ▢  
 





At what age did you develop your food allergy? 
o 0-18  
o 18-24  
o 25-34  
o 35-44  
o 45-54  
o 55-64  
o 65-74  
o 75-84  
o 85+  






Do you have Coeliac disease?  Coeliac disease is an autoimmune condition that causes inflammation and 
damage to the small intestine after ingesting gluten. Coeliac disease is not gluten sensitivity. 
o Yes  
o No  
o Don't know  
 
If yes, how were you diagnosed with Coeliac disease? 
o Positive biopsy  
o Results of a blood test  
o Other ________________________________________________ 
 
 
Do you have Irritable Bowel Syndrome (IBS)? IBS is condition of the digestive system consisting of frequent 
abdominal discomfort and bowel symptoms.  
o Yes  
o No  
o Don't know  
 
If yes. how were you diagnosed with IBS? 
o Medical practitioner  
o Self-Diagnosed  
o Other ________________________________________________ 
o Not applicable  
 
  
Have you ever been diagnosed by a medical professional / allied health professional for any of the following 
conditions? Please select all that apply. 
▢ Asthma  
▢ Ectoptic/atopic dermatitis  
▢ Hay fever/ allergic rhinitis / seasonal allergies  
▢ Insect sting allergy  
▢ Latex allergy  
▢ Medication allergy  
▢ Uticaria/Hives 

























Listed below are a number of symptoms that you may or may not have experienced since your food 
intolerance. Please indicate by clicking Yes or No , whether you have experienced any of these symptoms since 
your food intolerance, and whether you believe that these symptoms are related to your food intolerance. 
 
I have experienced this symptom since 
my food intolerance. 
This symptom is related to my food 
intolerance. 
 Yes No Yes No 
Pain  o  o  o  o  
Sore Throat  o  o  o  o  
Nausea  o  o  o  o  
Breathlessness  o  o  o  o  
Weight Loss  o  o  o  o  
Fatigue  o  o  o  o  
Stiff Joints / Joint 
Pain  
o  o  o  o  
Sore Eyes  o  o  o  o  
Wheeziness  o  o  o  o  
Headaches  o  o  o  o  
Upset Stomach  o  o  o  o  
Dizziness  o  o  o  o  
Loss of Strength  o  o  o  o  





We are interested in your own personal views of how you now see your food intolerance. 
Please indicate how much you agree or disagree with the following statements about food intolerance by 













Agree Strongly Agree 
1. My food intolerance will 
last a short time.  
o  o  o  o  o  
2. My food intolerance is 
likely to be permanent 
rather than temporary.  
o  o  o  o  o  
3. My food intolerance will 
last for a long time.  
o  o  o  o  o  
4. My food intolerance will 
pass quickly.  
o  o  o  o  o  
5. I expect to have this for 
the rest of my life.  
o  o  o  o  o  
6. My food intolerance is a 
serious condition.  
o  o  o  o  o  
7. My food intolerance has 
major consequences on my 
life.  
o  o  o  o  o  
8. My food intolerance does 
not have much effect on my 
life.  
o  o  o  o  o  
9. My food intolerance 
strongly affects the way 
others see me.  
o  o  o  o  o  
10. My food intolerance has 
serious financial 
consequences.  
o  o  o  o  o  
11. My food intolerance 
causes difficulties for those 
who are close to me.  
o  o  o  o  o  
12. There is a lot which I 
can do to control my 
symptoms.  
o  o  o  o  o  
13. What I can do can 
determine whether my 
food intolerance gets better 
or worse.  
o  o  o  o  o  
14. The course of my food 
intolerance depends on me.  
o  o  o  o  o  
15. Nothing I do will affect 
my food intolerance.  
o  o  o  o  o  
16. I have the power to 
influence my food 
intolerance.  
o  o  o  o  o  
17. My actions will have no 
effect on the outcome of 
my food intolerance.  




18. My food intolerance will 
improve in time.  
o  o  o  o  o  
19. There is very little that 
can be done to improve my 
food intolerance.  
o  o  o  o  o  
20. My treatment will be 
effective in curing my food 
intolerance.  
o  o  o  o  o  
21. The negative effects of 
my food intolerance can be 
prevented (avoided) by my 
treatment  
o  o  o  o  o  
22. My treatment can 
control my food 
intolerance.  
o  o  o  o  o  
23. There is nothing which 
can help my food 
intolerance.  
o  o  o  o  o  
24. The symptoms of my 
food intolerance are 
puzzling to me.  
o  o  o  o  o  
25. My food intolerance is a 
mystery to me.  
o  o  o  o  o  
26. I don't understand my 
food intolerance.  
o  o  o  o  o  
27. My food intolerance 
doesn't make any sense to 
me.  
o  o  o  o  o  
28. I have a clear picture or 
understanding of my food 
intolerance.  
o  o  o  o  o  
29. The symptoms of my 
food intolerance change a 
great deal from day to day.  
o  o  o  o  o  
30. My symptoms come 
and go in cycles.  
o  o  o  o  o  
31. My food intolerance is 
very unpredictable.  
o  o  o  o  o  
32. I go through cycles in 
which my food intolerance 
gets better and worse.  
o  o  o  o  o  
33. I get depressed when I 
think about my food 
intolerance.  
o  o  o  o  o  
34. When I think about my 
food intolerance I get 
upset.  










We are interested in what you consider may have been the cause of your food intolerance.  As people are very 
different, there is no correct answer for this question.  We are most interested in your own views about the 
factors that caused your illness rather than what others including doctors or family may have suggested to you.  
Below is a list of possible causes for your food intolerance. Please think of each question in relation to your 
food intolerance.  
35. My food intolerance 
makes me feel angry.  
o  o  o  o  o  
36. My food intolerance 
does not worry me.  
o  o  o  o  o  
37. Having this food 
intolerance makes me feel 
anxious.  
o  o  o  o  o  
38. My food intolerance 
makes me feel afraid.  












Agree Strongly agree 
1. Stress or worry  o  o  o  o  o  
2. Hereditary - it runs 
in my family  
o  o  o  o  o  
3. A germ or virus  o  o  o  o  o  
4. Diet or eating habits  o  o  o  o  o  
5. Chance or bad luck  o  o  o  o  o  
6. Poor medical care in 
my past  
o  o  o  o  o  
7. Pollution in the 
environment  
o  o  o  o  o  
8. My own behaviour  o  o  o  o  o  
9. My mental attitude 
(e.g. thinking about 
life negatively)  
o  o  o  o  o  
10. Family problems or 
worries caused my 
food intolerance  
o  o  o  o  o  
11. Overwork  o  o  o  o  o  
12. My emotional 
state (e.g. feeling 
down, lonely, anxious, 
empty)  
o  o  o  o  o  
13. Ageing  o  o  o  o  o  
14. Alcohol  o  o  o  o  o  
15. Smoking  o  o  o  o  o  
16. Accident or injury  o  o  o  o  o  
17. My personality  o  o  o  o  o  
18. Altered immunity  o  o  o  o  o  
 
In the table below, please list in rank-order the three most important factors that you now believe caused 
YOUR food intolerance. You may use any of the items from the list above, or you may have additional ideas of 
your own. 
 
The most important causes for me: 
o 1 ________________________________________________ 
o 2 ________________________________________________ 
o 3 ________________________________________________ 
 







Please think of all the things you do and experience in relation to food and meals (e.g., planning meals, 
shopping, preparing meals, eating meals) and then, using the scale below, indicate your agreement with each 





















1. Food and meals 
are positive elements 
in my life  
o  o  o  o  o  o  o  
2. When I think of my 
next meal, I only see 
problems, obstacles 
and disappointments  
o  o  o  o  o  o  o  
3. I am generally 
pleased with my food  
o  o  o  o  o  o  o  
4. Food and meals 
give me satisfaction 
in daily life  
o  o  o  o  o  o  o  
5. My life in relation 
to food and meals is 
close to my ideal  
o  o  o  o  o  o  o  
6. I wish my meals 
were a much more 
pleasant part of my 
life  
o  o  o  o  o  o  o  
7. With regard to 
food, the conditions 
of my life are 
excellent  
o  o  o  o  o  o  o  
 
 





















Please think of what you have experienced in the past week for these next questions. 
 
Tick the box beside the reply that is closest to how you have been feeling in the past week. Don’t take too long 
over your replies: your immediate response is best. 
 
I feel tense or 'wound up' 
o Most of the time  
o A lot of the time  
o From time to time, occasionally  
o Not at all  
 
I still enjoy the things I used to enjoy 
o Definitely as much  
o Not quite so much  
o Only a little  
o Hardly at all  
 
I get a sort of frightened feeling as if something awful is about to happen 
o Yes definitely and quite badly  
o Yes but not too badly  
o A little, but it doesn't worry me  
o Not at all  
 
I can laugh and see the funny side of things 
o As much as I always could  
o Not quite so much now  
o Definitely not so much now  
o Not at all  
 
Worrying thoughts go through my mind 
o A great deal of the time  
o A lot of the time  
o From time to time, but not too often  
o Only occasionally  
 
I feel cheerful 
o Not at all  
o Not often  
o Sometimes  
o Most of the time  
 
I can sit at ease and feel relaxed 
o Definitely  
o Usually  
o Not often  
o Not at all  
 
I feel as if I am slowed down 
o Nearly all the time  
o Very often  
o Sometimes  





I get a sort of frightened feeling like 'butterflies' in the stomach 
o Not at all  
o Occasionally  
o Quite often  
o Very often  
 
I have lost interest in my appearane 
o Definitely  
o I don't take as much care as I should  
o I may not take quite as much care  
o I take just as much care as ever  
 
I feel restless as if I have to be on the move 
o Very much indeed  
o Quite a lot  
o Not very much  
o Not at all  
 
I look forward with enjoyment to things 
o As much as I ever did  
o Rather less than I used to  
o Definitely less than I used to  
o Hardly at all  
 
I get sudden feelings of panic 
o Very often indeed  
o Quite often  
o Not very often  
o Not at all  
 
I can enjoy a good book or radio or TV program 
o Often  
o Sometimes  
o Not often  
o Very seldom  
 
























People's health difficulties sometimes affect their ability to do certain day-to-day tasks in their lives. Look at 
each section and determine on the scale provided how much your food intolerance impairs your ability to carry 
out daily activities.  Please think of each question in relation to your food intolerance.  
 
Not 















1. My ability to work is 
impaired. '0' means 'not 
at all impaired' and '8' 
means very severely 
impaired to the point I 
can't work  
o  o  o  o  o  o  o  o  o  
2. My home 
management (cleaning, 
tidying, shopping, 
cooking, looking after 
home or children, paying 
bills) is impaired  
o  o  o  o  o  o  o  o  o  
3. My social leisure 
activities (with other 
people e.g. parties, bars, 




o  o  o  o  o  o  o  o  o  
4. My private leisure 
activities (done alone, 
such as reading, 
gardening, 
collecting,sewing,walking 
alone) are impaired  
o  o  o  o  o  o  o  o  o  
5. My ability to form and 
maintain close 
relationships with others, 
including those I live 
with, is impaired  
o  o  o  o  o  o  o  o  o  
 
 

















Please think of symptoms you have experienced during the past 4 weeks for these next questions. Please think 
of each question in relation to your food intolerance.  
 
During the past 4 weeks, how much have you been bothered by any of the following problems? 
 Not bothered at all Bothered a little Bothered a lot 
1. Stomach pain  o  o  o  
2. Back pain  o  o  o  
3. Pain in your arms, legs, 
or joints (knees, hips, 
etc.)  
o  o  o  
4. Menstrual cramps or 
other problems with 
your periods (men leave 
blank)  
o  o  o  
5. Headaches  o  o  o  
6. Chest pain  o  o  o  
7. Dizziness  o  o  o  
8. Fainting spells  o  o  o  
9. Feeling your heart 
pound or race  
o  o  o  
10. Shortness of breath  o  o  o  
11. Pain or problems 
during intercourse  
o  o  o  
12. Constipation, loose 
bowels, or diarrhea  
o  o  o  
13. Nausea, gas, or 
indigestion  
o  o  o  
14. Feeling tired or 
having low energy  
o  o  o  
15. Trouble sleeping  o  o  o  
 
 













Birmingham IBS Symptom Questionnaire 
 
These questions ask you about any abdominal and bowel symptoms. When we use the word abdomen we 
mean belly/tummy. Some of the questions ask about passing a stool. By this we mean going to the toilet for a 
reason other than to urinate (pass water). All of these questions refer to what you have experienced during the 





End of Block: Birmingham IBS 
 
 




A good bit 
of the time 
Some of 
the time 




1. During the last 4 weeks, how often 
have you had discomfort or pain in 
your abdomen?  
o  o  o  o  o  o  
2. How often have you been troubled 
with loose, mushy or watery bowel 
motions during the last 4 weeks?  
o  o  o  o  o  o  
3. How often during the last 4 weeks 
have you been troubled with 
diarrhoea?  
o  o  o  o  o  o  
4. During the last 4 weeks how often 
have you been troubled by hard bowel 
motions?  
o  o  o  o  o  o  
5. During the last 4 weeks how often 
have you felt the need to strain to 
pass a motion (stool)?  
o  o  o  o  o  o  
6. During the last 4 weeks how often 
have you been troubled by 
constipation?  
o  o  o  o  o  o  
7. During the last 4 weeks how often 
did you experience pain or discomfort 
in your abdomen after eating?  
o  o  o  o  o  o  
8. How often has you abdominal pain 
prevented you from sleeping, or 
woken you during the night during the 
last 4 weeks?  
o  o  o  o  o  o  
9. During the last 4 weeks how often 
have you leaked or soiled yourself?  
o  o  o  o  o  o  
10. How often during the last 4 weeks 
have you suffered from a feeling of 
urgency (feeling that you must 
immediately rush to the toilet to pass 
a stool)?  
o  o  o  o  o  o  
11. How often have you passed mucus 
or slime in your stools over the last 4 
weeks?  







These items deal with ways you've been coping with the stress in your life. There are many ways that people try 
to cope with their difficulties. Don't answer on a basis of whether it seems to be working or not - just whether 




I haven't been 
doing this at all 
I've been 
doing this a 
little bit 
I've been doing 





1. I've been turning to work or other 
activities to take my mind off things.  
o  o  o  o  
2. I've been concentrating my efforts 
on doing something about it.  
o  o  o  o  
3. I've been saying to myself "this isn't 
real."  
o  o  o  o  
4. I've been using alcohol or other 
drugs to make myself feel better.  
o  o  o  o  
5. I've been getting emotional support 
from others.  
o  o  o  o  
6. I've been giving up trying to deal 
with it.  
o  o  o  o  
7. I've been taking actions to try and 
make the situation better.  
o  o  o  o  
8. I've been refusing to believe that it 
is happening.  
o  o  o  o  
9. I've been saying things to let my 
unpleasant feelings escape.  
o  o  o  o  
10. I've been getting help and advice 
from other people.  
o  o  o  o  
11. I've been using alcohol or other 
drugs to help me get through it.  
o  o  o  o  
12. I've been trying to see it in a 
different light, to make it seem more 
positive.  
o  o  o  o  
13. I've been criticizing myself.  o  o  o  o  
14. I've been trying to come up with a 
strategy about what to do.  
o  o  o  o  
15. I've been getting comfort and 
understanding from someone.  
o  o  o  o  
16. I've been giving up the attempt to 
cope.  
o  o  o  o  
17. I've been looking for something 
good in what is happening.  
o  o  o  o  



































19. I've been doing something to think 
about it less, such as going to movies, 
watching TV, reading, daydreaming, or 
shopping.  
o  o  o  o  
20. I've been accepting the reality of 
the fact that it is happening.  
o  o  o  o  
21. I've been expressing my negative 
feelings.  
o  o  o  o  
22. I've been trying to find comfort in 
my religion or spiritual beliefs.  
o  o  o  o  
23. I've been trying to get advice or 
help from other people.  
o  o  o  o  
24. I've been learning to live with it.  o  o  o  o  
25. I've been thinking about what 
steps to take.  
o  o  o  o  
26. I've been blaming myself for things 
that happened.  
o  o  o  o  
27. I've been praying or meditating.  o  o  o  o  
28. I've been making fun of the 
situation.  







The questions in this scale ask you about your feelings and thoughts during the last month. In each case, you 




End of Block: PSS 
 
 
You are just about finished this survey! Before you go, is there anything else that you would like to tell us about 
your food intolerance or your experience with food intolerance? 
________________________________________________________________ 
________________________________________________________________ 
Thank you very much for your participation! 
  
 Never Almost Never Sometimes Fairly Often Very Often 
1. In the last month, how often have 
you been upset because of something 
that happened unexpectedly?  
o  o  o  o  o  
2.  In the last month, how often have 
you felt that you were unable to 
control the important things in your 
life?  
o  o  o  o  o  
3.  In the last month, how often have 
you felt nervous and stressed?  
o  o  o  o  o  
4. In the last month, how often have 
you felt confident about your ability to 
handle your personal problems?  
o  o  o  o  o  
5. In the last month, how often have 
you felt that things were going your 
way?  
o  o  o  o  o  
6. In the last month, how often have 
you found that you could not cope 
with all the things that you had to do?  
o  o  o  o  o  
7. In the last month, how often have 
you been able to control irritations in 
your life?  
o  o  o  o  o  
8. In the last month, how often have 
you felt that you were on top of 
things?  
o  o  o  o  o  
9. In the last month, how often have 
you been angered because of things 
that happened that were outside of 
your control?  
o  o  o  o  o  
10. In the last month, how often have 
you felt difficulties were piling up so 
high that you could not overcome 
them?  



















N = 255 
Identify 
Female 




N = 19 




 n (%) n (%)  
18-44 163 (63.9%) 147 (57.6%) 16 (6.3%) 2 = 3.67, p = .04 phi = .12 
45-84 92 (36.1%) 89 (34.9%) 3 (1.2%)  
PFI Only 194 (76.1%) 182 (71.4%) 12 (4.7%) 2 = 1.75, p = .15, phi = .08 
PFI & FA 61 (23.9%) 54 (21.2%) 7 (2.7%)  
White 230 (90.2%) 216 (84.7%) 14 (5.5%) 2 = 6.33, p = .012, phi = 
.16 
Black/Minority Ethnic  25 (9.8%) 20 (8.5%) 5 (26.3%)  
     
Clinical Characteristics  n (%) n (%)  
Irritable Bowel 
Syndrome  
122 (47.8%) 112 (55.2%) 10 (4.9%) 2 = .042, p = .84, phi = -
.01 
Coeliac Disease  19 (8.6%) 17 (7.7%) 2 (0.9%) 2 = .33, p = .57, phi = -.04 
     
Baseline Scores  M (SD) M (SD) M (SD)  
SWFL  23.1 (7.0) 23.3 (6.9) 21.8 (9.3) t(17.35) = .65, p = .52 
HADS Anxiety  9.0 (4.9) 8.9 (4.9) 10.5 (5.2) t(237) = 1.28, p = .24 
HADS Depression  5.9 (4.4) 5.8 (4.3) 8.2 (5.5) t(236) = 2.19, p = .030 
HADS Total 15.0 (8.0) 14.7 (8.3) 18.7 (10.0) t(235) = 1.88, p = .062 
WSAS 10.2 (9.1) 10.1 (10.5) 11.7 (11.2) t(232) = .61, p = .54 
PHQ-15 11.7 (5.9) 11.8 (5.9) 11.8 (6.0) t(230) = .08, p = .93 
Birmingham IBS Scale 28.7 (17.4) 28.8 (17.4) 28.1 (17.1) t(223) = -.149, p = .88 
PSS  20.4 (7.9) 20.4 (7.8) 20.4 (9.1) t(222) = .04, p = .97 
Baseline Caseness n (%) n (%) n (%)  
HADS Anxiety  140 (59.6%) 128 (58.7%) 12 (70.6%) 2 = .92, p = .34, phi = -.06 
HADS Depression  76 (32.5%) 68 (31.3%) 8 (47.1%) 2 = 1.78, p = .18, phi = -.09 


















N = 255 
PFI Only 
N = 194 
PFI and FA 
N = 61 
Statistical Test & P Value 
Sociodemographic 
Characteristics 
 n (%) n (%)  
18-44 163 (63.9%) 119 (46.7%) 44 (17.3%) 2 = 2.60, p = .11 phi = -.10 
45-84 92 (36.1%) 75 (29.4%) 17 (6.7%)  
Identify Female 236 (92.5%) 182 (71.4%) 54 (21.2%) 2 = 1.88, p = .17 phi = -.09 
White 230 (90.2%) 178 (69.8%) 52 (20.4%) 2 = 2.22, p = .14, phi = -.09 
Black/Minority Ethnic  25 (9.8%) 16 (6.3%) 9 (3.5%)  
     
Clinical 
Characteristics 
 n (%) n (%)  
Irritable Bowel 
Syndrome  
122 (47.8%) 103 (50.7%) 19 (9.4%) 2 = 7.71, p = .006, phi = -.20 
Coeliac Disease  19 (8.6%) 11 (5%) 8 (2.6%) 2 = 3.69, p = .055, phi = .13 
     
Baseline Scores  M (SD) M (SD) M (SD)  
SWFL  23.1 (7.0) 23.5 (6.6) 21.9 (8.5) t(81.98) = 1.29, p = .20 
HADS Anxiety  9.0 (4.9) 8.8 (4.8) 9.8 (5.1) t(231) = -1.44, p = .15 
HADS Depression  5.9 (4.4) 5.9 (4.5) 6.2 (4.2) t(230) = -.54, p = .59 
HADS Total 15.0 (8.0) 14.7 (8.3) 16.0 (8.6) t(229) = -1.04, p = .30 
WSAS 10.2 (9.1) 10.1 (10.0) 10.9 (12.3) t(78.06) = -.49, p = .62 
PHQ-15 11.7 (5.9) 11.5 (5.8) 12.6 (6.4) t(224) = -1.18, p = .24 
Birmingham IBS 
Scale 
28.7 (17.4) 29.6 (16.6) 29.1 (19.5) t(220) = .111, p = .86 
PSS  20.4 (7.9) 19.9 (7.8) 22.1 (8.0) t(218) = -1.82, p = .07 
Baseline Caseness  n (%) n (%) n (%)  
HADS Anxiety  140 (59.6%) 103 (57.9%) 37 (64.9%) 2 = .89, p = .36, phi = .06 
HADS Depression  76 (32.5%) 54 (30.5%) 22 (38.6%) 2 = 1.29, p = .26, phi = .07 




Appendix VIII: Group Analysis Separated by PFI-Only vs IBS + PFI 
  
 Total 
N = 255 
PFI Only 
N = 133 
IBS + PFI 
N = 122 




 n (%) n (%)  
Identifies Female 236 (92.5%) 124 (93.2%) 112 (91.8%) 2 = .1, p = .66, phi = -..03 
18-44 163 (63.9%) 87 (65.4%) 76 (62.3%) 2 = .268, p = .60 phi = .03 
45-84 92 (36.1%) 46 (34.6%) 46 (37.7%)  
PFI Only 194 (76.1%) 91 (68.4%) 103 (84.4%) 2 = 8.96, p = .003, phi = - 
.19 
PFI & FA 61 (23.9%) 42 (31.6%) 19 (15.6%)  
White 230 (90.2%) 119 (89.5%) 111 (91%) 2 = 164, p = .69, phi = .03 
Black/Minority Ethnic  25 (9.8%) 14 (10.5%) 11 (29%)  
     
Clinical Characteristics  n (%) n (%)  
Coeliac Disease  19 (8.6%) 10 (8.5%) 9 (8.7%) 2 = .003, p = .96, phi = 
.003 
# of Offending Foods      
             1 food 72 (28.3%) 52 (39.1%) 23 (18.9%)  
             2 foods 59 (23.5%) 33 (24.8%) 26 (21.3%)  
             3 foods 55 (21.7%) 21 (15.8%) 34 (27.8%)  
             4+ foods 67 (26.5%) 27 (20.3%) 39 (32%)  
Baseline Scores  M (SD) M (SD) M (SD)  
SWFL  23.1 (7.0) 23.7 (7.7) 22.3 (6.3) t(239) = 1.75 p = .08 
HADS Anxiety  9.0 (4.9) 8.8 (5.0) 9.2 (4.7) t(233) = -.73, p = .47 
HADS Depression  5.9 (4.4) 5.9 (4.5) 6.1 (4.3) t(232) = -.31, p = .76 
HADS Total 15.0 (8.0) 14.8 (8.3) 15.3 (7.6) t(231) = -.67, p = .50 
WSAS 10.2 (9.1) 9.4 (9.4) 11.8 (8.7) t(228) = -2.3, p = .02 
PHQ-15 11.7 (5.9) 10.6 (5.8) 12.9 (5.8) t(226) = -.30, p = .003 
Birmingham IBS Scale 28.7 (17.4) 23.5 (15.4) 34.3 (16.7) t(220) = -.5.43, p = .00 
PSS  20.4 (7.9) 19.99 (7.9) 20.8 (7.7) t(218) = -.77, p = .45 
Baseline Caseness n (%) n (%) n (%)  
HADS Anxiety  140 (59.6%) 68 (57.1%) 72(62.1%) 2 = .59, p = .44, phi = .05 
HADS Depression  76 (32.5%) 40 (33.6%) 36 (31.3%) 2 = .14, p = .71, phi = -.03 




Appendix IX: Additional Causal Attributions of PFI 
 
Gut health ‘gut health’; ‘microbiome’; ‘imbalanced gut physiology’; 
‘damaged gut health’; ‘gut damage from modern diet’; 
‘intestinal changes’; ‘stomach bacteria’; ‘gut bacteria 
imbalance’; ‘stomach lining’; ‘microbiome deficiency’   
Previous Health Conditions ‘past anorexia’; ‘anorexia nervosa’; ‘past cancer and 
treatment’; ‘polycystic ovarian syndrome’; ‘Hashimoto’; 
‘fibromyalgia’; ‘autoimmune condition’; ‘binge eating in 
youth’; ‘thyroid problems’; ‘acquired brain injury’; 
‘chemotherapy’; ‘diabetes’ 
Medication ‘contraceptive pill’; ‘hormonal therapy’; ‘medication’; 








Appendix X: IPQ-R, Brief-COPE and Outcome Correlational Analysis 
 
*only correlations significant at 0.01 level (2-tailed) are shaded 
 
 































  1 2 3 4 5 6 7 8 
1) HADS-A 1               
2) HADS-T .913** 1             
3) SWFL -.325** -.388** 1           
4) WSAS .358** .467** -.385** 1         
5) PHQ-15 .560** .587** -.407** .552** 1       
6) PSS .702** .755** -.415** .408** .500** 1     
7) IBS Total .380** .384** -.427** .461** .667** .342** 1   










































Appendix XIV: Proposed 4-session ACT Intervention 





- Discussion of why we are here and that the aim of the intervention is to work towards 
continuing to live a meaningful life and being able to engage in what matters most, 
alongside difficulties relating to PFI 
 
Psychoeducation: 
- What is currently understood about PFI; symptoms experienced, unpredictability of 
symptoms and reactions, lack of diagnosis, treatment and/or cure and how people typically 
manage 
- The evolution of our brain to be ‘on the lookout’, and how this can contribute to 
vigilance, noticing symptoms, enhanced pain sensitivity, and anxiety 
- The gut-brain connection and the role of stress in contributing to the experience of GI 
symptoms 
- The connection between symptoms and the cognitive & emotional reaction to symptoms 
- The impact of food avoidance and reintroduction 
 
Discussion Content: 
- Explore what is currently done to cope with difficult thoughts, emotions and body 




- Set personally meaningful goal to work towards during intervention 
- Passengers on a Bus metaphor 
- Mindful eating exercise 
 
Between-Session Practice: 
- 1 mindful eating practice each day 
 
- Self-as-context 
- Present moment 
awareness 






Discussion + Psychoeducation Content: 
- Update on goal and progress towards it – problem solve as necessary. 
- Explore current cost of experiential avoidance (in relation to personal values and overall 
enjoyment of life) of trying to control these experiences & current cost of trying to 
maintain strict food avoidance.  
- Explore the paradoxical nature of control and what happens when things don’t go as 
planned, or when difficult experiences are encountered. 
- Introduce the choice point and discuss what takes one away/towards what matters most 
- Explore role of self-blame and disengagement, and clarify if they take one towards what 
matters most or if these contribute to further suffering 
- Discuss the human nature of responses and how they are understandable, but sometimes 
are not helpful in the long term. Connect with idea about compassionate mind and how to 
foster compassion for self. 
- Additional goal setting exercise (long-term goal) 
 
Experiential Components: 
- Start with mindfulness exercise 
- Choice Point 
- Self-compassion exercise 
 
Between-Session Practice: 
- 1+ mindful eating practices each day 
- 1+ additional mindfulness practices each day 
- Create own Choice Point during the week 











Discussion + Psychoeducation Content: 
- Update on goal and progress towards it – problem solve as necessary. 
- Explore willingness to experience an unpleasant symptom or a difficult emotion, followed 
by willingness practice and self-compassion following 
- Explore how the mind works, including the role of language, fusion and relational framing 
(e.g.  how even hearing or seeing the ‘offending food’ can make one feel anxious or upset) 
 
Experiential Components: 
- Start with mindfulness exercise 
- Willingness exercise 
- Defusion exercise ‘I am having the thought that’  
– Deliteralisation using the word of their food intolerance (e.g. milk) 
 
Between-Session Practice: 
- Continued daily mindfulness practice and mindful eating practice 
- Practice willingness each day and record how long tolerated 
- Continue creating own choice point and reflecting on what takes you away from and 
towards what matters most.  
 









4 Discussion + Psychoeducation Content: 
- Explore what values and goals are, the importance of values and goals, and how they 
relate to each other 
- Clarifying values & exploring willingness and values in the context of goal-setting 
- Explore barriers to goals and what skills can be used from sessions so far to help flexibly 
adapt 
- Explore how one can commit to doing what matters in the context of difficulty, and what 
helpers we might need to support commitment to that goal 
- Explore self-compassion & perspective-taking exercise 
- Reflect on past four sessions and how to help bring ideas with you on your journey 
 
Experiential Components: 
- Start with mindfulness exercise 
- 80th birthday exercise (values) 
- Goal setting exercise 
- Self-compassion exercise 
- Declaration of committed action 




- Committed action 
 
+ Self-compassion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ꟷENDꟷ 
 
 
 
 
 
 
 
 
 
 
 
 
 
